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ABSTRACT 
Title- Role of Central Sensitivity Syndromes in Women with Pelvic Organ Prolapse. 
Author- Monika Vij 
Pelvic Organ Prolapse (POP) is a dysfunction of pelvic floor support and have an ad-
verse effect on the quality of life (QOL). The predominant symptom is the feeling of a 
vaginal bulge. However, a considerable proportion of women report a sensation of drag-
ging, or pelvic pressure vaginally without a bulge or large objective prolapse being 
present. A mechanism suggested to explain this anomaly describes the augmentation of 
pain transmission secondary to central sensitization (CS). This explanation is like the 
pathophysiological changes postulated for central sensitivity syndromes (CSS) (a term 
collectively used for a group of pain disorders like fibromyalgia, chronic fatigue syn-
drome, temporomandibular disorder, chronic pelvic pain, and interstitial cystitis). The 
purpose of this thesis is to determine whether patients with central sensitivity syn-
dromes have different outcomes from the surgical treatment of prolapse, compared to 
those without CSS. 
The survey explored the level of awareness about CSS amongst healthcare profession-
als managing pelvic organ prolapse and identified that there is gap in knowledge about 
CSS in this specific group. The second part explored the proportion of women with 
central sensitivity syndrome attending the gynaecology outpatient clinic and revealed 
that around 32% of women with pelvic organ prolapse, and 40% with other gynaeco-
logical problems had evidence of CSS. The third part of the thesis reviewed the litera-
ture around the impact of CSS on post-surgical outcomes. This demonstrated that there 
is limited evidence currently available on the role of CSS on surgical outcomes. The 
fourth part of the thesis compared the outcomes of pelvic organ prolapse surgery be-
tween the two groups (i.e. those with and without CSS) and found that women with 
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CSS had a lower level of satisfaction and impression of improvement with persistence 
of symptoms compared to women without CSS. The qualitative study explored 
women’s views on reasons for poor outcome from surgery amongst women with CSS. 
Poor surgical technique and /or underlying unidentified bowel or bladder pathology 
was the perceived reason for poor outcome, rather than CSS. 
The above findings suggest that there is suboptimal awareness about this condition, 
amongst healthcare professionals and patients. The findings of the study also suggest 
that the presence of underlying CSSs could be one of the contributing factors responsi-
ble for poor outcomes. These findings will enable clinicians to adequately counsel 
women with CSS for the possible outcomes of the surgery, while also enabling those 
patients to have more realistic expectations from the surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
 
 
Table of Contents 
ABSTRACT ......................................................................................................................................1 
LIST OF TABLES ............................................................................................................................5 
LIST OF FIGURES ..........................................................................................................................7 
LIST OF ABBREVIATIONS ...........................................................................................................8 
CHAPTER 1 – BACKGROUND AND REVIEW ............................................................................9 
1.1. PAIN AND CENTRAL SENSITISATION ...................................................................................9 
1.2. FUNCTIONAL SOMATIC SYNDROMES OR MEDICALLY UNEXPLAINED SYMPTOMS (MUS) ..... 12 
1.3. PREVALENCE AND BURDEN ............................................................................................. 13 
1.4. ARE FSSS DISCRETE ENTITIES? ........................................................................................ 14 
1.5. FSS OR CENTRAL SENSITIVITY SYNDROME ....................................................................... 16 
1.6. MECHANISM OF CENTRAL SENSITISATION AND ITS ASSESSMENT ........................................ 19 
1.7. RECEPTORS AND NEUROTRANSMITTERS RESPONSIBLE FOR CENTRAL SENSITISATION ......... 22 
1.8. SUMMARY OF MECHANISM OF CENTRAL SENSITISATION ................................................... 25 
1.9. EVIDENCE OF NEUROENDOCRINE OR AUTONOMIC ABNORMALITIES IN CSSS ...................... 27 
1.10. EVIDENCE OF IMMUNE DYSFUNCTION AND ABNORMAL CYTOKINES IN CENTRAL 
SENSITISATION .............................................................................................................................. 28 
1.11. ROLE OF “SMALL FIBRE NEUROPATHY” IN CENTRAL SENSITISATION................................... 28 
1.12. ROLE OF GLIOPATHY IN CENTRAL SENSITISATION ............................................................. 28 
1.13. CLINICAL ASSESSMENT OF CENTRAL SENSITISATION ......................................................... 29 
1.14. SPECIFIC QUANTITATIVE EXPERIMENTAL TOOLS FOR ASSESSING CS .................................. 31 
1.15. PELVIC ORGAN PROLAPSE AND CENTRAL SENSITISATION .................................................. 34 
1.16. SUMMARY AND PURPOSE OF THE STUDY .......................................................................... 39 
CHAPTER 2 – A SURVEY ON “AWARENESS OF CENTRAL SENSITIVITY SYNDROMES 
AND CENTRAL SENSITISATION AMONGST GYNAECOLOGISTS AND HEALTHCARE 
PROFESSIONALS DEALING WITH PELVIC ORGAN PROLAPSE.” .................................... 43 
2.1. INTRODUCTION ............................................................................................................... 44 
2.2. METHOD ......................................................................................................................... 45 
2.3. RESULT........................................................................................................................... 46 
2.4. DISCUSSION .................................................................................................................... 51 
2.5. CONCLUSION .................................................................................................................. 53 
CHAPTER 3A - FACTOR ANALYSIS OF CSI IN A COHORT OF WOMEN ATTENDING 
GYNAECOLOGY OUTPATIENT DEPARTMENT .................................................................... 55 
3A.1. INTRODUCTION ............................................................................................................... 55 
3A.2. METHOD ......................................................................................................................... 56 
3A.3. RESULTS ......................................................................................................................... 57 
3A.4. DISCUSSION .................................................................................................................... 64 
3A.5. CONCLUSION .................................................................................................................. 66 
CHAPTER 3B- THE PROPORTION OF WOMEN WITH CENTRAL SENSITIVITY 
SYNDROME IN GYNAECOLOGY OUTPATIENT CLINICS (GOPD) ..................................... 67 
3B.1. INTRODUCTION ............................................................................................................... 68 
3B.2. METHOD ......................................................................................................................... 69 
3B.3. SAMPLE SIZE AND STATISTICAL ANALYSIS ........................................................................ 70 
3B.4. RESULTS ......................................................................................................................... 71 
3B.5. DISCUSSION .................................................................................................................... 74 
3B.6. CONCLUSION .................................................................................................................. 77 
CHAPTER 4- CLINICAL OUTCOMES OF SURGERY IN PATIENTS WITH CSS; A 
SYSTEMATIC REVIEW AND REVIEW OF LITERATURE ..................................................... 78 
4.1. INTRODUCTION ............................................................................................................... 78 
4 
 
4.2. METHOD-........................................................................................................................ 78 
4.3. EXCLUSION CRITERIA- ..................................................................................................... 79 
4.4. SEARCH STRATEGY ......................................................................................................... 79 
4.5. DATA COLLECTION .......................................................................................................... 80 
4.6. RISK OF BIAS (QUALITY) ASSESSMENT .............................................................................. 81 
4.7. STRATEGY FOR DATA SYNTHESIS ..................................................................................... 81 
4.8. RESULTS – ...................................................................................................................... 82 
4.9. SUMMARY AND COMPARISON OF THE STUDIES .................................................................. 86 
4.10. SUMMARY OF OVERALL QUALITY OF STUDIES ................................................................. 101 
4.11. DISCUSSION .................................................................................................................. 104 
4.12. CONCLUSION ................................................................................................................ 108 
CHAPTER 5 - A PROSPECTIVE COHORT STUDY TO COMPARE THE OUTCOMES OF 
PROLAPSE SURGERY BETWEEN WOMEN WITH EVIDENCE OF CENTRAL 
SENSITIVITY SYNDROME (CSS) AND WOMEN WITHOUT CSS ....................................... 110 
5.1. INTRODUCTION ............................................................................................................. 111 
5.2. METHOD ....................................................................................................................... 112 
5.3. RESULTS ....................................................................................................................... 117 
5.4. DISCUSSION .................................................................................................................. 126 
5.5. CONCLUSION ................................................................................................................ 134 
CHAPTER 6 - A QUALITATIVE STUDY OF WOMEN’S EXPERIENCES OF PROLAPSE 
SURGERY IN THOSE WITH EVIDENCE OF CENTRAL SENSITIVITY SYNDROME ...... 142 
6.1. INTRODUCTION ............................................................................................................. 142 
6.2. METHOD ....................................................................................................................... 143 
6.3. ANALYSIS ..................................................................................................................... 145 
6.4. RESULTS ....................................................................................................................... 145 
6.5. DISCUSSION .................................................................................................................. 149 
6.6. CONCLUSION ................................................................................................................ 153 
SUMMARY OF FINDINGS OF THE THESIS ........................................................................... 154 
IMPLICATIONS AND CONCLUSIONS .................................................................................... 155 
LIMITATIONS............................................................................................................................. 157 
RECOMMENDATIONS .............................................................................................................. 158 
REFERENCES ............................................................................................................................. 160 
APPENDICES .............................................................................................................................. 196 
APPENDIX 1: CENTRAL SENSITISATION INVENTORY ..................................................................... 196 
APPENDIX 2: MCGILL PAIN QUESTIONNAIRE ............................................................................... 198 
APPENDIX 3: PGI-I ..................................................................................................................... 199 
APPENDIX 4: POP-SS .................................................................................................................. 200 
APPENDIX 5: QUESTIONS USED FOR SURVEY – CHAPTER 2 ............................................................. 201 
APPENDIX 6: CONSENT FORM (STUDY 2/3)- VERSION2, 8/11/13 ............................................... 203 
APPENDIX 7: QUESTIONS FOR INTERVIEW- (CHAPTER 5) ............................................................... 204 
APPENDIX 8: ETHICS APPROVAL LETTER ...................................................................................... 204 
 
 
 
 
 
 
 
 
5 
 
List of Tables 
TABLE 1: SHOWING THE RESPONSE TO Q1- DESCRIBE YOUR ROLE. ................................... 47 
TABLE 2: SHOWING THE RESPONSE TO Q2-HOW OFTEN DO YOU SEE PATIENTS WITH 
PELVIC ORGAN PROLAPSE COMPLAINING OF DRAGGING SENSATION RATHER 
THAN BULGE? ...................................................................................................................... 47 
TABLE 3: SHOWING THE RESPONSE TO Q3- IN YOUR PRACTICE HOW OFTEN DO YOU SEE 
PATIENTS WHOSE SYMPTOMS OF PROLAPSE ARE OUT OF PROPORTION TO/ WITH 
THE DEGREE OF PROLAPSE?.............................................................................................. 47 
TABLE 4: SHOWING THE RESPONSE TO Q4- DO YOU BELIEVE THAT THERE IS AN 
ELEMENT OF CENTRAL SENSITISATION IN WOMEN WHERE THEIR SYMPTOMS ARE 
OUT OF PROPORTION TO THE OBJECTIVE PROLAPSE? ................................................. 48 
TABLE 5: SHOWING THE RESPONSE TO Q5- DO YOU BELIEVE THAT WOMEN WITH 
FIBROMYALGIA, CHRONIC FATIGUE SYNDROME, ME OR SOME VAGINAL PAIN 
HAVE WORSE SYMPTOMS THAN WOMEN WHO DO NOT HAVE THESE CONDITIONS?
................................................................................................................................................ 48 
TABLE 6A: SHOWING THE RESPONSE TO Q6 ‘A’ - HAVE YOU HEARD THE TERM CENTRAL 
SENSITIVITY SYNDROME? ................................................................................................. 48 
TABLE 6B: SHOWING THE RESPONSE TO Q 6B………………………………...48 
TABLE 7: SHOWING RESPONSES AMONGST DIFFERENT HEALTH CARE PROFESSIONALS 
FOR QUESTIONS 2-6............................................................................................................. 49 
TABLE 8: SHOWING RESPONSE BY BSUG MEMBERS TO QUESTION- DO YOU FEEL THAT 
THERE IS A NEED OF UNDERSTANDING THE ROLE OF CS IN PELVIC FLOOR 
DYSFUNCTION ..................................................................................................................... 51 
TABLE 9: SHOWING RESPONSE BY BSUG MEMBERS TO QUESTION- DO YOU THINK THAT 
WE SHOULD SCREEN FOR SYMPTOMS SUGGESTIVE OF CSS’S BEFORE OFFERING 
PELVIC ORGAN PROLAPSE SURGERY ? ........................................................................... 51 
TABLE 10: SHOWING RESPONSE BY BSUG MEMBERS FOR QUESTION-  DO YOU THINK 
THAT PATIENTS WITH CSS SHOULD HAVE A TRIAL OF OTHER TREATMENT 
STRATEGIES SUCH AS MYOFASCIAL RELEASE, COGNITIVE BEHAVIOURAL 
THERAPY OR USING NEUROMODULATORS EG GABAPENTIN BEFORE  PELVIC 
ORGAN. ................................................................................................................................. 51 
TABLE 11: SHOWING DESCRIPTIVE STATISTICS FOR THE FACTOR ANALYSIS OF CSI. .... 58 
TABLE 12: SHOWING  TOTAL EIGENVALUES AND VARIANCE OF EACH ITEM OF CSI ...... 59 
TABLE 13: SHOWING ITEMS LOADED ONTO FACTORS. (F-FACTOR, I-ITEM NO OF 
THE QUESTIONNAIRE)- PATTERN MATRIX. ................................................................ 61 
TABLE 14: SHOWING ITEM TOTAL CORRELATION OF CSI .................................................... 63 
TABLE 15: SHOWING EVIDENCE OF CENTRAL SENSITIVITY SYNDROME IN WOMEN 
WITH PELVIC ORGAN PROLAPSE AND OTHER GYNAECOLOGICAL CONDITIONS IN 
OUTPATIENT CLINICS ........................................................................................................ 72 
6 
 
TABLE 16: SHOWING MEAN CENTRAL SENSITISATION SCORES AND *STANDARD 
DEVIATION BETWEEN WOMEN WITH PELVIC ORGAN PROLAPSE AND OTHER 
GENERAL GYNAECOLOGICAL CONDITIONS. ................................................................. 72 
TABLE 17: SHOWING MEAN CSI SCORES AND *STANDARD DEVIATION IN PATIENTS 
WITH GENERAL GYNAE CONDITION WITH PAIN COMPARED TO THOSE WITHOUT 
PAIN. ...................................................................................................................................... 73 
TABLE 18: SHOWING MEAN CSI SCORES  AND *STANDARD DEVIATION IN PATIENTS  
WITH PELVIC ORGAN PROLAPSE WITH PAIN COMPARED TO THOSE WITHOUT....... 73 
TABLE 19: SHOWING MEAN CENTRAL SENSITISATION SCORES AND *STANDARD 
DEVIATION IN WOMEN WITH EVIDENCE OF CSS. .......................................................... 73 
TABLE 20: SHOWING ALL TYPE OF STUDIES INCLUDED. ...................................................... 83 
TABLE 21: QUALITY OF STUDIES USING NEWCASTLE-OTTAWA SCALE. ......................... 102 
TABLE 22: DEMONSTRATING QUALITY OF SYSTEMATIC REVIEW. .................................. 103 
TABLE 23: SHOWING DEMOGRAPHICS AND CSI SCORES IN BOTH GROUPS..................... 118 
TABLE 24: SHOWING PRE-OPERATIVE POPSS SCORES IN BOTH GROUPS. ........................ 119 
TABLE 25: SHOWING POSTOPERATIVE POPSS SCORES FOR BOTH GROUPS. ................... 119 
TABLE 26: SHOWING PREOPERATIVE POPSS SCORES WITH POP-Q SYSTEM POINT 
QUANTIFICATION FOR BOTH GROUPS........................................................................... 119 
TABLE 27: SHOWING PREOPERATIVE MCGILL’S PAIN SCORES IN BOTH GROUPS. ......... 120 
TABLE 28: POST-OPERATIVE MCGILL’S SCORE IN BOTH GROUPS..................................... 120 
TABLE 29: SHOWING SATISFACTION IN BOTH GROUPS ON VAS. ....................................... 121 
TABLE 30: SHOWING EXPECTATIONS AND GOALS OF WOMEN WITH CSS. ...................... 121 
TABLE 31: SHOWING EXPECTATIONS AND GOALS OF WOMEN WITHOUT CSS. .............. 122 
TABLE 32: SHOWING PGII SCALE IN BOTH GROUPS. ............................................................ 123 
TABLE 33: SHOWING PERSISTENCE OF OBJECTIVE PROLAPSE IN BOTH GROUPS. ......... 124 
TABLE 34: SHOWING PRE AND POST-OPERATIVE POP-Q IN GROUP1. ............................... 124 
TABLE 35: MODEL SUMMARY OF THE MULTIPLE REGRESSION ANALYSIS. .................... 125 
TABLE 36: SHOWING COEFFICIENTS OF EACH PREDICTORS AFTER MULTIPLE 
REGRESSION ANALYSIS. .................................................................................................. 125 
TABLE 37: DEMOGRAPHICS, TYPE OF SURGERY, PGII, POP-SS SCORES, MCGILL’S PAIN 
SCORES IN THIS GROUP OF WOMEN. .............................................................................. 146 
TABLE 38: SHOWING EXPECTATION, GOALS, SATISFACTION AND POP-Q SCORES IN THIS 
GROUP OF WOMEN. ........................................................................................................... 146 
 
 
 
 
 
 
 
7 
 
 
 
 
 
 
List of Figures 
FIGURE 1: SHOWING ABNORMAL PAIN SIGNALLING. ........................................................... 25 
FIGURE 2: NEUROTRANSMITTERS AND RECEPTORS INVOLVED IN POSSIBLE 
MECHANISM OF CS. (PKA/PKC-PROTEIN KINASE A/C; GLU R1- GLUTAMATE 
RECEPTORS, AMPARS- AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLE PROPIONATE 
RECEPTORS). ........................................................................................................................ 26 
FIGURE 3: SHOWING SCREE PLOT FOR VARIOUS ITEMS ON CSI RELATED TO EIGEN 
VALUE. .................................................................................................................................. 60 
FIGURE 4: GRAPH 1- DISTRIBUTION OF CSI SCORES IN PATIENTS WITH PELVIC ORGAN 
PROLAPSE AND CSS. THE X AXIS SHOWS THE CSI SCORES AND Y AXIS IS THE 
FREQUENCY OF THESE SCORES. ....................................................................................... 74 
FIGURE 5: GRAPH 2- DISTRIBUTION OF CSI SCORES IN WOMEN WITH GENERAL GYNAE 
CONDITION AND CSS. THE X AXIS SHOWS THE CSI SCORES AND Y AXIS IS THE 
FREQUENCY OF THESE SCORES. ....................................................................................... 74 
FIGURE 6: PRISMA FLOW CHART. ............................................................................................. 82 
FIGURE 7: CENTRAL SENSITIVITY SYNDROME RESULTS ................................................... 117 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8 
 
 
 
 
 
 
 
List of Abbreviations 
CS………………………………………………………………................................Central Sensitisation 
CSS………………………………………………………………................Central Sensitivity Syndrome 
GOPD……………………………………………………………...............Gynae Outpatient Department 
FSS…………………………………………………...…………....………Functional Somatic Syndrome 
POP………………………………………………...…………………................…Pelvic Organ Prolapse 
FM……………………………………………….…………………...............…................. Fibromyalgia 
CFS………………………………………………………..…………….........Chronic Fatigue Syndrome 
MUS………………………………………………………….……… Medically Unexplained Symptoms 
TMJ……………………………………...………………………...…  Temporomandibular Joint Disease 
CSI……………………………………………………………......………Central Sensitisation Inventory 
CPP………………………………………………………...…………........................Chronic Pelvic Pain 
IBS………………………………………………………..……….............…...Irritable Bowel Syndrome 
POP-Q…………………………………………..…………………Pelvic Organ Prolapse Quantification 
PGII……………………………………..…………………...Patient Global Impression of Improvement 
POP-SS....................... …………………….........................................................Prolapse Symptom Score 
EGGS…………………………………............…………Expectation, Goals, Goal achieved, Satisfaction
9 
 
Chapter 1 – Background and Review 
1.1. Pain and Central Sensitisation 
Pain is described by the International Association for the study of pain as an unpleasant 
sensory and emotional experience associated with actual or potential tissue damage or 
described in terms of such damage (Bonica JJ 1979; Loeser JD et al., 2008). It is usually 
regarded as a symptom of underlying pathology and encourages the individual to with-
draw from harmful situations to protect the body while it heals and prevents impairment 
of its normal function (The Neurobiology of Pain,1983). Pain can be categorised as 
acute, often provoked by an injury or a specific disease, seen as serving a specific bio-
logical purpose; or as chronic, where it can outlast the normal time of healing, persisting 
for months or years.  
Nociceptive pain perception usually begins with the stimulation of peripheral nocicep-
tors, either somatic or visceral. Nociceptors are the specialised sensory receptors re-
sponsible for the detection of noxious (unpleasant) stimuli, transforming the stimuli 
into electrical signals. These are then relayed to the central nervous system, including 
the higher brain centres (Hazem AA et al., 2016). 
Nociceptors typically have “unencapsulated” free nerve endings, which innervate the 
dermis (including connective tissue and arteriole walls) as well as extending into parts 
of the epidermis. Nociceptors are also found in viscera, joints and muscle tissue. The 
free nerve endings are polymodal since they can function as thermoreceptors, cutaneous 
mechanoreceptors, as well as nociceptors. 
The sensory afferent fibres are divided into Aa, Ab, Ad and C fibres, which vary ac-
cording to the degree of myelination and, hence, conduction speed; with Aa the fastest, 
and C fibres the slowest fibres. The primary afferent Aa fibres carry non-noxious stim-
uli from muscle spindles and golgi bodies. Aβ fibres respond to light touch and transmit 
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non-noxious stimuli. Aδ fibres respond to mechanical and thermal stimuli. These fibres 
are thinly myelinated and conduction speeds are much faster than the unmyelinated C 
fibres which also respond to chemical, mechanical and thermal stimuli.  
Ad and C fibres, which are distributed throughout the body (skin, viscera, muscles, 
joints, meninges) are historically thought to be the only primary afferent fibres carrying 
signals from somatic noxious triggers. However, it is accepted that there is some over-
lap in function, such that Ad and C fibres can carry non-noxious stimuli and Ab fibres 
can carry noxious stimuli. 
The threshold of nociceptors varies with their location. Cutaneous nociceptors and 
those supplying muscle typically have a high threshold of activation whereas visceral 
nociceptors have a lower threshold of activation (Miliner R et al., 2015). The somatic 
nociceptive neurons are differentiated to respond to high threshold input such as intense 
heat or sharp pressure. When stimuli reach this high threshold, first order nociceptive 
neurons transmit the signal to second order neurons in the dorsal horn of the spinal 
cord. Subsequently, the signals are transmitted to various regions of the thalamus and 
higher brain centres (Woolf CJ 2011).  
The traditional understanding of pain considered the afferent system as only relaying 
the nociceptive signals rather than the system having the ability to modulate the signals. 
This scientific view was prevalent until 1960 (Woolf CJ 2011). However, the Spinal 
Gate theory proposed by Melzack and Wall (1965) first demonstrated that this relay 
system could be modulated by inhibition in the spinal cord (Melzack R et al., 1965). 
Further studies revealed that pain signalling is modulated by complex and interactive 
processes in both the peripheral and central nervous system (Willis WD 1985). Thus, 
the experience of pain can be both inhibited and stimulated. There continues to be an 
11 
 
incomplete understanding of nociceptor cell biology; however, the demonstration of 
the potential modulation of nociceptive signalling markedly helps improve our inter-
pretation of this nociceptor influenced aspects of pain perception. 
The state of persistent heightened responsiveness to a painful stimulus can be referred 
to as pain “sensitisation”. Short term sensitisation following injury can be adaptive, for 
preventing the organism aggravating an injury, and hence, nurturing the healing pro-
cess. However, in many clinical syndromes, pain can stop being a healthy protective 
mechanism for the organism and become a dysregulated process. Indeed, in some situ-
ations, chronic pain can become a disease process in its own right, as evidenced by the 
new changes incorporated in the latest version of the International Classification of 
Diseases (ICD), version 11(Khoury et al., 2017). 
In these conditions, pain can arise spontaneously or can occur with innocuous stimuli 
(allodynia) due to a convergence of sensory processing. This convergence process is 
reflective of the development of central sensitisation and is believed to take place in the 
spinal cord and in pain networks directly controlled by the brain (Woolf CJ 2011). Pain 
can also present as an exaggerated and prolonged response to noxious stimuli (hyper-
algesia) and can spread well beyond the site of injury (secondary hyperalgesia). 
There are two types of sensitisation peripheral and central. In peripheral sensitisation, 
the nociceptor peripheral terminals can become ‘‘sensitised” after injury, reducing their 
threshold, particularly to heat stimuli within the site of injury where the terminal is 
exposed to inflammatory modulators as part of the “inflammatory soup” (Bishop T et 
al., 2010, Campbell JN et al., 1988).  
In central sensitisation, there appears to be pain perception beyond the area of injury 
and the nociceptive activity also includes components of the system that do not nor-
mally respond, such as large low-threshold mechanoreceptor myelinated fibres.  
12 
 
Thus, central sensitisation results from changes in the properties of neurons in the cen-
tral nervous system (CNS), and so can also produce pain hypersensitivity in non-in-
flamed tissue. It also increases pain sensitivity long after the initiating cause may have 
resolved and when no peripheral pathology might be present (Latremoliere A et al., 
2009). Some of the potential mechanisms involved in central sensitisation are activation 
of NMDA receptor, altered gene expression in dorsal horn neurons, microglial activa-
tion (Wieseler-Frank J et al., 2005), decreased descending inhibition and thalamic and 
somatosensory cortex changes (Guilbaud G et al., 1992). These are considered further 
in the thesis. 
1.2. Functional Somatic Syndromes or Medically unexplained symptoms 
(MUS) 
Functional Somatic Syndrome (FSS) is defined as an illness without an organic disease 
explanation: devoid of any demonstrable structural lesion or biochemical change (Lip-
kin M 1969; Smith RC 1991). Historic expressions used are hysteria, imagined illness 
(hypochondriasis) or psychogenesis (Sharpe M et al., 1995). Newer descriptions ap-
plied for FSS are Medically Unexplained Symptoms (MUS) although this term appears 
to be becoming less accepted clinically and a further, more recently used term is Body 
distress syndrome (Budtz-Lilly A et al., 2015).  
Conditions such as Irritable Bowel Syndrome (IBS), Chronic Fatigue Syndrome (CFS), 
Fibromyalgia (FM), Temporomandibular joint Disorder (TMJ), and Chronic Pelvic 
Pain (CPP) are some of the most common FSSs. They are typically described by the 
associated somatic symptoms whereas other clinical labels such as anxiety and depres-
sion highlight the psychological processes involved (Mayou R et al., 2002).  
Around 1 in 6 primary care consultations involve Medically Unexplained Symptoms 
(Steinbrecher N et al., 2011). Barsky and Borus (1999) suggested that FSSs are 
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essentially expressions of somatization (Barsky AJ et al., 1999). It was also found that 
patients with FSS have high rates of psychiatric comorbidities especially anxiety and 
depression. However, it is difficult to say which is the cause and which is the conse-
quence (Fiedler N et al., 1996) because most patients with FSS do not have a pathology 
or structural change in the areas where they report symptoms. For example, there are 
no definitive structural abnormalities or biomarkers for IBS, CFS or FM although they 
suffer from bowel symptoms, fatigue, and musculoskeletal pain respectively (Locke 
GR et al, 2004; Branco JC et al., 2010; Clauw DJ 2014; Morris G et al., 2013; Soares 
RL, 2014).  
There is an on-going debate regarding the aetiology of FSS with some theories suggest-
ing the possibility of anomalies in either the peripheral or central nervous system which 
cannot be easily assessed (Marianne R et al., 2017). The Diagnostic and Statistical 
Manual of Mental Disorders (DSM-5) introduced the term Somatic Symptom Disorder 
(SSD) to replace or augment prior diagnoses and no longer requires that symptoms have 
no medical basis to make the diagnosis. This may be appropriate in some situations. 
1.3. Prevalence and Burden  
It is hard to ascertain the extent of FSSs; however, studies show that the prevalence of 
Irritable Bowel Syndrome is 11% (Canavan C et al., 2014), Chronic Pelvic Pain (CPP) 
is between 5.7%-26.6% (Ahangari A 2014), Chronic Fatigue Syndrome is 9% (Ska-
pinakis P et al., 2003) and Fibromyalgia varies between 0.2% and 6.6% (Marques AP 
et al., 2017) in community samples. There is also a significant overlapping of symptoms 
among these patients. Fibromyalgia and medically unexplained symptoms (MUS) re-
sult in significant psychosocial impairment, work disability, and increased health care 
utilization by patients (Kevin CF et al., 2015). For example, for patients with mild, 
moderate, and severe FM, annual direct health care resource costs in the USA were 
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estimated at $4,854, $5,662, and $9,318 per patient respectively. Annual mean indirect 
costs (including absenteeism, unemployment, early retirement, and disability) for sub-
jects with mild, moderate, and severe fibromyalgia were estimated at $4,428, $14,664, 
and $29,996, respectively (Chandran A et al., 2012). 
Other functional conditions are also associated with a substantial economic cost to the 
patient, healthcare, and society. For instance, extrapolated annual UK population costs 
for treating IBS is £45.6 -200 million (Wells NE et al., 1997; Akehurst RL et al., 2002). 
Similarly, the estimated annual direct costs of treating each case of CPP are approxi-
mately $7000(£5400) (Clemens JQ et al., 2009).  
FSSs are strongly associated with reduced quality of life (QoL). Compared to healthy 
controls (HC), women with CFS report worse physical functioning, more bodily pain, 
loss of vitality, less productivity, worse general health, and social functioning, and, thus 
this condition has a significant impact on employment (Collin S et al., 2011; Anderson 
JS et al., 1997; Dickson A et al., 2009). Patients with IBS reveal the same pattern of 
QOL impairments (Monnikes H et al., 2011) as do patients with fibromyalgia (Hoffman 
D et al., 2008; Martinez JE et al., 1995). The studies also demonstrate that the functional 
limitations in FSS are as severe as those in medical disorders despite the absence of 
underlying organic pathology (Monica L et al., 2015). Thus, FSSs represent a signifi-
cant burden to sufferers, their families, society and the healthcare systems they use.  
1.4. Are FSSs discrete entities?  
Studies suggest that FSSs are not entirely discrete syndromes. (Kanaan RA 2007). Wes-
sely S et al (1999) found a considerable overlap of symptoms among FSSs such as - 
bloating or abdominal distension in 8 conditions, headache in 6, abdominal pain in 6 
and fatigue in 6. Aaron LA et al (2000) demonstrated that while all patients with chronic 
fatigue syndrome (CFS) report fatigue, 86% of patients with fibromyalgia (FM) do too; 
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conversely, while the vast majority of FM patients report arthralgia, so do 88% of 
chronic fatigue (CFS) patients. 
Aron and Buchwald reviewed 53 studies where patients with one FSS were assessed 
using the formal diagnostic criteria for another. They found that between 35 - 70% of 
patients with CFS met criteria for FM, 58-92% met criteria for IBS, and 53-67% 
showed multiple chemical sensitivities. Similarly, 75% of patients with FM met criteria 
for the temporomandibular disorder, 32-80% met criteria for IBS, and 55% described 
multiple chemical sensitivities (Aaron LA et al., 2000). 
Similarly, other studies revealed that IBS is present in 39% of Chronic Pelvic Pain pa-
tients (Nickel JC et al., 2010). There is also a high risk of a patient developing a new 
FSS in the future if there is a presence of one FSS in an individual; Warren JW et al 
found that having any FSS was associated with 2.4 greater odds (95% CI, 1.3-4.7) of 
developing a new FSS in the following year (Warren JW et al., 2013).  
It has been demonstrated that FSSs share many psychosocial and demographic corre-
lates. Mood disorders especially depression and anxiety, are more common in patients 
with FSSs compared to patients with organic disease and healthy comparison groups 
(Henningsen P et al., 2003). They have also been thought to be linked with a history of 
abuse and maltreatment. Paras ML et al., 2009, revealed in a meta-analysis of 23 studies 
with 4640 subjects that lifetime history of sexual abuse was associated with signifi-
cantly greater odds of developing functional gastrointestinal disorders (OR 2.43, 95% 
CI, 1.36-4.31) and CPP (OR 2.73, 95% CI 1.73-4.30).    
A recent meta-analysis of 71 studies examining multiple forms of psychological trauma 
including emotional, physical, and sexual abuse confirmed that exposure to any trauma 
was associated with 2.7 greater odds (95% CI, 2.27-3.10) of meeting criteria for an FSS 
(Afari N et al., 2014).  
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As well as environmental factors, genetic factors might also have an impact on devel-
oping FSSs (Vehof J et al., 2014). MUSs and FSSs are also found to be more common 
in women than in men (Kroenke K et al., 1993).  
Given the high rates of psychological comorbidity, it might be tempting to suggest that 
symptoms are largely due to catastrophizing, somatization or negative affect. However, 
mediation modelling approaches (a method to understand the relationship between de-
pendent and independent variable through a mediator variable), demonstrate that psy-
chological and environmental factors (e.g. neuroticism, abuse history, life events, anx-
iety, somatization and catastrophizing) account for just 36% of the variance in IBS se-
verity and 42% of the variance in pain experienced by fibromyalgia patients (VanTil-
burg MAL et al., 2013).Given the above caveats, whatever the eventual full explana-
tion, it seems unlikely that either specific physiological or psychological processes, 
alone, will account for the wide range of symptoms of FSSs.  
1.5. FSS or Central sensitivity syndrome 
Research has demonstrated that medically unexplained pain constitutes one of the im-
portant elements amongst all the symptoms of FSSs. For instance, IBS is characterized 
by pain in the lower or whole abdomen and pain associated with defaecation (Drossman 
DA et al., 2006).  
Fibromyalgia (FM) is  characterised by widespread pain including the back, neck, and 
extremities (Wolfe F et al  2010) and chronic fatigue syndrome (CFS) by headache, 
muscle pain, and joint pain without redness or swelling (Fukuda K et al., 1994); Tem-
poromandibular disorder (TMD) is characterised by jaw pain, earache, headache, facial 
pain (Robert LG et al., 2015) and chronic pelvic pain (CPP) by pelvic pain and myo-
fascial pain (Jane PD et al., 2010). Overall pain is also found to be the most common 
complaint for which patient with FSSs seek help (Hungin AP et al., 2005).  
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Recently, it has been proposed that these pain disorders are linked by a similar patho-
logical process of dysregulated centrally mediated nociception, referred to as “central 
sensitization”(Lindsay LK et al., 2011).In addition to a common mechanism of pain, 
these disorders often co-occur (Aggarwal VR et al., 2006), may act as a catalyst for the 
development of one another (Diatchenko L et al., 2006) and the pain may also transition 
from localized pain to a widespread pain disorder (Holm LW et al., 2007).  
Several of these disorders may have started from a peripherally mediated pain produc-
ing mechanism (inflammation and/or neural irritation). However, persistent nociceptive 
input can lead to physiological changes in the central nociceptive system, and, follow-
ing the induction of central sensitization, painful sensations can arise independently of 
peripheral nociceptive input (Latremoliere A et al., 2009). 
Given the potential shared pathophysiological mechanisms, these disorders, therefore, 
have been collectively termed by some researchers as “central sensitivity syndromes” 
(CSS) (Yunus MB 2008). This underlying connection might help us to understand the 
development of widespread hyperalgesia in some patients as well as provide a frame-
work for why central sensitivity syndromes often overlap with one another. The result-
ing diagnosis of the disorder is largely dependent on the patient’s main presenting com-
plaint and the attending clinician’s subspecialty (Aaron LA 2001).  
Various combination of symptoms which might suggest the presence of CSS are:  
§ Widespread pain including abdominal pain, non-specific chest pain, atypical facial 
pain, burning mouth syndrome, chronic low backache, migraine, myofascial pain, 
chronic pelvic pain, joint pains. 
§ Chronic fatigue particularly post exertional malaise. 
§ Perceptual sensitivity to light, noise, aromas, and touch. 
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§ Other symptoms including non-dermatomal paraesthesia, restless legs, temperature 
dysregulation, tinnitus, abdominal bloating, non- specific light headedness, poor 
concentration, and short-term memory. 
§ Other concomitant presentations including irritable bowel syndrome, anxiety, de-
pression, symptoms of post-traumatic stress disorder.  
The postulated aetiology is increasingly thought to be due to a process of central sensi-
tization (Kevin CF et al., 2015). 
A theoretical model which helps explain this and appears well accepted by patients is 
that of the Hyland Model (Michael EH et al., 2016). This proposes an intermediary 
theory, which incorporates both biological and psychological models to explain the 
evolution of central sensitivity syndromes. This has parallels with the bio-psycho-social 
model to help understand the pathophysiology and management of symptoms seen in 
CSS, but it is important to note that the biopsychosocial approach is also relevant in all 
chronic conditions and is not specific to CSS (Leah M et al., 2015). 
The above literature provides a concise overview of the burden and impact caused by 
medically unexplained symptoms. It highlights the variability of terminology associ-
ated with Functional Somatic Syndromes and further supports the potential utility of an 
umbrella term such as Central Sensitivity Syndromes to describe a group of disorders 
which share common symptoms with no underlying pathology but with pain being the 
leading feature.  
Whilst central sensitisation helps explain some dysregulated longer-term pain and hy-
persensitivity, the CS process does not invariably result in altered pain perception. An 
example of this is hyperacusis (where there is an increased sensitivity to certain levels 
of sound but does not necessarily result in pain). There is also debate as to whether the 
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cognitive symptoms noted in central sensitivity syndrome can be adequately explained 
by the central sensitisation model (Vardeh D et al., 2016).  
As CS is considered to be the common phenomenon in CSSs it is important to under-
stand the mechanism of central sensitisation and its assessment.   
1.6. Mechanism of central sensitisation and its assessment 
Central sensitisation is defined as a change in the functional state of neurons and noci-
ceptive pathways caused by increased membrane excitability and synaptic efficiency 
or also by decreased inhibition on this system (Wolf CJ 1983).   
Several possible phenomena involved include:  
1) Activation of wide dynamic range neurons (WDR), which starts to respond to no-
ciceptive and previously non- nociceptive stimuli (Hazem AA et al., 2016). These 
neurons carry the nociceptive stimuli to dorsal horn neurons in the spinal cord. 
Some of them are multi-modal responding to sensation from temperature, touch, 
pressure, and pain (Lindsay LK et al., 2011). 
2) Progressive increase of responses provoked by a standard series of repeated stimuli 
(temporal windup which can be homosynaptic i.e. response due to activation of the 
same synapse or heterosynaptic i.e. activity in one set of synapses augments subse-
quent activity in other non- activated group of synapses) (Hazem AA et al., 2016). 
3) Expansion of the spatial dimensions of the input; activating a series of changes that 
sustain longer than the initial stimulus (Latremoliere A et al., 2009). 
As well as changes from activity dependent synaptic plasticity, changes in microglial 
and astrocyte function is also gaining popularity as a scientific explanation for the 
maintenance of central sensitisation (Chacur M et al., 2009; Gao YJ et al., 2009; 
Chiechio S et al., 2009). This will be described in the later part of the thesis. 
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One of the first studies on central sensitisation demonstrated secondary cutaneous hy-
peralgesia induced by intradermal capsaicin injection (via activation of the TRPV1 re-
ceptor). This study demonstrated three areas of hyperalgesia. The primary area close to 
the injection site lasting 1-2 hrs, then an intermediate area of dynamic tactile allodynia 
spreading beyond this central area of heat hyperalgesia lasting for several hours. The 
final area is the largest, extending further from the injection site and lasted for more 
than 24 hrs. The last component is defined as secondary sensitisation resulting from 
changes within the central nervous system (CNS) (LaMotte RH et al., 1991). 
Further experiments indicated that capsaicin induced nociception is mostly transmitted 
via the C fibres and the transmission of information resulting in mechanical allodynia 
via low threshold myelinated fibres (Wolf CJ 2011). The stimulation of Ab fibres evok-
ing a non-painful tactile sensation before a capsaicin injection can subsequently result 
in the perception of pain if their receptive area is within the zone of mechanical hyper-
algesia as demonstrated by Torebjork in 1992 (Torebjork HE et al., 1992). Similar find-
ings were demonstrated by Koltzenburg et al using mustard oil as this could also acti-
vate TRPA1 receptors (Koltzenburg M et al., 1994). The central augmentation of Ad 
fibres following a C- fibre stimulation can contribute to pinprick/punctate secondary 
hyperalgesia as demonstrated by Ziegler et al (1999) using intradermal capsaicin (Zieg-
ler EA et al., 1999). 
The noxious stimulation from capsaicin has produced central plasticity within the no-
ciceptive system via activation of C-fibre nociceptors. As a result of this, the nocicep-
tive system is responding to stimuli outside the area of injury and to low-threshold af-
ferents that were not stimulated by noxious stimuli previously. It is thus hypothesised 
that there are activity dependent changes in the functional properties of neurons in the 
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dorsal horn of the spinal cord contributing to this pain hypersensitivity (Latremoliere 
A et al., 2009). Subsequently, similar changes were described in other studies particu-
larly in laminae I and V of spinal dorsal horn neurons (Cook AJ et al.,1986); as well as 
in the spinal trigeminal nucleus (Burstein R et al., 1998); thalamus (Dostrovsky JO et 
al., 1990); amygdala (Neugebauer V et al., 2003) and the anterior cortex cingulate areas 
(Wei F et al., 2001). 
The effects of central sensitisation can also be demonstrated using objective markers as 
well as from subjective pain measures. For example, the increased activity of neurons 
in the somatosensory cortex triggered by low threshold Ab stimulation from within the 
capsaicin-induced zone of secondary hyperalgesia can be shown by functional MRI 
imaging (Baron R et al., 2000). Various alterations in the patterns of cerebral processing 
can also be identified by Magnetoencephalography (Maihofner C et al., 2010). 
Early explanations of the molecular mechanism responsible for central sensitisation in-
cluded the proposal that the induction and maintenance of acute activity-dependent cen-
tral sensitization was dependent on NMDA receptors, (Woolf CJ et al.,1991) with key 
involvement of glutamate and its receptors. However, it is now perhaps better under-
stood that central sensitization comprises two temporal phases- 1. The early phosphor-
ylation-dependent and transcription-independent phase resulting mainly from rapid 
changes in glutamate receptor and ion channel properties (Woolf CJ et al., 2000). 2. 
The later, longer-lasting, transcription-dependent phase the synthesis of the new pro-
teins responsible for the longer-lasting form of central sensitization (Woolf CJ et al., 
2000). 
While the ascending pain pathways play an important part in the development of 
chronic pain, there is growing evidence that descending modulation of pain also has a 
22 
 
significant role in the generation and maintenance of central sensitisation. The peria-
queductal gray-rostral ventromedial medulla (RVM) system has been found to be a key 
component in the descending modulation of pain. Descending pathways can have a 
facilitatory as well as an inhibitory role (Suzuki R et al., 2004) and the predominance 
of descending facilitation is found to be a contributing factor to the development of 
central sensitisation and widespread hyperalgesia (Heinricher MM et al., 2009). In sit-
uations resulting in repeated nociceptive stimulation, changes in the neurons of the 
RVM may produce an imbalance in facilitatory influences, leading to the maintenance 
of hyperalgesia (Porreca F et al., 2002). Alterations in the ascending pathways in central 
sensitisation are likely to combine with abnormal descending modulation to initiate and 
maintain hypersensitivity and pain in Fibromyalgia (FM) (Staud R et al., 2006). 
1.7. Receptors and Neurotransmitters responsible for central sensitisation 
1. Glutamate, an excitatory neurotransmitter, binds to several postsynaptic receptors 
on the spinal dorsal horn, including the ionophores amino-3-hydroxy-5-methyl-4-
isoxazole propionate receptor (AMPAR), N-methyl D-aspartate (NMDAR), kainate 
(KA), metabotropic receptors (coupled to G protein) and other subtypes of gluta-
mate receptors (mGluR). 
AMPAR and NMDAR are expressed in high densities in the superficial laminae of 
the dorsal horn. Activation of NMDAR is important in both initiating and maintain-
ing activity-dependent potentiation as its blockade by non-competitive (MK801) or 
competitive (D-CPP) NMDAR antagonists prevent and reverse the hyperexcitabil-
ity of nociceptive neurons induced by nociceptor conditioning inputs.  
In normal conditions, NMDAR ionophore is blocked by magnesium ion (Mg++). 
Sustained release by glutamate nociceptors, neuropeptides, substance P (SP) and 
gene related peptide calcitonin (CGPR) leads to enough depolarization of plasma 
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membrane, forcing MG++ ion to leave the NMDA receptor pore. This then allows 
glutamate by binding to the receptor to generate an internal current and Calcium 
ion inflow (Hazem AA et al., 2016).  
A large amount of calcium ion inflow activates numerous intracellular pathways 
which can contribute to both development and the maintenance of central sensiti-
zation (Mayer ML et al., 1984; Wolf CJ et al., 1991). The activation of mGluRs by 
glutamate also seems to be important for the development of central sensitization.  
2. Substance P- Another neurotransmitter playing a part in central sensitisation is 
Substance P, co-released with glutamate by unmyelinated nociceptors (C fibres) 
(Afrah AW et al., 2002; Khasabov SG et al., 2002). Substance P binds to the neu-
rokinin receptor -1(NK1) resulting in long-lasting membrane depolarization.  
3. Calcitonin gene-related peptide (CGRP), synthesised by small neurons partici-
pates in central sensitisation due to activation of protein kinase A and C by CGRP1 
postsynaptic receptors. There is also an increase in brain derived neurotrophic fac-
tor (BDNF) release from trigeminal nociceptors by CGRP, which is a synaptic mod-
ulator and released in the spinal cord. (Sun RQ et al., 2003). 
4. Bradykinin a pro-inflammatory substance activating and sensitizing the primary 
afferent is produced in the spinal cord in response to intense peripheral noxious 
stimuli and acts by means of its B2 receptor, which is expressed by dorsal horn 
neurons. This increases synaptic efficiency by activating protein kinase A (PKA), 
protein kinase C (PKC) and kinases regulated by extracellular stimuli (ERK). ERK 
may also be activated by the serotoninergic descending pathway (5-HT) involving 
receptor 5-HT3 and possibly receptor 5-HT7. (Woolf CJ 2011). 
5. Calcium- Increased intracellular Calcium ions seem to be a primary trigger for the 
development of central sensitization. Increased intracellular calcium promotes 
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AMPAR and NMDAR receptors to be phosphorylated by PKA/PKC changing the 
activity of receptors. AMPAR and NMDAR receptor phosphorylation during cen-
tral sensitization increases the density and activity of such receptors leading to post-
synaptic hyperexcitability. This can trigger the activation of intracellular pathways 
which support central sensitisation and include phospholipase C pathway (PLC) 
and PKC, phosphatidylinositol-3-kinase pathway (PI3K) and protein kinase system 
pathways. 
6. Protein Kinase C (PKC) activation decreases NMDAR Mg++ block and making 
it easier for the NMDAR activated state (Chen L et al., 1992). Activated PKC also 
decreases inhibitory transmission, reducing descending inhibition via the periaque-
ductal gray matter PAG (Lin Q et al.,1996). Disinhibition is another mechanism 
resulting in fibres becoming more susceptible to excitatory stimuli and will also 
help maintain the process of central sensitisation.  
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1.8. Summary of Mechanism of Central sensitisation 
Figure 1 and Figure 2 summarise the possible mechanism of CS as well as the recep-
tors involved    
     
Figure 1: Showing abnormal pain signalling. 
Mechanisms identified in common painful conditions within the umbrella of Central 
Sensitivity Syndrome (CSS)which support the phenomenon of Central Sensitisation: 
1) Fibromyalgia (FM): The physiological and biochemical correlates of FM that sup-
ports the concept of central sensitisation are:  
§ Reduced pain thresholds 
§ Increased sensitivity outside of typical tender point locations 
§ Expansion of pain receptive area 
§ Increased level of Substance P and nerve growth factor in cerebral spinal fluid 
§ Abnormal wind up 
§ Persistent prolonged pain even after the removal of painful stimuli 
(Dadabhoy D et al., 2008; Staud R et al., 2001). 
 
BRAIN
Percieved pain as hyperalgesia
Allodynia
Dorsal Horn of Spinal cord
Pain amplification in ascending pathways
decreased inhibition in descending pathways
Stimuli
Increased Neuronal excitability in nociceptive  afferent fibres  resulting in higher release of 
neurotransmitters such as substance P and glutamate
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The neuroplastic changes of central sensitisation have been demonstrated in FM pa-
tients with the help of functional magnetic resonance imaging (fMRI) (Gracely RH et 
al., 2002). 
 
 
 
 
 
 
 
 
 
 
 
Activation of NMDAR and AMPAR                       Internalization of Glu R2 containing 
AMPAR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Neurotransmitters and receptors involved in possible mechanism of CS. (PKA/PKC-Protein 
Kinase A/C; Glu R1- Glutamate receptors, AMPARs- amino-3-hydroxy-5-methyl-4-isoxazole propionate 
receptors). 
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2) Temporomandibular joint disorder (TMD):  
§ Alterations in the central nervous system pain regulatory system (Sarlani E et 
al., 2005). 
§ Increased sensitivity to experimental pain modalities both at temporomandibu-
lar region and at regions away from head and neck (Sarlani E et al., 2005). 
§ Reduced pressure pain thresholds both contralaterally and ipsilaterally. 
§ A Defective central inhibitory mechanism (Sarlani E et al., 2003). 
3) Migraine: 
§ Increased excitability of medullary dorsal horn neurons which can be continued 
even after the removal of peripheral stimuli (de Tommaso et al., 2002). 
4) Chronic low back pain and neck pain: 
§ Decreased pain thresholds, higher pain response, more widespread and longer 
duration of pain as demonstrated in various experimental pain studies (O’Neill 
S et al., 2007; Staud R et al., 2007). 
In summary, there is strong evidence supporting the concept of central sensitisation to 
help explain the development of these painful disorders collectively labelled as Central 
Sensitivity Syndromes. However, further scientific enquiry is required to understand 
why some of these presents with focal pain symptoms rather than more widespread pain 
(for example, characteristic diagnostic features are seen in patients with interstitial cys-
titis on cystoscopy) while some of the patients develop centrally mediated pain disor-
ders like FM. 
1.9. Evidence of Neuroendocrine or autonomic abnormalities in CSSs 
Neuroendocrine and autonomic nervous system dysfunction could contribute to many 
of the symptoms of CSSs. Previous studies have noted that there is either hypo or hy-
peractivity of both the hypothalamic pituitary adrenal axis (HPA) and sympathetic 
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nervous system in patients with FM and related painful conditions. However, an abnor-
mal HPA as well as sympathetic dysfunction is not present in all but seen only in small 
group of patients with FM (Demitrack MA et al., 1998; Crofford LJ 1998) and data 
now suggests that these hormonal and autonomic changes are a possible consequence 
of pain or early life stressors rather than causing it (Mclean SA et al., 2005). 
1.10. Evidence of immune dysfunction and abnormal cytokines in central sensi-
tisation 
Although the main body of expert opinion suggests that FM and other related CSSs are 
not autoimmune disorders, there is some evidence that immune system may have a role 
in their pathogenesis (Gur A et al., 2008). The most common finding is an elevation of 
IL-8, a cytokine associated with the sympathetic function (Bazzichi L et al., 2007). 
However, this area is still underexplored and needs further research. 
1.11. Role of “small fibre neuropathy” in central sensitisation 
Many studies have shown that there is decreased intra-epidermal nerve fibre density 
(i.e. small fibre neuropathy) in patients with FM (Caro XJ et al., 2015; Levine TD et 
al., 2015). The reduction in nerve fibre density is a very non- specific feature observed 
in over 50 different pain and non-pain conditions (Clauw DJ 2015). These findings 
were created in an animal model of central sensitisation by increasing the insular glu-
tamate (Harte SE et al., 2017) and it has been suggested that this non-specific finding 
reflects adaptive structural and functional reorganisation of peripheral nervous system 
rather than due to changes in CNS (Harte SE et al., 2018). Overall, this area needs more 
investigation to confirm or refute any role of small fibre neuropathy in central sensiti-
sation. 
1.12. Role of gliopathy in central sensitisation 
In addition to the above mechanisms, there is growing evidence that there is a potential 
role of glial cells in the initiation and maintenance of chronic pain. Three types of glial 
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cells which are said to be involved are microglia and astrocytes of CNS and satellite 
glial cells of dorsal root and trigeminal ganglia. (Ji RR et al., 2013). Some of the mech-
anisms involved are: upregulation of glial markers such as glial fibrillary acidic protein 
(GFAP) along with changes in glial network and synthesis and release of glial media-
tors like cytokines and chemokines. These glial mediators are found to be able to mod-
ulate excitatory and inhibitory transmission at pre, post, and extra synaptic sites. Detloff 
MR et al., described the contribution of dysfunctional glial mechanism in the develop-
ment of central neuropathic pain after spinal cord injury (Detloff MR et al., 2008). Thus, 
chronic pain could be due to a “gliopathy,” that is, dysregulation of glial functions in 
the central and peripheral nervous system. Further understanding of the role of glial 
cells in chronic pain and central sensitisation may help us to develop potential treatment 
strategies which target only the negative influence of glial cells and not the neurons.  
1.13. Clinical assessment of Central sensitisation 
Symptom characteristics of CS are observed across many different chronic pain condi-
tions (Julien N et al., 2005; Campbell JN et al., 2006; Drewes AM et al., 2006; Woolf 
CJ 2011; Nijs J et al., 2014; Fingleton C et al., 2015). It is difficult to diagnose as there 
is no universally accepted definition or guideline criteria for diagnosing CS. 
The Pain Sensitivity Questionnaire (PSQ) and the Central Sensitivity Index (CSI), are 
two instruments which have been developed and validated (Ruscheweyh R et al., 2009; 
Mayer TG et al 2012; Nijs J et al., 2014) to assess various clinically relevant pain rat-
ings. Significant correlations have been observed between PSQ scores and pain inten-
sity ratings (Ruscheweyh R et al., 2009; Sellers AB et al., 2013). 
The CSI was originally designed to capture the patient’s multiple somatic and emo-
tional symptoms relating to central sensitization (Mayer TG et al., 2012). Part A of the 
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CSI assesses 25 symptoms common to central sensitivity syndromes (CSS) with a Lik-
ert scale from 0 (never) to 4 (always).  
The total score ranges from 0 to 100, and higher scores indicate a greater degree of 
symptomology relating to CSS (Neblett R et al., 2013).  
Part B of the CSI helps ascertains whether subjects have previously been diagnosed 
with one or more specific CSS diagnoses. 
A CSI score>40 is deemed supportive of a diagnosis of CSS. The following severity 
ranges have been recommended:  
§ Subclinical = 0 to 29;  
§ Mild = 30 to 39;  
§ Moderate = 40 to 49; 
§ Severe = 50 to 59;  
§ Extreme = 60 to 100 (Neblett R et al., 2016). 
Validation studies on the CSI have indicated a high sensitivity and specificity for the 
presence of an underlying CSS. The initial psychometric validity and clinical utility of 
the CSI were evaluated in two parts. In the first section, the CSI was evaluated for test-
retest reliability and internal consistency. A factor analysis was then used to identify 
specific items.  
In the second section, validation was undertaken by comparing scores between four 
subject groups, including fibromyalgia (FM), chronic widespread pain (CWP), regional 
chronic low back pain (CLBP), and a normative control group (Mayer TG et al., 2012). 
A recent systematic review of the measurement properties of the CSI suggests that this 
assessment instrument yields reliable and valid data which can help quantify the overall 
severity of a CSS (Scerbo T et al., 2018).  
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The CSI is currently widely used as a useful tool to identify a CSS, however, its use as 
an alternative to measures relating to neuropathic pain is under debate. One clinical and 
experimental research method used for assessing pain sensitivity is by quantitative sen-
sory testing (QST) (Roger AC et al., 2018) (See below pg. 31). 
A few other questionnaires have been developed such as the pain DETECT question-
naire used for assessing neuropathic components in chronic musculoskeletal pain, e.g. 
Chronic low back pain (LBP) (Freynhagen R et al., 2006) and Osteoarthritis (OA) 
(Hochman JR et al., 2013). Recently, a mechanism-based classification was also devel-
oped by Smart (2012), which includes signs and symptoms suggestive of CS in patients 
with low back (leg) pain, but the authors did not adequately indicate how these criteria 
should be used in day to day clinical practice (Smart KM et al., 2012). 
To improve the assessment of any developing pattern of pain sensitisation, it is useful 
to undertake a clinical mapping of the pain including the referred pain areas, as well as 
mapping areas with sensory hyposensitivity or hypersensitivity which can be followed 
quantitatively over time.  
Receptive field expansion and perceptual changes into a more diffuse pattern of the 
pain can be observed in patients developing additional painful comorbidities for exam-
ple in patients with knee OA, development of hand OA is a risk factor for the presence 
of diffuse generalised pain (Thompson LR et al., 2010).  
1.14. Specific quantitative experimental tools for assessing CS 
Clinical Quantitative Sensory Testing (QST) is one of the proposed methods to assess 
degree of central sensitisation. The defining feature of altered pain processing seen in 
central sensitisation was originally demonstrated in conditions such as FM by eliciting 
tenderness on palpation. Thereafter, QST was utilised to characterise pain and sensory 
mechanism in CS (Arendt-Nielsen L 2015; Wylde V et al., 2017). Various stimuli 
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(thermal, electrical, chemical) are used, utilising different techniques (e.g. electrophys-
iology or imaging).  In this method, the stimulus (mechanical, thermal or electric) is 
undertaken systematically on the area under review. The responses to these stimuli 
which include nonverbal behaviour (e.g. withdrawal), unpleasantness, a rating of the 
perceived stimuli intensity is recorded to measure sensory gain or loss. The previous 
studies have demonstrated a bell-shaped distribution curve in pain sensitivity across 
general population and most patients with chronic pain conditions (as of CSS) were 
found to be to the right side of the distribution curve (Ablin K et al., 2009; Gwilym SE 
et al., 2009; Giesecke J et al., 2004).  
Clinical mapping of pain areas is also useful to understand whether a given condition 
is localised to a certain neuronal segment or has spread across segments (Arendt-Nelson 
L et al., 2018) 
The efficiency of endogenous pain modulation networks can be measured by QST. Fur-
ther QST measures which can elicit altered endogenous pain modulation in patients 
with central sensitization include assessments of painful after-sensations (pain sensa-
tions that are slow to disappear after termination of the painful stimulation (Staud R et 
al 2007), and a counterbalance analgesia (an out of balance reduction in perceived pain 
after a slight decrease in the intensity of painful stimulation. (Hermans L et al., 2016). 
Simple methods such as tapping the skin with a nylon filament can also be used as a 
bed side testing of cutaneous temporal summation (Nikolajsen L et al., 1996) but for 
more standardisation automated user-independent methods, for example, thermal 
(Kong JT et al., 2013), or pressure (Nie H et al., 2009) should be utilised. These tests 
are used to elicit temporal summation seen in CS (which refers to an increase in the 
perceived intensity of pain in response to repeated stimuli of equal physical strength). 
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Conditioned pain modulation (CPM) is believed to represent the human behavioural 
correlate of diffuse noxious inhibitory control (DNIC). DNIC alludes to the pain mod-
ulatory pathway, often described as ‘pain inhibits pain’ (Le Bars D et al., 1979). It 
happens when the response from a painful stimulus is inhibited by another noxious 
stimulus.  CPM methods probe for the absence or impairment of inhibitory mecha-
nisms. Although deficient CPM has been observed in a subset of healthy individuals 
(Potvin S et al., 2016; Schoen CJ et al., 2016), it is more common in individuals with 
FM and other chronic pain conditions (Granot M et al., 2008; Nir RR et al., 2015). 
Potvin S et al in 2016 proposed that the patients can be divided into two groups: 
1. CPM reducers (resulting in pain inhibition) 
 2. CPM increasers (resulting in pain facilitation)  
Another cohort study involving 2199 healthy volunteers demonstrates the distribution 
of CPM responses. This study hypothesises that those patients in the lower quartile 
could be more prone to develop chronic pain and those in the upper quartile who may, 
on the other hand, have a more protective CPM framework (Skovbjerg S et al., 2016). 
CPM viability decreases with age (Grashorn W et al., 2013) and is affected by gender 
(Martel MO et al., 2013) and psychosocial factors such as depression (Nahman-Aver-
buch H et al., 2016). This might explain why psychiatric and psychological disorders 
are sometimes associated with symptom correlates for central sensitisation (CS) in the 
absence of any specific peripheral nociceptive triggers.   
A metanalysis undertaken in 2012 confirmed that CPM is debilitated in the majority of 
chronic pain conditions (Lewis GN et al., 2012) and clinically decreased CPM corre-
sponds to increased postsurgical pain and analgesia requirements, with the successful 
response to centrally acting analgesics (Edwards RR et al., 2005; Yarnitsky D 2015).  
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In summary, despite the multiplicity of experimental and clinical evaluations that have 
been undertaken on central sensitisation, there is a continuing paucity of understanding 
regarding its pathophysiological basis. In addition, variation has been observed in the 
development of the degree of sensitisation across different chronic pain patients sug-
gesting that central sensitisation may be a spectrum instead of being a dichotomous 
concept (i.e. present or absent). 
The clinical manifestations of CSSs may vary in different individual in different pain 
conditions. Therefore, there is a growing need to develop specific assessments to ana-
lyse sensitisation in specific pain conditions. For instance, having specific tools to an-
alyse the presentation of CS in musculoskeletal as opposed to visceral chronic pain 
conditions.  
Moreover, the scientific endeavour of linking pain phenotype with the treatment out-
come (surgical, conservative) in the context of pain is still at an early stage. It is also 
essential that tools are also developed which can improve the sensitivity and specificity 
of the predictors of the treatment outcome (Arendt-Nielsen L 2018). 
1.15. Pelvic organ Prolapse and central sensitisation 
Pelvic Organ Prolapse is a herniation of the pelvic organs (uterus, cervix, bladder, rec-
tum) through the vagina due to loss of pelvic floor support (muscle and fascia) usually 
secondary to childbirth injury.   
Pelvic organ prolapse (POP) is a frequent indication for hysterectomy and pelvic sur-
gery in women, with an annual age-related (surgical) incidence in the range of 10 to 30 
per 10,000 women confirmed in several large surgical database studies. For example, 
the National Health Service (England) Hospital Episode Statistics (HES), shows that 
the number of admissions for prolapse surgery was 1/1000 women in 2005 (Dhinagar 
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S et al., 2009). Out of 194,107 urogynaecology patients, 71,350 (36.6%) had prolapse 
surgery between 2008 and 2017 in England (HES data 2018). 
Around one in 12 women reports symptoms of prolapse (Cooper J et al., 2015) with a 
lifetime risk of surgery of 12-19% (Olsen AL et al.,1997; Wu JM et al., 2014; Smith FJ 
et al., 2010). These numbers might increase with the increasing ageing population and 
rising obesity (De sam Lazaro S et al., 2016). 
The population prevalence for POP beyond the hymen (>stage 2) is probably between 
3 and 6%, however the loss of uterine support or vaginal support is seen in 30-76% 
women populations seeking gynaecological care. (Ellerkmann RM et al., 2001; Swift 
SE 2000; Trowbridge ER et al., 2008).  
The prevalence of POP increases with age. There are suggestions that prevalence in-
creases by 40% with each decade of life (Swift S et al., 2005). 
The risk factors for pelvic organ prolapse are higher parity (Mant J et al., 1997), vaginal 
childbirth (Lukacz ES et al., 2006), and forceps delivery (Moali PA et al., 2003), ad-
vancing age (Swift S et al., 2005), obesity, chronic constipation, occupations involving 
heavy lifting, and connective tissue disorders such as those associated with variation of 
collagen type1 gene (COL1A1) (Cartwright R et al., 2015). 
The principal symptom manifested in prolapse is the feeling of a bulge within the 
vagina that can be seen or felt (Barber MD et al., 2006). A significant proportion of 
women might also complain of a dragging sensation or pelvic pressure (Barber MD 
2005). Other associated symptoms include urinary incontinence, overactive bladder, 
voiding difficulty, position change to start or complete voiding, incontinence of flatus 
or faeces (liquid or solid), a feeling of incomplete emptying, faecal urgency, 
dyspareunia, decreased sensation or pain in the vagina, bladder or rectum.  
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Women can present with single or combination of symptoms. Other than the vaginal 
bulge, none of the symptoms are specific for POP and considerable overlap exists with 
other pelvic floor disorders (Barber MD et al., 2006). 
Pelvic examination is required to define the extent of POP/prolapse and also to identify 
the segments of the vagina affected. The pelvic organ prolapse quantification system 
(POPQ) is the grading system for prolapse with the highest reliability and is the most 
widely used system. This examination defines systematically the amount of anterior, 
posterior, and vault/apical segment prolapse in centimetres relative to a fixed anatomi-
cal structure—the vaginal hymen (Bump RC et al., 1996).  
Additional testing is required only when associated bladder or bowel symptoms are 
present e.g. urodynamics, defecating proctography, anal manometry, and imaging.   
The treatment options for the management of POP include both conservative and sur-
gical management. The conservative management strategies are pelvic floor muscle 
training (PFMT) and insertion of a vaginal pessary along with lifestyle advice e.g. 
weight and avoiding constipation. Supervised pelvic floor muscle training is advised to 
be undertaken at least for 12-16 weeks (Hagen S et al., 2014; Wiegersma M et al., 
2014). Hagen S et al showed improvement in prolapse symptoms in 45% of women 
whereas, Wiegersma M et al in her study demonstrated improvement in all prolapse 
symptoms in 57% of women with POP following 3 months of PFMT. 
Vaginal Pessaries are the mechanical devices inserted in the vagina to reduce the pro-
lapse. There are different type of pessaries (e.g. Gellhorn, ring, shelf). Cundiff GW et 
al (2007) conducted a randomised crossover trial to compare symptom relief of POP 
with ring pessary (with support) and Gellhorn pessary. They found that both types of 
pessaries are effective and equal in relieving symptoms of bulge, protrusion and voiding 
difficulties (Cundiff GW et al., 2007). However, overtime a majority of women opts to 
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discontinue the pessary. Sarma S et al in 2009 found that only 13.7% women continued 
using pessaries for the treatment of pelvic organ prolapse over a period of 6 years. 
About 27.5% discontinued due to complications experienced and 29.9% discontinued 
as they wanted the surgery. Various complications encountered were bleeding, extru-
sion, pain, vaginal discharge etc and the complication rate noted in this study was 56% 
(Sarma S et al., 2009). 
The aim of the surgical treatment is not only to restore anatomy but also to improve 
bowel, bladder, and sexual function. Surgery is usually offered to women who have 
failed conservative treatment and/or with a stage 2 POP or beyond on examination and 
who report bothersome symptoms. The risks associated with surgery include haemor-
rhage, recurrence, trauma to bladder, bowel, internal organs, dyspareunia.  
It is therefore important to assess the symptoms and their effect on quality of life in 
order to select the appropriate treatment and in some cases by preventing unnecessary 
surgery with its attendant risks.  
For example, in the clinical setting, it has been observed that a significant proportion 
of women can present with heaviness or dragging sensation without a physically con-
firmed bulge/prolapse on examination. It is known that anomalies exist between the 
pathology i.e. prolapse and the degree of dragging sensation experienced by the patient. 
A mechanism suggested to explain this anomaly, describes the augmentation of pain 
transmission secondary to central sensitization (CS). Thus, the explanation is similar to 
the pathophysiological changes postulated for central sensitivity syndromes like Fi-
bromyalgia and chronic fatigue syndrome.  
Specific presentations such as hyperacusis (increased sensitivity to sounds, usually to 
specific frequencies and volumes) are significant but under recognised symptoms in 
conditions such as FM (Aries PS et al., 2017); Could a dragging sensation in the 
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absence of objective prolapse also be a poorly understood symptom of FM or other 
CSSs rather than due to prolapse? Current medical literature provides little clarification 
to this question. 
Some evidence base relates to the potential role of Levator myalgia as a contributor to 
pelvic floor pain and sexual dysfunction. This has been reported in 24% of female pa-
tients attending a urogynaecologists practice (Adams K et al., 2013). 
Levator myalgia might be considered as another manifestation of central sensitisation, 
with pain as well as pelvic pressure, vaginal bulge, and urinary and defecatory dysfunc-
tion (Adams K et al., 2014).  
Previously studies have shown that female patients with fibromyalgia (FM) are more 
likely to have had a hysterectomy compared with those without FM and that their sur-
gery does not relieve the symptom of pain (Pamuk ON et al., 2009; Santro MS et al., 
2012).  
Likewise, patients with Chronic Pelvic Pain (CPP) when contrasted with those without 
CPP appear to have worse outcomes or even worsening of the symptoms after revision 
following transvaginal mesh surgery for POP (Danford JM et al., 2015).  
FSSs were found to be an independent risk factor for hysterectomy in patients with 
bladder pain syndrome (BPS)/interstitial cystitis (IC). A retrospective study by Warren 
et al demonstrated that 12% of women with BPS/IC underwent hysterectomy (Warren 
JW et al., 2014). The risk of hysterectomy was higher in the patients with BPS/IC than 
in non-BPS/IC cohort (Lee MH et al., 2016). It was suggested that women who have 
multiple FSSs and think that hysterectomy might relieve their pain should try alterna-
tive therapies including treatment of the FSSs rather than surgery (Warren JW et al., 
2014). 
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Female patients with FM appear to report considerably more severe symptoms relating 
to pelvic floor complications compared to women without FM when attending urogy-
naecology practices although they had been in the similar age group (Jones K et al., 
2015). It is considered possible that enhanced sensory and nociceptive processing may 
raise the level of awareness amongst female patients regarding the symptoms of organ 
prolapse in comparison with patients without FM. It has been suggested that this en-
hanced sensory processing could be due to the lack of activation of endogenous inhib-
itory systems (Julien N et al., 2005).  
The available literature also provides little further clarification as to whether women 
with FM have different outcomes from the surgical treatment of pelvic organ prolapse 
than women without FM (Jones K et al., 2015). This information could have an im-
portant influence on decision making particularly as to whether to continue conserva-
tive treatment rather than offer surgical intervention. 
1.16. Summary and Purpose of the study 
The findings observed so far from this review can be summarised as follows:  
FSSs or CSSs can be considered as important sources of increased clinical complexity 
for healthcare service providers. These conditions have a negative effect on QOL and 
affect patient care.  Central sensitisation appears to be the common underlying potential 
mechanism. 
POP is a dysfunction of pelvic floor support. This can have a detrimental effect on QOL 
and is seen in 30-70% of gynaecological consultations. The most predominant symp-
tom of prolapse is the feeling of a vaginal bulge. However, a considerable proportion 
of women report a sensation of dragging or pelvic pressure vaginally without a bulge 
or large objective prolapse being present. 
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Levator myalgia is indicated to be present in 24% of gynaecological patients presenting 
with pelvic pain. This might represent another form of central sensitisation in women 
with pelvic floor dysfunction. It may present as a dragging sensation and pelvic pres-
sure. 
Women with CSSs or FSSs have high symptom bother with such symptoms of prolapse 
compared with women without CSSs. 
These conclusions appear to support the hypothesis that women presenting predomi-
nantly with a dragging sensation / pelvic pressure but not a vaginal bulge could have 
underlying FSS or CSS contributing to their symptoms.  
Surgery for prolapse is usually considered after conservative management has failed 
and when the degree of bother or symptoms of the prolapse are perceived to be greater 
than the risks of surgery. Owing to increased bother, women with evidence of CSS 
might request treatment for prolapse at a stage of descent that would typically be con-
sidered less significant e.g. stage 1 on POP-Q.  
Studies have demonstrated that if a patient carries a diagnosis of fibromyalgia, 35 % of 
women reporting a bulge will have the leading edge of the prolapse within the hymen 
i.e. not thought to be clinically significant (Adams K et al., 2014). Surgery might not 
improve the bulge or pressure sensations in these patients and could lead to a “mis-
match” between patient and physician expectations. Without an understanding of this 
mechanism, such patients may undergo additional surgical procedures without a suc-
cessful outcome. 
There may be a time critical component to successful surgery: requiring intervention 
before the onset of enhanced pain response (Petersen KK et al., 2015b). For example, 
those patients with pain after revision surgery may have continued enhanced temporal 
summation within the central nervous system as compared with patients without pain 
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(Skou ST et al., 2013) resulting in exacerbation of more diffuse pain after further sur-
gery (Skou ST et al., 2014a). 
The current state of understanding has raised several questions including:  
§ What is the impact of CSSs in the development of chronic postoperative pain 
after prolapse surgery? 
§ What is the role of CSSs in predicting the success of surgical treatment for pro-
lapse?  
§ Could dragging sensation be one of the symptoms seen in patients with CSSs? 
§ Does identifying and understanding CS/CSS help patients to have more realistic 
expectations from treatment and prevent disappointments? 
§ Is CS a useful conceptual construct for explaining reduced surgical success in 
those with CSS? 
§ How should the perioperative management strategies be optimised in the pres-
ence of CSSs? i.e. how do you choose the right treatment for the patients with 
CSS? Is there a downregulatory cascade i.e. is there any way by which the 
heightened pain response can be downregulated or minimised? 
The aim of this study is to enable us to explore in depth some of these questions. The 
study consists of five parts as following: 
§ To capture the awareness of central sensitisation and CSS amongst gynaecol-
ogists and allied health professionals dealing with women with pelvic organ 
prolapse.  
§ To identify the proportion of women having evidence of CSSs presenting with 
different gynaecological disorders. Before conducting this part of the study, fac-
tor analysis of CSI was undertaken in our cohort to decide whether a total score 
or a subset should be used to identify women with CSS. 
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§ To conduct a systematic review and a critical appraisal of literature on clinical 
outcomes of surgery in patients with CSS   
§ To compare the outcome of pelvic organ prolapse surgery in women with and 
without evidence of CSSs.  
§ A qualitative study of patients with CSS who’ve feel they have had a poor out-
come following surgery i.e. with persistent or new symptoms. The purpose of 
the interviews will be to explore a patient’s perception of the effectiveness of 
surgery for their condition. 
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Chapter 2 – A survey on “Awareness of Central Sensitivity Syndromes and Cen-
tral Sensitisation amongst gynaecologists and healthcare professionals dealing 
with pelvic organ prolapse.” 
Abstract- 
Background- 
Central sensitisation (CS) has been found to contribute to many unexplained medical 
symptoms as in functional somatic disorders or central sensitivity syndromes (CSS). 
The clinical management of these group of patients can become quite challenging due 
to lack of awareness of coexisting CSS. This study aims to capture the awareness of 
CS/CSS amongst health professionals dealing with pelvic organ prolapse (POP). 
Method: 
This was a single point online survey of understanding about central sensitisation and 
its potential role in pelvic organ prolapse. The survey was undertaken in month of Au-
gust 2017and sent to urogynecologists, gynaecologists (UK), to members of South 
Wales Incontinence group and General practitioners (Wales) by a single electronic 
mailing of the questionnaire. The responses were in either yes /no or in form of rarely, 
occasionally, frequently and always respectively.  
Result: 
 A total of 70/200 (35%) responded to the survey. Thirty -four (48%) do not believe 
that there is an element of central sensitisation where the symptoms are out of propor-
tion to the objective prolapse. Significant number (45%) of health professionals are 
unaware that patients with fibromyalgia or CFS or vaginal pain have high bother with 
their symptoms. Similarly, significant number of health professionals have not heard 
the term central sensitisation or Central sensitivity syndrome (CSS) (48.5%). 
Conclusion 
Our survey identified the gap in knowledge about CS among health professionals 
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dealing with pelvic organ prolapse (POP). It is clear that there is need for more under-
standing of CS/CSS and its role in POP 
Key words: Central sensitisation, Pelvic organ prolapse, gynaecologists, awareness, 
survey 
2.1. Introduction 
Pelvic Organ Prolapse (POP) can profoundly affect a woman’s quality of life. Around 
1 in 12 women living in the UK report symptoms of pelvic organ prolapse (Cooper J et 
al., 2015). However, frequently clinicians come across a clinical situation where symp-
toms are out of proportion of objective prolapse. As mentioned earlier this discrepancy 
might be due to variation in the processing of sensory stimuli.  
The suggested mechanism involves the augmentation of pain/dragging transmission 
secondary to a process known as central sensitisation (CS) which has been suggested 
to be a contributor to many unexplained medical conditions as in functional somatic 
disorders or central sensitivity syndromes (CSS) (Woolf CJ 2011). The issues with 
CSSs and central sensitisation might be overlooked by the clinicians due to lack of 
awareness regarding these conditions and this phenomenon (Kaur P et al., 2015). As a 
result, the management of these patients could be compromised with poor patient-re-
ported outcomes leading to frustration and dissatisfaction amongst both clinicians and 
patients. 
Although there is growing recognition of CSSs, variation exists in professional 
knowledge and understanding among different specialities of medicine. This forms the 
basis of the current survey distributed to general gynaecologists, urogynaecologists, 
continence nurse specialists, general practitioners and physiotherapists who manage 
women with Pelvic Organ Prolapse (POP). 
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The purpose of this study was to capture the awareness of the concept of central sensi-
tisation and CSSs amongst healthcare professionals dealing with pelvic floor dysfunc-
tion including general gynaecologists, urogynecologists, continence nurse specialists, 
general practitioners and physiotherapists.  
We hypothesise that there is - 
1. Suboptimal awareness about the existence of central sensitisation amongst this 
group of healthcare professionals. 
2. Suboptimal awareness of the increased bother with symptoms of pelvic organ pro-
lapse in patients with Central Sensitivity Syndrome. 
2.2. Method 
This was a single point on-line survey of understanding about CS/CSSs amongst 
healthcare professionals dealing with pelvic floor dysfunction. The survey was sent to 
urogynaecologists, gynaecologists (UK), physiotherapists, continence nurse specialists 
and General practitioners (Wales) who were members of Wales incontinence group by 
a single electronic mailing of the questionnaire. Closed questions were used in an at-
tempt to have a better response rate (O’Brien S et al., 2016).  
The questions were designed by a group of sub-specialists urogynaecologists with as-
sistance from a clinical psychologist and cover domains in which it was felt that there 
was a lack of understanding about CSS and central sensitisation. (survey questionnaire 
attached in appendix section: page 201) 
For example, 1) Whether they have heard about central sensitivity syndromes and what 
are the common conditions contributing to the term central sensitivity syndrome. 2) 
Whether they see patients with symptoms of prolapse out of proportion to the objective 
prolapse. The responses were in a yes /no format and if a ‘yes’ response to elaborate 
whether this was: rarely, occasionally, frequently or always. Before rolling out the 
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survey, a pilot was undertaken in the local department to six health professionals in-
cluding 2 gynaecology consultants, 2 physiotherapists, 1 continence nurse specialist 
and 1 obstetrics and gynaecology trainee. This was done to check that the related cate-
gories had been covered and to check for the understanding of the survey. Minor 
amendments were done to the final survey based on the responses. Survey Monkey was 
used to collate and analyse the responses to the questionnaire.  
All questions and responses are listed in tables 1-7. The result was analysed on com-
plete datasets following closure at 12 weeks after initial circulation. Two  
reminders were sent at 4 and 8 weeks after the initial circulation to all potential  
respondents. Statistical significance was calculated using one sample t-test. XLSTAT 
was used for statistical analysis. 
2.3. Result 
The initial invitation went to 200 healthcare professionals. A total of 70/200 (35%) 
responded to the survey. Of those 31% responded after initial circulation, 44% after the 
first reminder and 25% after the second reminder. The survey covered responses from 
both primary care (represented by GP’s in the group) and secondary care. Out of 70 
responses, 48 were gynaecologists with 22 being urogynaecologists, 13 were GP’s, 7 
were physiotherapists and 2 were continence nurse specialists (Table 1). 
Thirty-three (47%) out of 70 responded that they encounter majority of the time with 
patients where the predominant complaint about prolapse is a dragging sensation rather 
than a bulge. (Table 2). Twenty-eight (40%) felt that they frequently see patients where 
symptoms are out of proportion to the objective prolapse (Table 3).  
Thirty-four (48.6%) do not believe that there is an element of central sensitisation where 
the symptoms are out of proportion to the objective prolapse findings and 10 (14.2%) 
do not know (Table 4). A Significant number (32/70 -45.7%) of healthcare 
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professionals were unaware that patients with fibromyalgia or CFS or vaginal pain have 
higher bother with their symptoms than those without these conditions (table 5). Simi-
larly, a significant number of healthcare professionals had not heard the term Central 
Sensitisation or Central sensitivity syndrome (CSS) (48.6%). (Table 6)  
Table 1: Showing the response to Q1- Describe your role. 
Role Number-70 (100%) 
Gynaecologist with a special interest 
in urogynaecology 
16 (22.9%) 
Subspecialist urogynaecologists 6 (8.6%) 
General Gynaecologists 26(37.1%) 
Physiotherapist 7(10.0%) 
Continence specialist nurse 2(2.8%) 
General practitioner 13(18.6%) 
 
Table 2: Showing the response to Q2-How often do you see patients with pelvic organ prolapse com-
plaining of dragging sensation rather than bulge? 
Frequency Number(n-70) 
Rarely (once in 2-3 months) 15(21.5%) 
Occasionally (once in a month) 22 (31.5) 
Frequently (every week) 28 (40%) 
Almost always (every patient) 5 (7%) 
 
Table 3: Showing the response to Q3- In your practice how often do you see patients whose symptoms 
of prolapse are out of proportion to/ with the degree of prolapse? 
Frequency Number (n-70) 
Rarely (once in 2-3 months) 16 (22.8%) 
Occasionally (once in a month) 26 (37.2%) 
Frequently (twice in a month) 25 (35.7%) 
Almost always (every week) 3 (4.3%) 
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Table 4: Showing the response to Q4- Do you believe that there is an element of central sensitisation in 
women where their symptoms are out of proportion to the objective prolapse? 
Yes 26(37.2%) 
No 34(48.6 %) 
Do not Know 10 (14.2% 
 
Table 5: Showing the response to Q5- Do you believe that women with Fibromyalgia, chronic fatigue 
syndrome, ME or some vaginal pain have worse symptoms than women who do not have these condi-
tions? 
Yes 38 (44.3%) 
No 4 (5.7%) 
Do not Know 28 (40%) 
 
Table 6a: Showing the response to Q6 ‘a’ - Have you heard the term central sensitivity syndrome? 
Yes 36 (51.4%) 
No 34 (48.6%) 
 
Table 6b: Showing the response to Q6b -Please circle the following conditions that can contribute to 
central sensitivity syndrome 
Conditions responses 
Fibromyalgia 8 
Chronic fatigue syndrome 47 
Migraine 3 
Anxiety 0 
Depression 5 
Neck whiplash injury 0 
Temporomandibular joint dysfunction 0 
All of the above 13 
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Table 7: Showing responses amongst different health care professionals for questions 2-6 
 
The group of physiotherapists and urogynaecologists within the group were more aware 
of CSS/CS compare to other groups (GP, general gynaecologist and incontinence nurse 
specialist).  (Table 7) 
As shown in table 7 urogynaecologists seems to have more awareness about CS com-
pared to other groups but the number were small. To eliminate the risk of under cover-
age bias we conducted another survey to British Society of Urogynaecologist (BSUG). 
The society is a nationally accredited society for urogynaecologists and hence, allows 
us to capture a wider perspective about patients with pelvic floor dysfunction.  
The BSUG research committee approves the survey and the timing of survey and I was 
allowed to conduct the survey in the month of October 2018. By this time, I had some 
preliminary results from the cross-sectional study. Hence, thought of repeating the sur-
vey with 3 additional questions. These questions were added in order to help us identify 
the areas of future research regarding management of women with pelvic floor 
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dysfunction and CSS. The questions were designed in the MDT group involved in the 
care of patients with pelvic floor dysfunction at Singleton Hospital, Swansea. The group 
involved, continence nurse advisor, Urogynecologists, physiotherapist and psycholo-
gist. Additional questions were as follows-  
1. Do you feel that there is a need of understanding the role of CS in pelvic floor dys-
function?. The responses were in the form of Agree, Disagree, neither agree or disagree. 
2. Do you think we should screen patients for symptoms suggestive of CSS’S before 
offering Pelvic Organ Prolapse surgery? The response were in the format of yes/no and 
not sure. 
3. Do you think that patients with CSS should have a trial of other treatment strategies 
such as myofascial release, Cognitive Behavioural therapy or using neuromodulators 
eg gabapentin before pelvic organ prolapse surgery? 
The survey was piloted again within the department with these extra questions before 
submission to the BSUG research committee. 
After the pilot, the survey was submitted to the BSUG research committee for their 
approval. The research committee checks the appropriateness of the questions and topic 
of the survey. Once the survey was approved, it was sent out to the BSUG members by 
the BSUG administration staff via the survey monkey link. Two reminders were sent 
at 6 and 10 weeks before the survey was closed in 12 weeks. Total 61 responses were 
received. The survey confirmed the results of the previous survey. Although, majority 
of them felt that women with FM, CFS or ME have worse symptoms, only 52% be-
lieved that there is underlying central sensitisation (CS) or heard the term CS.  Majority 
(72%) agree that there is need of understanding of the role of CSS’s/CS in pelvic floor 
dysfunction. However, only 32% believed that we should routinely screen for CSS and 
offer them alternate treatment before pelvic organ prolapse surgery. (Table 8-10) 
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Table 8: Showing response by BSUG members to question- Do you feel that there is a need of under-
standing the role of CS in pelvic floor dysfunction 
Response Total no-61 
Agree 44(72.13%) 
Disagree 3 (4.92%) 
Neither agree or disagree 14(22.95%) 
 
Table 9: Showing response by BSUG members to question- Do you think that we should screen for symp-
toms suggestive of CSS’S before offering Pelvic Organ Prolapse surgery ? 
Response Total no-61 
Yes 20(32.79 %) 
No 18 (29.51%) 
Not Sure 23 (37.70%) 
 
Table 10: Showing response by BSUG members for question-  Do you think that patients with CSS should 
have a trial of other treatment strategies such as myofascial release, Cognitive Behavioural therapy or 
using neuromodulators eg gabapentin before  pelvic organ. 
Response Total no-61 
Yes 19(31.15%) 
No 12(19.67%) 
Not Sure 30 (49.18%) 
 
2.4. Discussion 
Our survey demonstrated that a significant number of healthcare professionals dealing 
with pelvic organ prolapse encounter women where their symptoms of prolapse are out 
of proportion to the objective prolapse. A significant proportion of them were not aware 
that women with conditions such as fibromyalgia or CFS, may have increased bother 
with their symptoms of pelvic organ prolapse and nearly half of them are unaware of 
the terms Central sensitisation or Central Sensitivity Syndrome. 
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Patient management and treatment choices are based on an understanding of the disease 
or disorder patterns. In the absence of this, the symptoms and distress for the patients 
can persist. This can impact adversely on patient well-being as well as the patient-doc-
tor relationship. (Marianne R et al., 2017).   
It has already been established that women with fibromyalgia, CFS, (CSSs) seek inter-
ventions at a stage which is clinically less significant than those without these condi-
tions due to increased bother from their symptoms (Adams K et al., 2014). In these 
women, a lack of understanding of the underlying CSS conditions can lead to misdiag-
nosis and as a result inappropriate and ineffective therapies including surgical interven-
tion. For example- such women can have pain in other parts of the body such as the 
bladder, bowel, and pelvic floor muscles with or without evidence of pathology e.g. 
endometriosis and end up with multiple laparoscopies and/or hysterectomy. 
Managing patients and their expectations where symptoms are inconsistent with the 
observable pathological findings can be challenging. Some might consider surgery to 
be the appropriate treatment and so awareness of the phenomenon of central sensitisa-
tion and presence of underlying central sensitivity syndromes by clinicians might help 
to focus on treatment strategies which are less invasive and potentially provide a better 
outcome e.g. those related to the central nervous system such as medication, exercise, 
mindfulness, and cognitive behavioural therapy. This might also avoid unnecessary sur-
gery (Barron K 2017) with its attendant risks and possibly improved patient satisfac-
tion. 
Raising awareness about Central Sensitivity Syndromes should be widened to include 
not only pain specialists who regularly manage patients with these presentations but 
also other relevant clinical disciplines including GP, surgery, and gynaecology. This is 
of great significance, as chronic pain patients often are unable to comprehend why a 
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relatively minor trauma (such as localised knee/ shoulder injury or perineal repair) or 
in some having no confirmed trauma can result in disabling pain. Explaining that the 
pain system is a dynamic system which undergoes changes, can help the patients to 
have a better understanding of their current situation (Arendt-Nielson L et al., 2018). 
This can also help the clinician to offer appropriate treatment strategies. 
The strength of our survey is that this is the first survey (to our knowledge) to explore 
the understanding of CSS among Gynaecologists and other healthcare professionals.  
The main limitation of the survey is that the numbers are small and possibly unrepre-
sentative of all clinicians. Because of low response rate there is an element of under 
coverage bias . There may be also a geographical effect on the responses of the clinician 
as there can be variation in the complexity of cases encountered by clinicians (some 
areas see more complex cases than others). Also, the results showing contradictory re-
sponses may be due to the fact that some clinician esp primary care physicians and 
continence nurse specialist may not manage women with pelvic organ prolapse and 
refer them to see specialists in first instance. In order to eliminate these shortfalls, we 
repeated the survey with the urogynaecologists (who routinely manages women with 
pelvic organ prolapse) nationally. However, we still need further survey to assess global 
awareness amongst the health care professionals managing pelvic floor dysfunction. 
2.5. Conclusion 
 Our survey appears to have identified a gap in knowledge about Central Sensitivity 
Syndromes and phenomenon of central sensitisation amongst clinicians and other 
health care professionals managing women with pelvic organ prolapse. It is clear that 
there is a growing need for more understanding of central sensitivity syndromes and its 
relevance to patient’s symptoms as lack of it might affect decision making and the out-
come of treatment. Understanding about CSSs might enable different management 
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strategies and reduce unnecessary surgical intervention. The survey has also identified 
the need of future research to assess the effect of downregulation of central sensitisation 
in symptoms of pelvic floor dysfunction. 
Future research ideas- 1. To conduct the survey amongst members of International 
and European Urogynaecology Society to assess global awareness of CSS/CS in 
healthcare professionals dealing with pelvic floor dysfunction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 
 
Chapter 3a - Factor analysis of CSI in a cohort of women attending Gynaecology 
outpatient Department (GOPD) 
Abstract- This part of the study aimed to perform a factor analysis of CSI in a cohort 
of women presenting in GOPD with various gynaecological problems to reveal the un-
derlying structure in this cohort. Factor analysis of the CSI collected from the period of 
March 2014 to June 2014 from patients presenting in GOPD at University Hospitals 
Plymouth NHS Trust was conducted. 333 questionnaires were evaluated. The results of 
this part of the study supported the use of the total cut off score rather than subset scores.  
3a.1. Introduction 
As alluded to in the literature, Central Sensitization (CS) refers to the amplification of 
neural signalling within the central nervous system (Woolf, 2011). Various mechanism 
have been described such as dysregulation of ascending and descending tracts in the 
CNS (Yunus 2007, Heinricher et al., 2009), overactivation of glial cells (Nijs et al., 
2017), excess production of brain-derived neurotrophic factor (Phillips and Claw 2011) 
and dysfunction of the stress system (Van Houdenhove & Luyten, 2009). Initially, CS 
had been considered as an explanatory mechanism in Fibromyalgia but now has also 
been proposed to be responsible for chronic pain in other patients with evidence of 
tissue trauma or pathology e.g. multiple sclerosis (Fernandez-de-las-Pefias et al., 2015), 
Osteoarthritis (Akinci et al., 2016) and post-surgical breast pain (Fernandez -Lao et al 
2011) as well as in conditions where the pain is not the dominant symptom, such as in 
– post-traumatic stress disorder, multiple chemical sensitivities, restless leg syndrome 
(Yunus, 2015) and overactive bladder (Reynolds et al., 2016). Yunus described these 
latter groups of disorders collectively under the umbrella term Central Sensitivity Syn-
dromes. It was also evident in the literature that various other symptoms such as insom-
nia, feeling “unrefreshed” after sleeping, difficulty concentrating, some bladder or 
bowel problems and fatigue are frequently noted within these disorders (Yunus, 2015). 
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As well as these aforementioned co-morbid symptoms, psychiatric disorders, emotional 
symptoms (anxiety and depression) and childhood abuse experiences are associated 
with CSS (Phillips and Clauw., 2011). Thus, the CSI was developed incorporating 
many of these features/symptomologies.  
The CSI was originally composed to screen symptoms suggestive of the presence of 
CSS (Mayer et al., 2012). The items of this inventory were evolved from an extensive 
literature search around somatic and emotional health-related symptoms found in these 
conditions. It contains a heterogenous list of 25 questions (widespread pain, sleep dis-
turbance, digestive and urologic symptoms etc). The CSI has been validated in various 
languages such as English, French, Serbian, Gujrati, Dutch, Spanish and Brazilian. 
However, factor analysis in these different languages has yielded conflicting results. 
Factor analysis has been undertaken of the original version developed in English in a 
cohort of subjects having chronic musculoskeletal pain disorder. This determined 4 fac-
tors (domains) with 3 items not loading to any of the factors. It has been suggested that 
the overall score, and not the scores of any individual domain is most appropriate for 
use.  
This study aimed to conduct a factor analysis of CSI in our cohort of women with gy-
naecological conditions presenting in the Plymouth gynaecology outpatient department 
to have a better understanding of the patient’s symptom presentation to draw specific 
patient profiles based on these domains and also to consider whether a particular do-
main can be used for screening instead of a total score. 
3a.2. Method 
This was a prospective study conducted at a tertiary University hospital and was ap-
proved by the West of Scotland Research Ethics Committee. The study was conducted 
from March 2014 to June 2014. All women attending GOPD and were above the age 
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of 18 were included in the study. Women who were not able or willing to consent were 
excluded. The patient information leaflet was sent to all women before the clinic ap-
pointment. All women were asked to complete a validated Central Sensitisation Inven-
tory (CSI) (see pg. 30) whilst they were in the clinic waiting area prior to their appoint-
ment. 
Factor analysis was then conducted on the collected CSI. This is a statistical method to 
reduce a collected dataset into a set of measurement variables (domain scales) based on 
correlations (Meyer et al 2012). To evaluate the suitability of data for factor analyses, 
the Kaiser-Mayer-Olkin measure of sample adequacy and the Bartlett test of Sphericity 
was used and to produce the results comparable to that original reported by Meyer 
(Meyer et al 2012), a principal component analysis (PCA) was carried out using oblique 
PROMAX rotation. Items obtaining a factor loading of >0.4 were retained and the num-
ber of suggested domains were indicated by components achieving Eigenvalue (raw 
sum of the squares) of 1 or more. The cut off for the loading was set at 0.4. Cronbach’s 
alpha coefficient which reflects the average intercorrelations among items was used to 
test internal consistency. The acceptable value being reported between 0.70-0.90 
SPSS version 26.0 was used to conduct the statistical analyses 
3a.3. Results 
Three hundred and thirty-three questionnaires were completed. The majority of the 
items did not have questionable univariate normality based on their skewness and kur-
tosis values (Table 11). The items obtained a corrected item-total correlation that was 
higher than the rule of thumb” minimal value of 0.25 (Devellis RF, 2006)  
The Kaiser- Mayer-Olkin (KMO) test revealed a coefficient of 0.895 and the Bartlett 
test of sphericity demonstrated the figure of 2072.120(p 0.000) indicating the sampling 
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adequacy was excellent and confirming that the correlation matrix was suitable for fac-
tor analysis.  
 
 
Table 11: Showing descriptive statistics for the factor analysis of CSI. 
 
N 
Mini-
mum 
Maxi-
mum Mean 
Std. Devia-
tion Variance Skewness 
Statistic Statistic Statistic Statistic Statistic Statistic Statistic 
Std. 
Error 
I1 331 .00 4.00 2.1752 1.05577 1.115 -.138 .134 
I2 331 .00 4.00 2.1631 1.17961 1.391 -.097 .134 
I3 328 .00 4.00 .8476 1.02025 1.041 .987 .135 
I4 327 .00 4.00 .9572 1.18192 1.397 .846 .135 
I5 330 .00 13.00 1.7879 1.38725 1.924 1.691 .134 
I6 326 .00 4.00 .6350 1.10044 1.211 1.612 .135 
I7 329 .00 14.00 .9301 1.39620 1.949 3.182 .134 
I8 328 .00 4.00 1.8750 1.20127 1.443 .051 .135 
I9 328 .00 4.00 1.0915 1.21315 1.472 .868 .135 
I10 329 .00 4.00 1.7356 .97216 .945 .170 .134 
I11 329 .00 4.00 1.4438 1.21626 1.479 .408 .134 
I12 330 .00 4.00 2.1212 1.19669 1.432 .011 .134 
I13 328 .00 4.00 1.6646 1.08522 1.178 .308 .135 
I14 327 .00 4.00 1.5902 1.28594 1.654 .365 .135 
I15 328 .00 4.00 1.7043 1.21448 1.475 .160 .135 
I16 329 0 4 1.64 1.093 1.194 .185 .134 
I17 330 .00 4.00 1.9091 1.12889 1.274 .027 .134 
I18 332 .00 4.00 1.8283 1.30212 1.696 .016 .134 
I19 330 .00 4.00 .6879 1.01785 1.036 1.369 .134 
I20 328 .00 4.00 .5793 .97042 .942 1.734 .135 
I21 323 .00 4.00 2.2724 1.24115 1.540 -.284 .136 
I22 325 .00 4.00 1.7323 1.34682 1.814 .169 .135 
I23 327 .00 4.00 1.6850 1.05458 1.112 .168 .135 
I24 309 .00 4.00 .5210 1.01469 1.030 1.894 .139 
I25 319 .00 4.00 1.5141 1.31236 1.722 .322 .137 
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Table 12: Showing total Eigenvalues and variance of each item of CSI 
Component 
Initial Eigenvalues 
Extraction Sums of Squared Load-
ings 
Rotation 
Sums of 
Squared 
Loadings 
Total 
% of Vari-
ance Cumulative % Total 
% of Vari-
ance Cumulative % Total 
1 7.357 29.428 29.428 7.357 29.428 29.428 5.143 
2 1.625 6.501 35.929 1.625 6.501 35.929 3.465 
3 1.282 5.129 41.058 1.282 5.129 41.058 3.511 
4 1.231 4.924 45.982 1.231 4.924 45.982 2.560 
5 1.086 4.345 50.327 1.086 4.345 50.327 1.583 
6 1.029 4.116 54.443 1.029 4.116 54.443 3.499 
7 .966 3.865 58.308     
8 .891 3.563 61.871     
9 .857 3.427 65.298     
10 .801 3.203 68.501     
11 .788 3.153 71.654     
12 .754 3.015 74.669     
13 .685 2.740 77.409     
14 .661 2.644 80.054     
15 .639 2.555 82.609     
16 .612 2.449 85.059     
17 .555 2.219 87.277     
18 .524 2.095 89.372     
19 .493 1.971 91.343     
20 .467 1.867 93.210     
21 .433 1.733 94.942     
22 .368 1.472 96.414     
23 .346 1.385 97.799     
24 .282 1.127 98.926     
25 .268 1.074 100.000     
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Figure 3: Showing scree plot for various items on CSI related to Eigenvalue. 
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The analysis revealed 6 factors with eigenvalues >1 which accounted for 54.43% of 
the variance. The first component elucidated 29.42% of the variance, whereas the other 
5 components interpreted 6.5%, 5.12%,4.9%,4.3% and 4.116% respectively. The ei-
genvalues of 6 components were 7.35, 1.62, 1.28, 1.23, 1.08 and 1.02 (Table 12). 
However, the Scree plot suggested that 2 factors were clearly forming the basis of CSI. 
(Figure 3). These two methods (eigenvalue and scree) produce different suggestions. 
We looked at 6 factors, on the basis that 2 would not explain enough of the variance 
demonstrated. 
Secondary analysis after oblique PROMOX rotation revealed 6 factors with the ma-
jority of items loading onto 4 factors and 4 questions not loaded to any factor (table 
13).  
 
 
Table 13: showing items loaded onto factors. (F-factor, I-item no of the questionnaire)- Pattern Matrix. 
 F1 F2 F3 F4 F5 F6 No factor 
I1   .805     
I2       x 
I3      .552  
I4    .670    
I5       x 
I6  .887      
I7  .542  .464    
I8 .576 .410      
I9  .531      
I10 .565       
I11     .715   
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I12   .,721     
I13       x 
I14 .711       
I15 .762       
I16 .605       
I17 .627       
I18   .460     
I19    .760    
I20    .641    
I21     .758   
I22  .430 .405     
I23  .474      
I24      .708  
I25       x 
 
The items included in each factors are: Factor 1 (8,10,14,15,16,17), Factor 2 
(6,7,8,9,22,23), Factor 3(1,12,18,22), Factor 4 (4,7,19,20), Factor 5 (11,21) Factor 6 (3, 
24).  This further suggest that there are only 4 strong factors and Factors 5 and 6 are 
rather weak ‘factors’ which may be due to not having enough questions relating to these 
latter two factors. 
Based on the analysis following domains have been identified (depending on the items 
loaded) – 
1. Factor1 – General physical symptoms ranging from 0.57-.76 (item 8 “I get tired eas-
ily) to item 15 “Stress makes my physical symptoms worse” 
2.Factor 2 -CS-related symptoms 
3.Factor 3- sleep disturbances 
4.Factor 4- predominant temporomandibular 
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5 Factor 5- urological 
6 Factor-6 psychological. History of abuse (from 0.55- 0.70 “I have anxiety attacks” to 
“I suffered trauma as childhood” 
The internal consistency reliability analysis yielded values (Cronbach’s alpha) between 
0.884-.894. Regarding, item-total correction, all values were above >.4 except for item 
5 (I have problem with diarrhoea or constipation), Item 10 (I have headaches)  Item 21 
(I have to urinate frequently ) and Item 24 (I suffered trauma as a child) where the 
values were 0.34, 0.338, 0.285 and 0.259 respectively (represents the values if these 
items were removed) (table 14). This might infer that these symptoms are not directly 
related to CS and need further evaluation.  
 
 
Table 14: Showing item-total correlation of CSI 
Item-Total Statistics 
 
Scale Mean if 
Item Deleted 
Scale Variance if 
Item Deleted 
Corrected Item-
Total Correlation 
Cronbach's Alpha 
if Item Deleted 
I1 33.3750 215.874 .411 .890 
I2 33.3824 208.370 .606 .886 
I3 34.7059 216.740 .423 .890 
I4 34.5809 214.385 .412 .891 
I5 33.7757 213.628 .347 .893 
I6 34.9191 213.469 .487 .889 
I7 34.7316 214.027 .453 .890 
I8 33.7022 205.376 .665 .884 
I9 34.4963 206.037 .663 .884 
I10 33.8382 219.273 .338 .892 
I11 34.1765 213.260 .438 .890 
I12 33.4375 213.088 .439 .890 
I13 33.9118 210.870 .585 .887 
I14 33.9559 211.585 .430 .890 
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I15 33.8640 206.856 .619 .885 
I17 33.6471 207.904 .643 .885 
I18 33.6912 210.354 .473 .889 
I19 34.8051 214.667 .466 .889 
I20 34.9632 218.043 .401 .891 
I21 33.3051 217.969 .285 .894 
I22 33.8493 209.021 .504 .888 
I23 33.8787 212.742 .523 .888 
I24 34.9926 221.151 .259 .893 
I25 34.0662 212.055 .433 .890 
I16 33.9485 211.289 .565 .887 
 
3a.4. Discussion 
There has been increasing interest in that central sensitisation might be accountable for 
many conditions collectively termed as CSS. Various tools were used in literature in an 
attempt to screen patient symptoms suggestive of central sensitisation.  The tools in-
cluded the Sensory hypersensitivity scale (Dixon et al 2016), Pelvic pain convergence 
criteria (Levesque A et al., 2018) and the CSI. However, CSI is to date the most widely 
validated tool used for screening of patients with symptoms suggestive of CSS. The 
psychometric properties of CSI have been validated in a cohort of chronic pain patients. 
During the process of validation, these studies have also evaluated its factor model but 
produced conflicting results. We conducted this study to determine the scale structure 
and internal reliability in a cohort of women attending GOPD. 
Our study has demonstrated a 6-factor model of CSI with 4 items (2,5,13,25) not loaded 
to any factor compared to the 4-factor model proposed in the analysis of the original 
English version of the CSI where 3 items (1,5and 14) not loaded to any factor(Mayer 
et al 2012).  In our study, the questions loaded to each factor were also different com-
pared to the original English version.  
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The results of our study, therefore, implies that a 21 item CSI remains and 4 items are 
not valuable in any domains however when working with a total score of CSI, there is 
no problem to implement these items as the original article by Meyer where items 1, 5, 
and 14 did not load sufficiently on any factor in the factor analysis still these items 
remained in that study (Meyer et al., 2012) and subsequent studies Such as the French 
version which was comparable to the English version of the CSI with 4 factors and 
same items not loading to any factors (Pitance  et al., 2016), the Dutch version con-
firmed a 4-factor structure but with different items in each factor and 5 items not relat-
ing to any factor (Kruegel et al., 2016) and the Japanese version which established a 5-
factor model (Tanaka et al., 2017). To eliminate this variation and to produce good 
quality evidence, a large multi-country study was undertaken pooling 1987 subjects in 
a single database. This study also produced 4 factors but at the same time recommended 
that the reliability of the four factors was too low to be recommended for consideration 
of individual domain (Cuesta-Vargas et al., 2017).  
Because of this variation and poor reliability in the results of these factor analyses, for 
practical implications, it is advisable to continue the use of 25 item questionnaire and 
use total scores for the screening of the symptoms suggestive of central sensitivity syn-
drome. Thus, we have used total CSI scores with a cut off of 40 to screen patients with 
CSS’s attending the Gynaecological outpatient department in the next part of the study.  
However, the factor structure may be helpful for clinicians where a specific assessment 
of CS problems is warranted so that specific treatment strategy can be adopted.  
The results of our study have shown excellent internal reliability similar to other studies 
on CSI. (Mayer et al., 2012, Pitance et al., 2016, Kruegel et al., 2016) 
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 The strength of this factor analysis is that:1 this is the first study to determine domains 
and internal reliability of CSI in women with gynaecological problems 2. Use of ap-
propriate statistical analysis  
The limitation of this study is that these domains were extracted in a cross-sectional 
manner. Secondly, there was no test-retest reliability analysis undertaken 
In the future, these domains must be tested longitudinally in terms of test-retest relia-
bility in the same cohort. Further studies are also required to measure a clinical change 
in these domains of CSI following treatment to assess whether this can be a useful 
outcome tool or not. 
3a.5. Conclusion 
The results of the above study demonstrate that total scores for CSI should be used for 
screening purpose.  
Suggestion for Future Research  
1. Comparing the surgical outcome after pelvic organ prolapse surgery in patients with 
CSS using scores for factor 5 (urological) vs total scores of the Central sensitisation 
inventory. 
2. To assess whether an item (on dragging sensation or heaviness in the pelvis) can be 
added in the CSI that can be loaded on factor 5 as one of the possible symptoms of 
central sensitization and creating short-form of CSI to be used in this population 
3. Assessing patient perception of CSI whether they find it bothersome or useful using 
a validated QQ-10 tool. 
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Chapter 3b- The proportion of women with central sensitivity syndrome in Gy-
naecology Outpatient Clinics (GOPD) 
Abstract- 
Patients in Gynae outpatient clinic (GOPD) may present with symptoms not correlat-
ing well with the observed pathology and are usually labelled as having functional 
disorder or medically unexplained symptoms (MUS). Underlying central sensitivity 
syndrome (CSS) with central sensitisation (CS) as potential mechanism may be re-
sponsible for some of their symptoms. The aim of this study is to identify the propor-
tion of women with Central sensitivity syndrome attending GOPD. 
Method- 
This was a prospective study conducted at University Hospital Plymouth NHS Trust 
between the month of March 2014-June 2014. All women attending GOPD included 
in the study were asked to complete a validated Central Sensitisation Inventory (CSI). 
The responses were graded on Likert scale from 0 (never) to 4 (always). Total score 
ranges from 0 to 100. For screening purpose, a single cut-off score of 40 of the CSI 
was used to identify the group of women who may have syndrome of central sensiti-
sation. 
Result - Three hundred and twenty-six women participated in the study. Overall, 123 
(37%) women achieved a score above 40. This could be interpreted as at an increased 
risk of underlying central sensitisation. Out of these, 43 had earlier confirmed diagno-
sis of migraine, 55 (44%) had depression, 39(31.7%) had anxiety, 11 had fibromyal-
gia (FM), 34 had confirmed diagnosis of Irritable Bowel Syndrome(IBS) and 16 had 
Chronic fatigue syndrome(CFS/ME).  
Conclusion- 
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Managing patients and their expectations in gynaecological outpatient departments, 
when symptoms are inconsistent with observable pathological findings, is challeng-
ing. This is further complicated when patients have a concomitant Central Sensitivity 
Syndrome which can also influence surgical outcome. Identifying these patients is a 
key factor for appropriate management. 
Key words- 
Central sensitivity syndrome, central sensitisation, pelvic organ prolapse, gynaecol-
ogy outpatient clinic. 
Summary-  
Central sensitivity syndrome influences the outcome of any treatment and identifying 
this is a key factor for appropriate clinical management 
3b.1. Introduction 
Patients presenting in gynaecological outpatient departments frequently have symp-
toms which are not consistent with observable pathology. Some will have persistent 
pain which is disproportionate to the pelvic pathological changes noted and on a more 
thorough evaluation, will also have other more generalised symptomology such as fa-
tigue, poor sleep pattern and perceptual sensitivities. This requires clinical vigilance 
particularly when patients are keen on definitive symptom relief despite modest clinical 
findings. Patients will often be distressed during the consultation, highlighting impaired 
dysfunction which they feel needs to be addressed by more aggressive management e.g. 
surgery. Anecdotally, many request hysterectomy in the belief that this will be benefi-
cial. 
Whilst it is common in primary care to manage patients having no clear diagnosis there 
has been little evaluation of the prevalence of this problem in secondary care. Historic 
evidence (Nimnuan C et al., 2001) suggests that over 50% of those attending secondary 
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care clinics do not have a clear diagnosis resulting in disappointment and frustration for 
both patient and clinician and the potential for ineffective treatments.  
Patients can often find themselves being referred for further medical opinions particu-
larly if there have been previous unsuccessful attempts at surgical resolution.  
Such patients may or may not have a pre-existing diagnosis of a functional disorder 
including fibromyalgia, chronic fatigue syndrome (CFS) or myalgia encephalitis (ME), 
medically unexplained symptoms (MUS), Central sensitivity syndromes or more re-
gionally based diagnoses such as irritable bowel syndrome and interstitial cystitis/pain-
ful bladder syndrome. These are overlapping diagnoses, which are inconsistently used 
and there is continued debate about the aetiology and conceptualization of these various 
functional disorders. One diagnostic label which appears to be acceptable to both clini-
cians and patients is Central Sensitivity Syndrome (CSS) (Yunus MB, 2008). 
Recent research studies have shown that surgical intervention is less effective in those 
with a central sensitivity syndrome and potentially might exacerbate the symptoms in 
some e.g. shoulder pain (Gwilym SE et al., 2011).   
There is currently little evidence clarifying the prevalence of a central sensitivity syn-
drome among women presenting to a gynaecological outpatient’s department especially 
with pelvic organ prolapse. This study was, therefore, designed to estimate the propor-
tion of women who might have symptoms suggestive of a central sensitivity syndrome 
attending with pelvic organ prolapse compared with women with general gynaecolog-
ical conditions. 
3b.2. Method 
This was a prospective study conducted at a tertiary University hospital and was ap-
proved by the West of Scotland Research Ethics Committee. The study was conducted 
from March 2014 to June 2014. All women attending gynaecology out- patient clinics 
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and were above the age of 18 were included in the study. Women who were not able or 
willing to consent were excluded. The patient information leaflet was sent to all women 
before the clinic appointment. All women were asked to complete a validated Central 
Sensitisation Inventory (CSI) (see pg. 30) whilst they were in the Gynaecology clinic 
awaiting their appointment.  
For screening purpose, a single cut-off score of 40 of the CSI was used to identify the 
group of women who might have central sensitivity syndrome (Neblett R et al., 2013). 
To obtain a clinically significant value of CSI score, Neblett compared the CSI scores 
between the CSS patient group and non- patient group using ROC analysis. The score 
of 40 on the CSI provided good sensitivity (81%, to correctly identify CSS patients) 
and specificity (79%).  
Due to variation and poor reliability of the results of factor analysis, it’s not recom-
mended to use the individual domains of CSI to screen patients with CSS. This was 
also confirmed in our study (see chapter 3a). The CSI was also not used to classify 
conditions based on the severity level. 
3b.3. Sample size and statistical analysis 
Following STROBE recommendations (An international, collaborative initiative of ep-
idemiologists, methodologists, statisticians, researchers and journal editors involved in 
the conduct and dissemination of observational studies), a formal sample size estimate 
for the survey was conducted. For the overall population, a sample of 300 would give 
a precision of the point estimate for the proportion with CSS of between 3.4% and 5.2% 
with a two-sided 95% CI and expected proportions of 10% and 30% with CSS. The 
CSI scores were calculated from the individual question responses using cut-off of 40 
to define CSSs.  Proportions and confidence intervals were calculated using SPSS ver-
sion 17. Fisher’s exact test was used to calculate p value.  
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The CSI scores for pelvic organ prolapse (POP) patients were also then compared to 
those with other general gynaecological diagnoses including menorrhagia, pelvic pain, 
ovarian cyst, request for sterilization, overactive bladder, intermenstrual bleeding, post-
menopausal bleeding, cervical polyp and endometriosis.  
The comparison of CSI scores was performed between the POP group and other general 
conditions to understand whether a dragging sensation (one of the symptoms of pro-
lapse) is attributed to presence or absence of CSS which might subsequently help in 
comparing the outcomes of surgical treatment of prolapse (see chapter4). Two sample 
Kolmogrov-Smirnov test/Two tailed test was used to compare the distribution of CSI 
scores in women with evidence of CSS and pelvic organ prolapse and in women with 
evidence of CSS and other gynaecological conditions using XLSTAT. 
3b.4. Results 
About 480 women attended gynaecological clinics during this period. Three hundred 
and twenty-six women participated in the study. Overall 123 (37%) women achieved a 
score above 40 suggesting underlying CSS. Out of these, 43 had earlier confirmed di-
agnosis of migraine, 55 (44%) had depression, 39(31.7%) had anxiety, 11(25%) had 
FM, 34(27.6%) had confirmed diagnosis of IBS and 16 (13%) had CFS/ME. These 
conditions were identified from the CSI and were found to be in a combination of 2-3 
in women with CSI scores between 40-60. Women (25%) with high CSI scores (60-91) 
were found to have a combination of 4-5 conditions. This might suggest that higher 
scores are reflecting the presence of more conditions coming under the umbrella of CSS 
and so more symptoms.  
Out of 326 women, the main complaint of 86 women that attended the outpatient clinic 
was pelvic organ prolapse, while 240 women attended with other gynaecological symp-
toms. The evidence of central sensitivity syndrome was established in 27 women (32%) 
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with pelvic organ prolapse and 96 women (40%) with other gynaecological conditions 
(table 15).  
The other general gynaecological conditions referred were menorrhagia, pelvic pain, 
ovarian cyst, request for sterilization, overactive bladder symptoms, intermenstrual 
bleeding, postmenopausal bleeding, cervical polyp, endometriosis, fibroids, lichen scle-
rosis, women for Fenton’s reverse perineorrhaphy and, women referred for manage-
ment of menopausal symptoms. The CSI scores for the general gynaecological condi-
tions (excluding pelvic pain) were the range of (18-54). The CS scores for pelvic or 
vaginal pain were in the range of (32-91). There were 2 cases of known endometriosis 
and the scores were 59 and 60 respectively. 
Table 15: Showing evidence of central sensitivity syndrome in women with pelvic organ prolapse and 
other gynaecological conditions in outpatient clinics 
Total no-326 Pelvic Organ 
Prolapse- n-86 
Other Gynaecologi-
cal conditions. n-240 
Fischer test 
With CSS.n-123 
 
27(32%) 96(40%)  
Without CSS.n-
203 
 
59(68%) 144(60%) P=0.25 
Mean CS scores for the pelvic organ prolapse group and other gynaecological condi-
tions were 33.9(SD 15.2) and 37.2 (SD 15.8) respectively. There was no statistical dif-
ference in overall mean central sensitisation scores between women with pelvic organ 
prolapse and other general gynaecological conditions (table 16). However, women pre-
senting with pelvic or vaginal pain were found to have higher central sensitization 
scores(p<.001) whether they are in POP group or General Gynae group (table 17,18). 
Table 16: Showing mean central sensitisation scores and *standard deviation between women with pel-
vic organ prolapse and other general gynaecological conditions. 
Conditions Mean CS score t test 
Pelvic Organ Prolapse 
 
33.9 (*SD-15.2) *p=0.098 
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Other Gynaecological conditions 
 
37.2 (*SD-15.8)  
  
Table 17: Showing mean CSI scores and *standard deviation in patients with general gynae condition 
with pain compared to those without pain. 
Conditions  Mean CS Score  t test 
General gynae condition without 
pain 
  34.6 (*SD 14.9) P=0.000 
General gynae condition  with pain  53.6 (*SD 15.6)   
 
Table 18: showing mean CSI scores  and *standard deviation in patients  with pelvic organ prolapse 
with pain compared to those without. 
Conditions  Mean CS Score  t test 
Pelvic organ prolapse without pain   32.47 (*SD 15.06) P=0.000 
Pelvic organ prolapse with pain  48.5(SD 16.8)  
 
The mean CSI score in women with POP with established evidence of CSS was 
51.81(SD-9.11) and mean CSI score in other gynaecological conditions with evidence 
of CSS was 52.7(SD-10.43) (Table 19). The distribution of CSI scores in patients with 
evidence of CSS in both groups is shown in graph1(fig 4) and graph 2 (fig 5) respec-
tively. Two sample Kolmogrov-Smirnov test/Two tailed test used to compare the dis-
tribution, demonstrate that both groups follow very similar distributions (p value 
0.998). 
Table 19: Showing mean central sensitisation scores and *standard deviation in women with evidence 
of CSS. 
Conditions Mean CS Score 
Pelvic Organ Prolapse 51.81(*SD-9.11) 
Other Gynae Conditions 52.7(*SD-10.43). 
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Figure 4: Graph 1- Distribution of CSI scores in patients with pelvic organ prolapse and CSS. The X 
axis shows the CSI scores and Y axis is the frequency of these scores. 
 
Figure 5: Graph 2- Distribution of CSI scores in women with General Gynae Condition and CSS. The 
X axis shows the CSI scores and Y axis is the frequency of these scores. 
3b.5. Discussion 
Clinicians will often assess patients who experience somatic symptomology which does 
not fit the clinical findings. Some of these patients will have a clinical label of 
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“functional disorder” with the symptoms not demonstrably due to a specific underlying 
disease process (Engel GL1977). Research indicates that the widespread symptomol-
ogy may be due to a dysfunction in central processing and possibly peripheral pro-
cessing (Bourke JH et al., 2015).  
Central sensitisation is a plausible theoretical explanation the persistence of such symp-
toms. Previously the term Medically Unexplained Symptoms (MUS) was used but was 
often felt to be unhelpful to both patients and clinicians and could result in disengage-
ment by the patient with the perceptions that the clinician thought that “the symptoms 
were all in their head” (Sharpe M 2013). 
A potentially more acceptable ‘umbrella’ term that is being increasingly adopted is cen-
tral sensitivity syndrome (CSS). This includes conditions such as fibromyalgia, IBS, 
Temporomandibular joint disease (TMJ), chronic fatigue syndrome, tension headache/ 
migraines, restless leg syndrome, multiple chemical sensitivities, interstitial cystitis, 
myofascial pain syndrome, post-traumatic stress disorder (PTSD) and neck injuries 
such as whiplash (Yunus MB, 2007). 
 The patients suffering from this syndrome often have higher symptom bother due in 
part to underlying central sensitization (Adams K et al., 2014; Shin Hyung K et al., 
2015). As discussed in the literature review, the development of this syndrome can also 
result in considerable psychosocial impairment, work disability, and increased utiliza-
tion of health care resources (Creed FH et al., 2012, Barsky AJ et al., 2001; Shraim M 
et al., 2013).  
The clinical challenge is to recognize, diagnose and manage this syndrome since it can 
be detrimental to the patient-doctor relationship as well as put patients at risk of unnec-
essary diagnostic and surgical interventions (Fink P., 1992; Warren JW et al., 2014; 
Flynn TW et al., 2011). It is thought that some patients can potentially lose trust in the 
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medical system as they perceive medical disbelief in their presentations while clinicians 
might consciously or unconsciously, develop negative attitude towards them.  
It is, therefore, imperative to identify patients with evidence of central sensitivity syn-
drome during the clinical decision making, provide a detailed explanation to the patient 
and ensure appropriate interventions.  
This part of the thesis explores the extent of CSS within the gynaecological arena. Our 
study has demonstrated that around 37% of patients attending our general gynaecolog-
ical outpatient clinics (32% with POP and 40% with other Gynae disorders) could be 
considered as having a central sensitivity syndrome when using a validated CSS instru-
ment.  The CSI scores in both groups followed very similar distributions.  The study 
indicated that women with pelvic pain and vaginal pain had higher scores on the CSI. 
This supports the potential pathophysiological role of central sensitization in chronic 
pelvic pain, irritable bowel and bladder pain syndrome where the symptom complex is 
out of keeping with the clinical presentation as suggested by other authors (Neblett R 
et al., 2013). 
The strength of this study is that it is the first study to our knowledge to identify women 
having evidence of central sensitivity syndrome presenting with pelvic organ prolapse 
and general gynaecological conditions. This might have implications for the poor out-
come of surgical intervention for POP (Olsen AL et al., 1997) as has previously been 
seen in patients with shoulder pain (Gwilym SE et al., 2011). 
The weakness of this study is that there is no objective test utilized to identify CSS and 
so a specific independent measure cannot currently be used with confidence. The pres-
ence of a central sensitivity syndrome is based on a questionnaire only; however, the 
CSI has been validated and tested for its reliability in diagnosing CSS (Mayer TG et 
al., 2012; Kregel J et al., 2015; Yunhee C., 2013). 
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There is very little in the literature to assess the role of CSSs for the outcomes of surgery 
for POP. This is addressed in the next part of the thesis. 
3b.6. Conclusion 
Managing patients and their expectations in gynaecological outpatient clinics, when 
symptoms are inconsistent with observable pathological findings is challenging. This 
is further complicated when patients have a concomitant Central Sensitivity Syndrome 
which might influence surgical outcome. Further research is required to elucidate the 
way this syndrome is best understood and managed in the gynaecological arena. 
 Suggestion for Future research- A Longitudinal study to assess the role of pregnancy 
and delivery on CSI scores and development of central sensitisation. 
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Chapter 4- Clinical outcomes of surgery in patients with CSS; a systematic re-
view and review of literature 
4.1. Introduction 
As alluded to earlier, Fibromyalgia and medically unexplained symptoms (MUS) result 
in significant psychosocial impairment, work disability, and increased health care uti-
lization by patients. The term FSS/ MUS has been largely fallen out in favour of another 
umbrella term Central Sensitivity Syndromes (CSS’s). Previous research studies have 
demonstrated that patients suffering from these conditions have higher symptom bother 
than those without. Invasive options are often performed in these patients, with a higher 
risk of unexplained suboptimal results. This systematic review aims to establish, 
through the available literature whether the presence of Central Sensitivity Syndromes 
or Functional somatic disorders (described in chapter 1) influences the clinical postop-
erative outcome.  
4.2. Method- 
The study design is based on “PICOS”( see below) and follows the PRISMA guidelines 
(Preferred Reporting Items for Systematic reviews and Meta-Analyses) 
PICOS: 
Participants (P) 
This review will consider all studies that involve patients who underwent any type of 
surgery 
Intervention (I) 
Diagnosis of CSS /FSS/FM/CFS/MUS/CS/ME /central sensitisation 
Comparison- (C) 
Patient without CSS/FSS/FM/MUS/CFS/ME 
Outcome measure (O) 
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The outcomes of interest are quality of life (QOL), patient satisfaction, complications, 
physical functioning, length of hospital stay and recovery following surgery  
Types of Studies (S) 
case series, retrospective studies, observational studies, open-label studies, randomized 
clinical trials, systematic reviews and meta-analyses 
4.3. Exclusion criteria-  
Articles in another language than English, commentaries, letters to the editor and bio-
mechanical studies and studies with pain as primary clinical outcome were excluded.  
The reason for excluding pain as the primary outcome was that the thesis focussed on 
pelvic organ prolapse and pain (as opposed to heaviness and dragging) is not a symptom 
of prolapse. Secondly, we analysed the symptom improvement, effect on the quality of 
life (as primary outcome) with patient satisfaction and patient global impression of im-
provement (PGI-I) following prolapse surgery in patients with CSS (in the next part of 
the study) and focussed on any literature available on these clinical postoperative out-
comes. 
4.4. Search Strategy 
Database search included PubMed, Medline, Embase, Web of Science and Ovid data-
base Only articles written in English were selected. Database MeSH terms used were 
central sensitivity syndrome, central sensitization, fibromyalgia, functional somatic 
syndrome, medically unexplained symptoms, chronic fatigue syndrome, ME, surgical 
outcome post-surgical outcome, quality of life scores, patient satisfaction, length of stay 
and complications. 
Literature was independently searched by me after receiving training from a member 
of the library team and then all search results were screened based on title and abstract 
by two authors (MV, AD). The full-text article was retrieved if the citation was 
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considered potentially eligible and relevant. In the second phase, each full-text article 
was again evaluated whether it fulfilled all criteria. If any of the eligibility criteria were 
not fulfilled, the article was excluded. Disagreements on inclusions and exclusions were 
resolved by discussion and did not require a third reviewer.  
4.5. Data collection  
The studies retrieved during the searches were entered into EndNote and then trans-
ferred to Covidence software for screening. In the first phase of screening, two re-
searchers screened the abstracts of the retrieved for eligibility, and any conflicts were 
resolved after discussion.  
All quantitative papers on post-surgical clinical outcomes, relating to complications, 
length of stay, readmission rates, QOL, and patient satisfaction in patients with central 
sensitisation, central sensitivity syndromes, fibromyalgia, chronic fatigue syndrome, 
migraine or the functional somatic syndrome were included. Papers, where the primary 
outcome was pain or postoperative opioid consumption, were excluded for the reasons 
mentioned above.  
In the second phase of screening, each full-text article was evaluated as to whether it 
met all eligibility criteria. If any were not fulfilled, the articles were excluded.  
Covidence software was then used to extract data from the studies selected for inclusion 
and to record the results of the assessments of the methodological quality of each paper, 
and both were used to create this final report. 
Data were extracted for the following: (1) study design and purpose; (2) characteristics 
of the study population; (3) measured variable(s) of central sensitization and central 
sensitivity syndromes pre-surgery and method of assessment; (4) post-surgical outcome 
variable(s) regarding the length of stay, complications, readmission, patient satisfac-
tion, physical function, and QoL and assessment method; (5) length of follow-up, 
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important results for this review such as correlation coefficient, risk ratio, odds ratio 
and information on the risk of bias. 
As mentioned above, two reviewers independently performed the data extraction, and 
any controversies were resolved through discussion to reach a unanimous decision, 
therefore, did not require the third person 
4.6. Risk of bias (quality) assessment 
Covidence software was then used to extract data from the studies selected for inclusion 
and to record the results of the assessments of the methodological quality of each paper, 
and both were used to create the final report. An assessment of bias in the included 
randomized controlled trials was performed according to the guidelines laid out in the 
Cochrane Handbook for Systematic Reviews of Interventions, to give a clear idea of 
the strength of clinical indications (i.e. the role of CSS/CS on clinical outcomes after 
surgery) in this review (Higgins J et al 2011). Allocation, blinding, attrition, reporting, 
and other potential sources of bias were assessed using this approach. The Newcastle- 
Ottawa quality assessment scale was used for non-randomized observational studies to 
assess the quality. The protocol was submitted to the PROSPERO registry, registration 
number (CRD 42020165140). 
4.7. Strategy for data synthesis 
A narrative synthesis of the findings from the included studies, structured around the 
type of intervention, target population characteristics, type of outcome and intervention 
content was provided. The summaries of intervention effects for each study by calcu-
lating risk ratios (for dichotomous outcomes) or standardised mean differences (for 
continuous outcomes), along with evidence of publication bias, is also provided 
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4.8 Results – 
The figure (fig 6) demonstrates the selection process of this review. 16 studies were 
included in the qualitative synthesis. Most studies were excluded based on the popula-
tion studied and the nature of the predictor. 
 
Figure 6: PRISMA Flow chart. 
 
 
No Randomised controlled studies were found. There were no studies to evaluate the 
clinical outcomes following any gynaecological surgery. There was 1 systematic re-
view, 8 case-control studies, 1 cross-sectional study and 7 cohort studies for review. 
(Table 20). The methodological quality of the studies is summarised in table-21,22.  
Meta-analysis was not undertaken due to high heterogenicity among the studies regard-
ing study design and outcome measures. 
 
 
 
341 studies 
imported for 
screening
•3 duplicates 
removed
338 studies 
screened
•313 studies 
irrerelevant
25  full text 
studies for 
elligibility
• 8 studies excluded
• 6 Wrong outcomes
• 1 Wrong comparator
• 1 Wrong study design
17  studies 
included
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Table 20: Showing all type of studies included. 
Author Study de-
sign 
Sample size Type of inter-
vention 
Outcomes conclusion Follow 
up 
Soler et al 
2008 
Nested 
case-con-
trol 
analysis 
283 pa-
tients, in-
cluding 25 
with FM 
and 258 
without FM  
Endoscopic si-
nus surgery 
Assessment on 
QOL by Pre-op-
erative RSDI, 
CSS scores 
And a change in 
these scores 
post-operative 
 
Preoperative scores 
higher in patients 
with FM. Both 
groups showed im-
provement after sur-
gery with no differ-
ence on QOL in pa-
tients with FM or 
without FM 
However, medica-
tion requirement was 
higher in the FM 
group  
Average 
11.7 mths 
(3-21) in 
the FM 
group 
and 
14.7(6-
21) in pa-
tients 
without 
FM 
Bican et al., 
2011 
Prospec-
tive Case-
control 
study 
59 patients 
(90 knees) 
with FM 
matched 
with 59 
controls 
Total Knee Ar-
throplasty 
Post-operative 
satisfaction and 
functional out-
come using Lik-
ert scale and SF-
36 
FM patients were 
less satisfied with the 
surgery 
3.4 yrs. 
Gwilym et 
al., 2011 
Prospec-
tive case-
control 
20 pa-
tients,17 
patients se-
lected with 
Shoulder 
Impinge-
ment syn-
drome 
matched 
with 17 
controls 
who were 
free from 
shoulder 
pain with 
OSS of 48 
Subacromial 
decompression 
Primary out-
come- Improve-
ment in OSS 
scores and Sec-
ondary outcome- 
Diagnosis of Hy-
peralgesia by 
QST 
Preoperative hyper-
algesia had a signifi-
cant role as a predic-
tor of postoperative 
OSS (I.E presence of 
referred pain and a 
higher level of hy-
peralgesia were asso-
ciated with worse 
outcome 
3 months 
D’Apuzzo 
et al., 2012 
Retro-
spective 
cohort 
study 
110 patients 
for TKA 
with FM 
(141 knees)  
102 patients 
for final 
analysis 
Total knee ar-
throplasty 
(TKA) 
Knee Society 
Knee Score, Sat-
isfaction  
Secondary out-
come- postopera-
tive complica-
tions 
85 patients (108 
knees) reported im-
provement (82%) 
however, patients 
with FM have a high 
prevalence of com-
plications esp. ar-
throfibrosis (9%) 
7 years 
(2-16 
yrs.) 
Bionna et 
al., 2013 
Retro-
spective 
observa-
tional 
286 patients 
including 
18 with FM 
(5 under-
went sur-
gery-11 
joints) 
Orthopaedic 
evaluation for 
shoulder pain 
and shoulder 
surgery 
Diagnosis of FM, 
new OSS, SF-12, 
and global SOD 
score 
Fibromyalgia may be 
a cause of failure in 
the treatment of con-
comitant painful 
shoulder 
15 
months 
(range 
12-27) 
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DeConde et 
al., 2014 
Retro-
spective 
analysis of 
a prospec-
tive case-
control 
study 
225 patients 
with refrac-
tory CRS, 
46 had a 
comorbid 
migraine 
and 186 
were with-
out mi-
graine 
Endoscopic Si-
nus surgery 
RSDI, CSS, 
SNOT-22 
Patients with comor-
bid migraine and 
CRS are more likely 
to have less severe 
evidence of disease 
and worse preopera-
tive baseline QOL 
scores. Both groups 
demonstrated com-
parable improve-
ment after surgery 
Mean 6.3 
months 
(6, 12 
and 18 
months) 
Bennett EE 
et al., 2017 
Retro-
spective 
cohort 
study 
1404 pa-
tients out of 
which 788 
had CSI 
scores 40 or 
more 
Cervical and 
spinal fusion 
surgery 
QoL measures- 
Patient Health 
Questionnaire-9 
(PHQ-9); Eu-
roQOL-5D in-
dex; Pain and 
Disability Ques-
tionnaire (PDQ) 
High CSI score is 
significantly associ-
ated with worse 
QOL outcomes fol-
lowing cervical and 
spinal fusion surgery 
comparing to those 
with low CSI scores 
6 weeks 
to 1 year 
Roh et al., 
2015 
Prospec-
tive cohort 
prognostic 
study 
93 recruited 
from 109 
eligible pa-
tients 
Surgical treat-
ment for hand 
fracture 
Post-op grip 
strength, total ac-
tive range of mo-
tion and disabil-
ity 
Pre-operative high 
catastrophizing and 
anxiety were associ-
ated with weaker 
grip strength, de-
creased range of mo-
tion, and increased 
disability after surgi-
cal treatment for a 
hand fracture at 3 
months. This effect 
was not seen beyond 
6 months  
 
3 and 6 
months 
Baert et al., 
2015 
System-
atic re-
view 
Total 16 
studies, 10 
studies on 
function 
and 1 on 
QOL, pa-
tients be-
tween 43-
241 
Total Knee re-
placement 
Presurgical pain 
modulation in 
the context of 
“cognitive-emo-
tional modula-
tion”, WOMAC 
physical function 
questionnaire 
Conflicting evidence 
for the role of de-
pressive symptoms 
and anxiety in pre-
dicting knee function 
as well as for the role 
of pain catastrophis-
ing in predicting 
knee function. 
Limited evidence on 
the effect of depres-
sion on QOL after 
TKA and for coping 
strategies and knee 
function 
6 weeks 
to 5 years 
Ablin et al., 
2017 
The pro-
spective 
observa-
tional co-
hort study 
39 patients, 
11 with FM 
and 28 
without FM 
 Cervical or 
Lumbar lami-
nectomy or 
foraminotomy  
Change in WPI 
and SSS scores, 
SF36, 
The negative correla-
tion between presur-
gical severity of FM 
symptoms and post-
operative SF36 and 
may have less favor-
able outcome after 
spinal surgery 
10-12 
weeks 
85 
 
De Groef et 
al., 2017 
Cross-sec-
tional 
study 
274 patients 
who had 
surgery for 
breast can-
cer 
Breast cancer 
surgery (mas-
tectomy, 
lymph node 
dissection 
Disability of 
Arm, Shoulder, 
and Hand 
(DASH) ques-
tionnaire, CSI 
At long term, pain 
and central sensitisa-
tion contributes to 
upper limb dysfunc-
tion in breast cancer 
survivors 
1.5 years 
Nelson et 
al., 2018 
Retro-
spective 
case-con-
trol 
76,103 pa-
tients with 
FM com-
pared with 
76,103 
without FM 
Total Knee Ar-
throplasty 
(TKA) 
Medical and im-
plant complica-
tions, 90 days re-
admission rates 
Increased risk of 
post-operative com-
plications in patients 
with FM 
90 days 
Duckworth 
et al., 2018 
Retro-
spective 
study 
103 patients Total Hip Re-placement 
Pain catastro-
phising and Ox-
ford Hip Score 
(OHS) 
 Higher preoperative 
catastrophising tends 
to correspond with 
poorer improve-
ments in OHS pre- to 
postoperatively. 
12 
Months 
Leung et al., 
2019 
Prospec-
tive cohort 
study 
243 patients 
with knee 
OA 
Outcome 
data in 232 
patients at 6 
months and 
235 at 12 
months 
Knee replace-
ment 
Patient satisfac-
tion at 4 and 6 
months using a 
4-point Likert 
scale 
WOMAC to as-
sess pain and 
function con-
cerning central 
sensitization 
measured by 
PPT at forearm 
Preoperative central 
sensitisation was not 
statistically signifi-
cantly associated 
with satisfaction 
6 and 12 
months 
Donnally et 
al., 2019 
Retro-
spective 
case-con-
trol review 
9346 pa-
tients with 
FM with 
degenera-
tive lumbar 
pathology 
and 9346 
patients 
without FM  
Primary 1 to 2 
level posterol-
ateral lumbar 
spine fusion 
Readmission 
rate, length of 
stay and postop-
erative complica-
tion 
Patients with FM had 
a higher rate of post-
operative anaemia, 
pneumonia, cost of 
care and readmission 
30 and 90 
days 
Moore et 
al., 2019 
Retro-
spective 
case-con-
trol 
152,755 pa-
tients with 
FM 
TKA Complications following TKA 
patients diagnosed 
with fibromyalgia 
are more likely to de-
velop several medi-
cal complications 
than non-fibromyal-
gia patients.  
 
90 days 
Lopiz et al., 
2019 
Retro-
spective 
case-con-
trol 
293 pa-
tients, 26 
with FM, 
20 included 
(6 had no 
follow up) 
compared 
with 20 pa-
tients with-
out FM 
Isolated Ar-
throscopic 
Subacromial 
decompression 
(IASD) 
DASH (Disabil-
ity Arm Shoulder 
and Hand, con-
stant score (CS), 
relative constant 
score (RCS), 
VAS pain score 
and patient satis-
faction question-
naire 
FM is a prognostic 
factor of a poor out-
come after an IASD 
36.8 
mth(23-
84 
month) 
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4.9. Summary and comparison of the studies 
The study by Soler et al (Soler MZ et al 2008) demonstrated no difference in QOL 
following sinus endoscopic surgery in patients with FM compared to those without FM 
in chronic rhinosinusitis condition (CRS). They assessed the quality of life scores by 
using the Rhinosinusitis disability index (RSDI) and the Chronic Sinusitis Survey 
(CSS). The RSDI measures rhinology health by way of 30 questions separated by phys-
ical, functional, and emotional subscales with possible scores ranging from 0 (lowest 
level of disease impact) to 120 (greatest level of disease impact). The chronic rhinosi-
nusitis survey is an 8-week- duration monitor of sinusitis-specific outcomes comprised 
of six questions in two subscales (symptom and medication) with possible scores rang-
ing from 0 (lowest level of functioning) to 100. A total of 283 patients were selected 
including 25 patients with FM. The control patients were matched 1:1 on potential con-
founding variables including gender, age (<3 years), and preoperative sinus opacifica-
tion CT scores (<4). A total of 18 matched patients in each group were then compared.  
The study demonstrated that the patients with fibromyalgia were more likely to be 
women (96% versus 55%) and indicate clinical depression (48% versus 17%) but less 
likely to have nasal polyposis (8% versus 35%) than those without fibromyalgia. Pa-
tients with fibromyalgia were found to have less evidence of pathological changes such 
as sinus opacification on CT scan compared with patients without fibromyalgia. No 
significant differences were found in nasal endoscopy exam scores. Patients with fi-
bromyalgia showed worse preoperative QOL responses compared with all other pa-
tients on the RSDI total (57.0 +/-16.6 versus 48.3+/- 21.4, p < 0.05), the RSDI func-
tional subscale (18.1+/- 5.5 versus 15.5+/- 7.4; p < 0.084), CSS total (28.0+/- 17.0 ver-
sus 35.1+/-20.2; p< 0.092), and the CSS symptom subscale (18.3+/- 20.7 versus 28.9 
+/-26.3, p <0.053).  
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Statistically significant improvements in QOL scores were noted in both fibromyalgia 
and non-fibromyalgia groups. For patients with fibromyalgia, mean RSDI total scores 
improved by 19.4+/-19.9 (p<0.001). There was also significant improvement seen in 
the CSS total score (22.4 +/-19.2; p < 0.002) as well as the symptom subscale (33.8+/-
24.5; p < 0.001). Patients without fibromyalgia also showed significant improvements 
in all QOL domains except for the RSDI emotional subscale. There was no statistical 
difference in mean change for the RSDI total or subscale scores between the two 
groups. Similarly, there was no difference in the change score for the CSS total or 
symptom subscale between both groups. However, patients with fibromyalgia were 
shown to have less improvement in the chronic sinusitis survey medication subscale 
than patients without fibromyalgia (11.1+/-22.5 versus 28.2+/-23.9; p< 0.027).  
Conclusion- This study showed that patients with comorbid CRS and fibromyalgia are 
more likely to be female, experience depression, and show worse baseline QOL scores 
when compared with everyone with chronic rhinosinusitis. Patients with fibromyalgia 
showed significant improvements in most sinus specific QOL measures following sur-
gical intervention despite worse baseline scores. When compared with matched con-
trols, these improvements were as great as those seen in patients without FM in nearly 
every sinus specific QOL measure studied. 
 The study by Gwillym (Gwillym et al., 2011) was aimed to investigate the evidence 
for augmented pain transmission (central sensitization) using QST (see chapter 1) in 
patients with shoulder impingement, and the relationship between pre-operative central 
sensitization and the outcomes following arthroscopic subacromial decompression us-
ing Oxford Shoulder score (OSS) of a single centre. They found that a significant pro-
portion of patients awaiting subacromial decompression had referred pain radiating 
down the arm and had significant hyperalgesia to the punctate stimulus of the skin 
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compared with controls (p < 0.0001). The study also demonstrated that the presence of 
either hyperalgesia or referred pain pre-operatively resulted in a significantly worse 
outcome (in terms of OSS scores) from decompression three months after surgery (un-
paired t-test, p = 0.04 and p = 0.005, respectively). 
Ablin (Ablin et al., 2017) reviewed in an observational cohort study about the impact 
of FM symptoms on the outcome of spinal surgery. He analysed 39 patients, out of 
which 11 had FM and 28 had no symptoms of FM. 27 patients had lumbar spinal sur-
gery and 12 had a cervical operation. They used the following validated instruments: 
Widespread pain index (WPI) and Symptom Severity scale (SSS) and the change in the 
various components of the SF-36(36-item Short-Form Health Survey questionnaire to 
assess QOL) to evaluate the association between fibromyalgia symptoms observed be-
fore surgery and the postoperative outcome. The SF-36 questionnaire was analysed ac-
cording to the conventional method of eight components: physical functioning, physical 
role functioning, bodily pain, general health perceptions, vitality, social role function-
ing, emotional role functioning, and mental health. These components grouped into two 
sets: the physical component summary (PCS) and the mental component summary 
(MCS) with each component measured with a value ranging from 0 to 100, with 0 and 
100 corresponding to the poorest and optimal health.  
Overall, a significant 34% reduction in WPI (widespread pain) was observed post-sur-
gically (P < 0.01), but no significant change was observed in SSS (symptom severity).  
Fibromyalgia syndrome (FMS)negative patients were found to have highly significant 
reductions of both SSS and WPI (-50.1% and -42.9%, respectively, P<0.01), while 
FMS-positive patients experienced no reduction of SSS symptoms (+3.6%, p=0.76) and 
only a marginally significant reduction in WPI (-20.3%, P=0.04). The study also 
demonstrated a significant negative correlation between results of presurgical WPI and 
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SSS and change in physical role functioning SF-36 component post-surgery(p=0.02) 
suggesting that patients with FM symptoms have less improvement in physical func-
tioning after the surgery. 
With regression analysis, the study demonstrated a difference in trend between FMS-
positive and FMS-negative patients regarding postop changes in SSS, as well as a dif-
ference in trend regarding the general health role limitation due to emotional problems 
and pain components of the SF-36. Conclusions- Patients with symptoms typical of 
fibromyalgia may have a less favourable outcome after spinal surgery.  
De Groef (De Groef et al 2017) and his team evaluated whether central sensitisation 
affects the upper limb function after breast surgery in breast cancer patients. They used 
CSI, Pain catastrophizing scale (PCS) and Disability of Arm, Shoulder, and Hand 
(DASH) questionnaires to assess the correlation between CS and upper limb dysfunc-
tion1 year following the surgery.The DASH consists of a 30-items, self-report ques-
tionnaire. Item responses range from 1 (no difficulty/no effort) to 5 (unable). Total 
scores range from 0 to 100, a higher score indicates greater disability. An impaired 
upper limb function has been defined as a score of 15 or more. Scores between 16 and 
40 indicate a problem with upper limb function, whereas scores above 40 indicate that 
these patients are unable to work and the minimal clinically detectable change is 8 to 
15 points for this questionnaire.  
Two hundred and seventy- four (274) patients were analysed and the mean DASH score 
was 23. An impaired upper limb function (>15 on DASH) was reported in 170 (62%) 
of patients with 52 patients (19%) having a score above 40. The highest correlation was 
found for signs of central sensitization (mean score of CSI was 33) with a correlation 
coefficient of 0.615 (P<.001). Central sensitisation alone was found to be responsible 
for 40% of the variance in upper limb function. The mean score of the PCS scale was 
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10 with a correlation coefficient of 0.533(p< 0.001) suggesting that patients with higher 
pain catastrophizing scores are at increased risk of impaired function following surgery. 
Conclusion- At long term, pain and central sensitisation contributes to upper limb dys-
function in breast cancer survivors. 
The study by Blonna (Blonna D et al., 2013). evaluated retrospectively the prevalence 
of fibromyalgia in a cohort of consecutive patients attending the shoulder and elbow 
service of a single centre. Patients with a final diagnosis of fibromyalgia were 18 out 
of 286 (6.3%). These patients were subsequently asked to complete a validated shoulder 
questionnaire, the new Oxford shoulder (OS) score, quality of life questionnaire, the 
short form-12 (SF-12), and a global Summary Outcome Determination score (SOD 
score- a tool with a categorical and numerical component to compare surgical outcomes 
to presurgical states) (Blonna D et al., 2010). Authors found that, among the 18 patients 
with fibromyalgia, only five had already received a diagnosis of fibromyalgia or re-
ceived a diagnosis of fibromyalgia during the first appointment, with the remaining 13 
patients diagnosed during one of the follow-up examinations. Five patients had a total 
11 surgeries. After an average follow-up of 15 months, 56% of patients reported having 
severe symptoms with the OS score and 44% had mild to moderate symptoms. 
Based on the SOD score, one patient stated that the shoulder was worse than before the 
treatment, 56% of patients reported that shoulder symptoms were unchanged, 28% re-
ported some improvement, and 11% reported great improvement. The average score 
was 1.3(-3 to 6) None of the patients reported that the shoulder was normal or almost 
normal. All of these patients reported mild to severe symptoms at the last follow-up.  
Conclusions - Fibromyalgia could be the cause of failure in the treatment of concomi-
tant painful shoulder 
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The study by D’Apuzzo and his colleagues (D’Apuzzo et al., 2012) demonstrated that 
patients with FM had higher postoperative complications such as arthrofibrosis follow-
ing TKA surgery.  Clinical outcome was assessed using the Knee Society Score pre and 
postoperatively, patient satisfaction (improvement, no improvement or worsening of 
symptoms) and the rate of postoperative complications. 
110 patients with FM awaiting TKA were identified and 102 patients were included in 
the final analysis. The average age was 64yrs (39-86 yrs.) with a mean BMI of 33. Pt 
had TKA for degenerative joint disease, inflammatory arthritis, avascular necrosis, and 
post-traumatic arthritis. Eighty-Five (85) patients reported improvement and were sat-
isfied with the surgery (82%). The Knee Society Score improved from an average of 
60 to 84 postoperatively, however, this cohort of patients was found to have a higher 
rate of arthrofibrosis (9% -compared to 1.3-4.7% after primary TKA) followed by in-
stability (12%) following TKA. This may be due to the baseline characteristics of these 
patients as found in the study by Hudson that 36% of FM patients had underlying hy-
permobility of joints (Hudson et al 1998). There are several limitations to this study 
such as the diagnosis of FM was difficult from chart review, no information on baseline 
laxity and information about physical examination of the knee following surgery avail-
able in only half cases making the overall quality of the evidence poor. 
Similarly, Bican (Bican et al., 2011) and his colleague compared satisfaction and func-
tional outcome following total knee arthroplasty in patients with FM to those without. 
They included 59 patients (90 knees). The majority of patients with fibromyalgia were 
women (57 patients, or 97%), with only two men (3%) in the cohort. The patients with 
FM were matched with one control based on type and date of surgery, diagnosis (oste-
oarthritis), fixation method, surgical approach, anaesthesia, surgeon, Charlson comor-
bidity index, age, height, and weight. 
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For evaluating pre- and postoperative functional status, as well as improvement in func-
tional status after surgery, they utilised the SF-36 survey. Patient satisfaction was de-
termined using the validated four-question 4-point (very dissatisfied, dissatisfied, sat-
isfied and very satisfied. Responses scored as 0-100; 67 being satisfied, 100 -very sat-
isfied). Fibromyalgia patients were less satisfied with the surgery overall than the con-
trol patients (p = 0.0042). There was a significant difference between the groups across 
all four dimensions measured (pain relief [p = 0.0018), ability to return to daily activi-
ties (p = 0.0062), functional recovery (p = 0.0280), and overall surgery (p = 0.0124).  
FM patients had lower pre and post-operative SF-36 scores than those without FM. 
Preoperatively, patients with FM were found to have lower scores in 4 out of 9 compo-
nent scores i.e. body pain, general health, vitality, and social functioning as well as 
overall scores. Postoperatively, patients with FM had lower scores in seven of nine 
components i.e.  physical role, body pain, general health, vitality, social functioning, 
emotional, mental health and overall scores (p = 0.0104, p = 0.0006, p = 0.0064, p = 
0.0068, p = 0.0031, p = 0.0119, p = 0.0061 and p =0.0013 respectively). There were 
comparable changes in SF-36 scores in both groups following surgery however, there 
was no significant difference between the two groups (p=0.08). Conclusion- Although 
patients with FM were less satisfied with the surgery, they appear to show improvement 
in respect of function compared to those without the following surgery. 
Donnally (Donnally JC et al., 2018) compared the postoperative complication rate, hos-
pital readmission rates and hospital cost in patients with FM who had L1, L2 spinal 
fusion surgery for the degenerative lumbar spine. 9346 patients with FM were com-
pared to 9346 patients without FM.  Patients were identified from a national database 
and those with current spine trauma, infection, metastasis of the spine, revision fusion 
surgery, three-level or greater surgeries, concomitant cervical, thoracic, anterior lumbar 
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fusion, or posterior/transforaminal lumbar interbody fusion were excluded. They were 
matched based on age, sex, race, region, and the comorbidities such as acquired im-
mune deficiency, body mass index (BMI), chronic kidney disease, chronic liver disease, 
chronic obstructive pulmonary disease, diabetes, hypertension, hyperlipidaemia, sys-
tolic dysfunction, and tobacco use using Charlson Comorbidity Index (CCI).  
77% of patients were females giving a 3.3:1 female to male ratio. During the first 30 
postoperative days, patients with FM had higher rates of acute post haemorrhagic anae-
mia (0.52% vs. 0.20%, OR: 2.58; P < 0.001). This may not be important in the clinical 
context as the rate of transfusion was not significantly elevated compared to controls 
(0.32% vs0.20%).There was no statistically significant difference found in wound-re-
lated complications within first 30 days (0.19% vs. 0.23%, OR: 0.81; P = 0.520).  Dur-
ing the first 90 postoperative days, the group found that patients with FM had signifi-
cantly higher rates of pneumonia (0.43% vs. 0.12%, OR: 3.73; P < 0.001) and postop-
erative anaemia (1.03% vs. 0.37%, OR: 2.79; P<0.001). The rates of DVT (0.12% vs. 
0.12%, OR: 1.09; P=0.832), and need for blood transfusion (0.32 vs. 0.20%, OR: 1.58; 
P1⁄40.113) were not significantly different.  
Patients with FM had greater 30-day readmission rates compared to patients in the con-
trol group (RR: 1.23; P 1⁄4 0.007). No difference was found in 90-day readmission rates 
between the two groups. Both groups had an equivalent length of stay (3.60 vs. 3.53 
days; P < 0.08).  However, the postoperative cost within the first 90 days was 1.24% 
higher for patients with FM (P<.001).  Conclusion- Primary 1- to 2-level lumbar fusions 
performed on FM patients have higher rates of postoperative anaemia and pneumonia 
as well as increased overall cost of care and increased readmission rates which can be 
explained due to increased cost of intra-hospital workup and treatment of the compli-
cations. 
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Bennett demonstrated that higher pre-operative CSI scores are associated with worse 
QOL outcomes following cervical and spinal fusion surgery (Bennett EE et al 2017). 
They evaluated the relationship of preoperative central sensitization inventory (CSI) 
scores and QOL by evaluating Patient Health Questionnaire (PHQ-9), EuroQol-5D, and 
Pain Disability Questionnaire (PDQ) which assess depression, quality of life and post-
operative function status resp. A higher score is associated with worse outcome for 
PDQ and PHQ-9 whereas for EQ-5D a low score is associated with worse outcome. 
Total 664 patients were included and 374 patients had CSI score more than 40 and 290 
patients had CSI score <40.  They found that higher CSI score was associated with 
higher (worse) postoperative PDQ total score (P=0.02), higher (worse) PHQ-9 score 
(p=0.001) and lower (worse) EQ-5D index (p<0.001).  For each 10-unit increase in CSI 
score, the average LOS increased by 6.4% (P - 0.035).  
The study by Roh (Roh HY et al 2015) and his colleagues demonstrated a positive 
relationship between high catastrophising and anxiety with decreased grip strength and 
increased disability following surgery for hand fracture. The severity of the injury was 
assessed with the Hand Injury Severity Scale (HISS). They measured the catastrophis-
ing and anxiety using the Pain catastrophising scale (PCS) and pain anxiety symptom 
scale (PASS). The study demonstrated that catastrophic thinking (beta = -1.29, partial 
R2 = 11%, p =0.001) and anxiety (beta = -0.83, partial R2 = 7%, p = 0.007) was asso-
ciated with decreased grip strength at 3 months, but by 6 months, only anxiety (beta = 
-0.74, partial R2 = 7%, p = 0.010) remained an important factor. Decreased total active 
range of motion was associated with pain catastrophizing (beta = -0.63 partial R2 = 6 
%, p = 0.024) and anxiety (beta = -0.28, partial R2 = 3%, p = 0.035) at 3 months but 
not at 6 months. Similarly, increased disability was associated with pain catastrophizing 
(beta = -1.09, partial R2 = 12%, p <0.001) and anxiety (beta = 0.93, p=0.001) at 3 
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months and not at 6 months. Conclusion- Pre-operative high catastrophizing and anxi-
ety were associated with weaker grip strength, decreased range of motion, and increased 
disability after surgical treatment for a hand fracture at 3 months. This effect was not 
seen beyond 6 months suggesting that the recovery might be delayed in these patients 
but overall, there was no difference in the long-term outcome. This is likely due to 
overcautious activity restriction in patients with ineffective coping strategies which 
may, in turn, lead to stiffness and delayed recovery. 
 The study by Nelson (Nelson S et al 2018) evaluated the postoperative outcomes in 
terms of readmission rate, postoperative complications and total global (90 days) care 
cost in patients with FM compared to those without following TKA. 76,103 patients 
were assessed in both groups. Patients with FM were found to have greater incidence 
of developing 90-day medical complications (2.88% vs. 1.43%; OR: 2.05, P<0.001) 
such as shortness of breath (OR: 3.38, 95% CI: 2.64–4.32, P<0.001), cerebrovascular 
accidents (OR: 3.27, 95% CI: 1.66–6.43, P<0.001), pneumonia (OR: 2.67, P<0.001), 
non-healing surgical wound (OR: 2.27, P<0.001), urinary tract infections (OR: 2.10, 
P<0.001), acute post-haemorrhagic anaemia (OR: 1.95, 95% CI: 1.70–2.25, P<0.001), 
thrombocytopenia (OR: 1.84, P=0.032), requiring transfusions (OR: 1.69, P<0.001), 
and acute kidney failure (OR: 1.58, P=0.005) compared to patients without  
No statistical difference was seen in the rate of delirium (OR: 1.90, P=0.082), acute 
pancreatitis (OR: 1.76, P=0.100), deep vein thrombosis (OR: 1.22, P=0.183), postop-
erative wound infections (OR: 1.12, P=0.531), paralytic ileus (OR: 1.11, P=0.739), and 
pulmonary embolism (OR: 1.04, P=0.886) between the two groups.  
Patients with FM were found to have a greater incidence and risk of (12.5% vs. 11.6%; 
OR: 1.71, P<0.001) of 90-day readmission rates with high total care cost ($71,081.10 
vs. $70,969.65, P<0.001) compared to matched controls. The study is limited due to its 
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nature (database analysis study), where miscoding and noncoding by the providers 
could be a potential source of error. Additionally, analysis of a single insurer’s data 
may not give a true cross-sectional depiction of FM.  
 
Similarly, Moore (Moore et al 2019) compared the rate of medical complications fol-
lowing total knee arthroplasty (TKA) between patients with FM and those without FM. 
A total cohort of 305,510 patients was studied. Both groups had an equal number of 
patients i.e. 152,755 patients in each group. Overall, 5,537 medical complications were 
found among fibromyalgia patients compared to 2,889 among non-fibromyalgia pa-
tients (odds ratio (OR): 1.95, 95% CI: 1.86–2.04, P<0.001] compared to the matched 
cohort. Patients with FM were significantly more likely to have UTI 
(OR:2.08,p<0.001), thoracic or lumbar neurites or radiculitis (OR : 5.85, p<0.001), 
acute post haemorrhagic anaemia (OR: 1.56,p<0.001), respiratory complications such 
as SOB (OR: 3.02, p<0.001), pneumonia (OR- 2.17, p<0.001, lung disease (OR: 2.17, 
p<0.001), higher transfusion(0R : 1.69p<0.001), acute kidney failure (OR: 1.27, 
p<0.001), neuralgia neurites (OR : 5.29, p<0.001).  
The results of the study by Moore are limited as they are based on the examination of 
a total data rather than on raw data, which may have the potential to loss of information 
and inability to analyse individual-level data. Moreover, Fibromyalgia is a risk factor 
for the development of medical complications following TKA. FM patients were found 
to have reduced respiratory muscle endurance, inspiratory muscle strength, and thoracic 
mobility (Forti et al., 2016) and these changes may be responsible for higher respiratory 
complications compared to controls. There is a significant relationship seen between 
levels of Ferritin, vitamin B12 and folic acid with the development of FM. Serum Fer-
ritin levels were found to be usually lower in FM patients compared to those without. 
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(Ortancil O et al., 2010) This may explain why these patients are more likely to develop 
acute post-operative anaemia requiring transfusion  
The study by Lopiz (Lopiz Yet al., 2019) and his team evaluated whether FM could 
have an adverse impact on the clinical outcome after isolated arthroscopic Subacromial 
decompression (IASD). They compared 20 patients with FM who had IASD with those 
without FM. The outcome was assessed using Disability Arm Shoulder and Hand 
(DASH), constant score (CS), relative constant score (rCS), VAS pain score (visual 
analogue scale). Patient satisfaction was assessed using a single 2-level question (The 
yes/no question, ‘‘Are you satisfied with the result of the surgery?’’)  
 Failure of the procedure was defined as persistent pain (VAS>3). Mean follow up was 
36 months.  The mean preoperative constant score among participants with FM versus 
the control group was 37 vs 42 (p = .16), the mean rCS was 49.2 vs 55.3 (p = .18), the 
mean DASH was 45 vs 32 (p = .02), and the mean VAS was 6.1 vs 5.3 (p = .05).  
The only parameter in which significant preoperative differences were found between 
both groups was on the DASH outcome measure. A statistically significant improve-
ment was seen on all the mean values of both groups compared with the mean preoper-
ative values.  However, the mean postoperative DASH was found to be significantly 
worse (i.e. higher score) among the patients in the FM group compared with the control 
group (38.9 vs. 20.7; p = .009). There were no statistically significant postoperative 
differences in the range of movement, strength, or pain between the FM group and the 
control group. The revision rate was 28% in FM group compared to 15% in the control 
group (p = .45). Eighty-five per cent of patients in the control group were satisfied with 
the surgery compared with 55% in the FM group (p=.03). Failure of the procedure based 
on pain was 60% in the FM group, and 30% in the control group (p = .056).  
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Although patients had significant clinical improvement (as shown by DASH scores), 
they were less satisfied with the surgery. This may be due to their different expectations 
from the surgery. 
The systematic review by Baert and his team (Baert et al., 2015) evaluated whether the 
presence of altered central pain modulation pre-surgical influences outcome after total 
knee replacement (TKR) in patients with knee osteoarthritis (OA) and if so which in-
dices of central pain modulation predict poor outcome after TKR. All studies included 
in their review were prospective cohort studies.  
The Western Ontario and McMaster Universities Arthritis Index questionnaire 
(WOMAC) was the most commonly used questionnaire to measure pain, function and 
QoL. The five most frequently evaluated psychological features were depression, anx-
iety, pain catastrophizing, fear of movement and coping strategy. A score for each sub-
scale was calculated and transformed into a 0-100 scale; with a higher score indicate 
worst symptoms.   Various questionnaires such as the Beck Depression Inventory, the 
State-Trait Anxiety Index and the Spielberger Strait Trait Anxiety Inventory were used.  
Five studies incorporated in the review demonstrated that presence of presurgical de-
pression relates to worse knee function 3 months (Faller et al., 2003), 6 months (Lopez-
Olivo et al., 2011) and 1 year (Faller et al., 2003, Utrillas-Compaired et al., 2014, Han-
usch et al., 2014) whereas 3 studies found no contribution to knee function at 6 weeks 
(Sullivan et al., 2009), 6 months (Riddle et al., 2010) or 12 months after surgery. Only 
1 study analysed the effect on QOL, demonstrating worse QOL 1 year after surgery in 
patients with presurgical depressive symptoms. (Utrillas-Compaired et al., 2014). 
Seven studies evaluated the effect of anxiety and 1 demonstrated that high presurgical 
anxiety was associated with worse knee function (Hanusch et al., 2014) whereas rest of 
the studies found no significant influence on knee function at 6 months (Riddle et al., 
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2010) or 5 years (Brander et al., 2007). Regarding the role of Pain catastrophizing: 2 
studies in the review found a positive correlation between knee function and pain 
catastrophizing (Yakobov et al., 2014, Sullivan et al 2011) whereas 2 studies did not 
find any significant association (Sullivan et al., 2009, Riddle et al., 2010). Two studies 
investigated the role of coping strategies in predicting knee function after TKR (Lopez-
Olivo et al., 2011, Attal et al., 2014). They found that less problem solving and more 
dysfunctional coping was associated with worse knee function at 6 months (Lopez-
Olivo et al., 2011). Conclusion- There is conflicting evidence for the role of depressive 
symptoms, anxiety and pain catastrophizing in predicting knee function after surgery. 
The evidence relating to the effect of depression on QOL after TKA and for coping 
strategies and knee function is also limited. 
The study by DeConde and his colleagues assessed the impact of migraine on the qual-
ity of life outcomes after endoscopic sinus surgery (ESS) (DeConde et al., 2014). They 
analysed 229 patients with medically refractory chronic rhinosinusitis (CRS) following 
ESS using disease-specific QOL surveys:  Rhinosinusitis Disability Index (RSDI), the 
Chronic Sinusitis Survey (CSS), and the Sino-nasal Outcome Test-22 (SNOT-22). 
Forty-six patients had a comorbid migraine and preoperative and postoperative QOL 
was compared with patients without migraine (n =183). Patients with migraine and CRS 
were more likely to be female (63.0% vs 44.3%, P=0.023); have fibromyalgia (10.9% 
vs 8.2%, P =0.009), and depression (30.4% vs 14.2%P= 0.010); and be less likely to 
have nasal polyposis (P 5 0.003). These patients were found to have higher pre-opera-
tive RSDI (54,6 vs 46.7, p=0.025) and average SNOT-22 scores (68.9 vs 54,6, 
p=0.019). QOL in both patients with and without migraine improved significantly after 
ESS (P = 0.003) and by comparable magnitudes (P =0.062).  
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Conclusion: Patients with comorbid migraine and CRS are more likely to have less 
severe evidence of disease and worse preoperative baseline QOL scores. This may im-
ply that patients with comorbid migraine seek surgical management earlier in the dis-
ease process. However, ESS provides comparable improvement for both patients with 
and without comorbid migraine.  
The study by Leung (Leung et al 2019) did not show any relationship between central 
sensitisation and patient satisfaction following Knee replacement in patients with OA. 
Central sensitization was assessed by measuring Pressure pain threshold (PPT) using 
digital algometer at the forearm. 249 consecutive patients with severe knee osteoarthri-
tis (KOA) for knee replacement surgery were included. Patients with other diagnosis 
and revision surgery, with cognitive impairment or dementia (established by the short 
portable mental status question), were excluded. PPTs were measured at two body sites: 
the index knee and the right forearm to provide evidence of peripheral sensitization 
(index knee) and central sensitization (forearm) resp. Assessment of central sensitiza-
tion was undertaken at the mid-point between the wrist and elbow of the volar aspect 
of the right forearm (PPT forearm). All patients had no pain in their right forearm at the 
time of assessment. Satisfaction was assessed using a 4-point Likert scale (satisfied, 
somewhat satisfied, dissatisfied and somewhat dissatisfied). Pain, stiffness and physical 
function of the knee were measured using the self-administered Western Ontario and 
McMaster Universities Index (WOMAC). A score for each subscale was calculated and 
transformed into a 0-100 scale; with a higher score indicate worst symptoms.   
 At 6 and 12 months, 8.2% and 5.1% of patients were “very dissatisfied” or “somewhat 
dissatisfied” with the outcome of their KR. Among those who reported "satisfied", 
40.6% had slight or no improvement in function (40.6%) at 6 months, with similar re-
sults at 12 months after KR. There was not enough empirical evidence to suggest any 
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association between the PPT arm with dissatisfaction (RR-0.99 at 6 months and RR-
1.002, p-0.8 at 12 months) and dissatisfaction with percent change in WOMAC scores 
in terms of function (rr-1.020, p-0.177). There was also no statistically significant in-
teraction between radiographic severity of KOA with PPT measured at both knee and 
forearm for change in WOMAC outcomes. Conclusion- Pre-operative central sensiti-
zation measured by handheld digital algometry was found not to be statistically signif-
icantly associated with satisfaction or improvement in pain and function after KR.  
The study by Duckworth (Duckworth et al 2018) assessed the relationship with pain 
catastrophising Scale (PCS) with improvement in Oxford Hip Score following THR. 
They found that Preoperative PCS had a weak negative correlation with the postopera-
tive change in the OHS (r=-0.248; P=0.0114) and the only statistically significant pre-
dictor of postoperative OHS was the PCS (P=0.0207). Conclusion(s): Preoperative PCS 
has a negative correlation with the change in OHS following THR, demonstrating that 
higher preoperative catastrophising tends to correspond with poorer improvements in 
OHS pre- to postoperatively. However, as there is no paper available to assess this di-
rectly, it is difficult to comment on the quality of evidence. 
 
4.10 Summary of overall quality of studies 
The quality of studies was assessed using Newcastle -Ottawa quality assessment score 
for cohort and case-control studies (table 21) and overall quality was scored according 
to Agency for Health Research and Quality (AHRQ), while the quality of the systematic 
review was assessed using the scale shown in Table 22 
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Table 21: Quality of studies using the Newcastle-Ottawa scale. 
Study Newcastle-Ottawa quality assessment 
score 
Overall Quality acc to 
AHRQ standard 
Soler et al., 2008 Selection-4, comparability-1, out-
come-2 
good 
Gwillym et al., 2011 Selection-3, comparability-1, out-
come-3 
good 
Bican et al., 2011 Selection-3, comparability-1, outcome 
3 
good 
D’Apuzzo et al., 
2012 
Selection-3, comparability-0, out-
come-3 
fair 
Bionna et al., 2013 Selection-3, comparability-0, out-
come-2 
poor 
DeConde et al., 2014 Selection-3, comparability -2, out-
come-3 
good 
Roh et al., 2015 Selection-2, comparability-o, out-
come-3 
poor 
De Georff et al., 2017 Selection-2, comparability -0, out-
come--1  
poor 
Bennett et al., 2017 Selection-3, comparability-0, 
outcome-2 
poor 
Ablin et al., 2017 Selection-2, comparability-0, out-
come-3 
poor 
Nelson et al., 2018 Selection- 3, comparison-2, outcome-
2 
good 
Duckworth., 2018 Only Abstract available N/A  
Donnally et al., 2018 Selection-4, comparability-1, out-
come-3 
good 
Leung et al., 2019 Selection-3, comparability-0, out-
come-3 
poor 
Lopiz et al., 2019 Selection-3, Comparability-2, out-
come-3 
good 
Moore et al., 2019 Selection-4, comparability-2, out-
come-3 
good 
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The quality of systematic review by Baert et al., 2016 was good quality review assessed 
using the scale below- overall good quality  
 
Table 22: Demonstrating the quality of the systematic review. 
Criteria Yes No Other (CD, NR, NA) * 
1. Is the review based on a focused question that is 
adequately formulated and described? y      
2. Were eligibility criteria for included and ex-
cluded studies predefined and specified?  y     
3. Did the literature search strategy use a compre-
hensive, systematic approach? y      
4. Were titles, abstracts, and full-text articles du-
ally and independently reviewed for inclusion and 
exclusion to minimize bias? 
 y     
5. Was the quality of each included study rated in-
dependently by two or more reviewers using a 
standard method to appraise its internal validity? 
 y     
6. Were the included studies listed along with im-
portant characteristics and results of each study?  y     
7. Was the publication bias assessed?  y     
8. Was heterogeneity assessed? (This question ap-
plies only to meta-analyses.) 
Not ap-
plicable 
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4.11 Discussion 
The goal of this review was to review the literature around the role of CSS in surgical 
outcomes in terms of patient satisfaction, length of stay, complications, physical func-
tion and QOL following surgery. There was no evidence available regarding these out-
comes in gynaecological surgery (hence why this MD thesis was undertaken by using 
surrogate markers looking at outcome measures in other surgeries) 
 Most of the studies identified were in the shoulder, spinal and knee surgery. One sys-
tematic review, 8 case-control, 1 cross-sectional study, and 7 cohort studies were iden-
tified and the relationship of CSS with various outcomes were broadly categorised into 
3 headings: 
1. CSS and physical function and improvement in symptom score - 
There was only one systematic review available to consider. The review indicated that 
there is conflicting evidence on the role of depressive symptoms, anxiety and pain 
catastrophizing in predicting post-operative knee function with limited evidence on the 
effect of depression on QOL after TKA and for coping strategies and knee function 
The conclusion from this review is limited by the heterogeneity of the psychosocial 
predictors evaluated and varied outcome measures in the included studies.  
As an example, several different instruments were used to measure depression- these 
included the Beck Depression Inventory, the Patient Health Questionnaire-935, the Pa-
tient Health Questionnaire-841, the Depression, Anxiety and Stress Scale. There was 
also variation in patient populations and patients’ characteristics. There was wide vari-
ation in the length of follow up period amongst the included studies which can influence 
the results (6 weeks to 5 years). In some studies, the nature of confounders was different 
which made the comparison more difficult. 
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Six studies looked at the change in symptom score and physical function after surgery. 
Out of these, only two were case-control studies (Gwilym et al, Lopiz et al., 2019) and 
in general, non-randomized observational studies do not provide good quality evidence 
(Higgins J et al., 2011). These studies demonstrated that FM, evidence of CS and pain 
catastrophizing is associated with worse outcomes, however, the study by Blonna et al 
had no information on pre-operative Oxford Score and SF-12 scores and only 5 patients 
with fibromyalgia underwent surgery. Thus, robust conclusions regarding its influence 
on outcomes of surgery cannot be drawn from such limited data. Similarly, in the study 
by Roh et al, the questionnaires used (PCS, PASS) have not been specifically validated 
in a trauma setting thus reducing the validity of their usage in this setting. There was 
no long-term data on functional outcomes as there could be improvements in motion 
and grip beyond 6 months. A single questionnaire was used to assess function (DASH) 
and analysis does not include other factors such as several damaged structures, level of 
injury, associated nerve injury which may affect the function postoperatively. Overall, 
our confidence in the results of the studies included is low. The conclusion by Ablin et 
al is limited by a relatively small number of patients and a short period of follow up 
along with the inherent patient heterogeneity due to various surgical indications.  
Future research should aim to have more studies (case-control) with more homogeneity 
and adequate sample size and follow up to achieve a stronger recommendation. 
2. CSS and postoperative complication, readmission rates, and length of stay- 
Three studies looked at the rate of postoperative complication, readmission, and length 
of study (2 case-control and 1 cohort study). All studies found a higher rate of post-
operative complications in patients with FM. However, there are limitations in study 
design particularly with the study by D’Apuzzo. There was no information on baseline 
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tissue laxity and no diagnostic criteria were used to identify patients with FM and sub-
sequently the majority of patients were satisfied with the surgery.  
Although, the study by Donally was a large retrospective study and found a higher rate 
of postoperative anaemia in patients with FM, the differences in these rates were < 1% 
and may not be relevant in actual clinical context considering that this is one of the 
common risks in orthopaedic surgery. Also, there was no information on whether pa-
tients were on any medication before surgery which could affect bleeding such as SSRI.  
The study by Moore (Moore et al 2019) has also some limitations.  The study looked at 
the aggregated data rather than raw data and therefore is a possibility of a loss of some 
information. The short duration of follow up (90 days) is also a limitation since this 
would miss any medical complications that could arise outside of the 90-day window. 
The study by Nelson is a database analysis study and the validity of such studies are 
dependent on accurate diagnostic coding and miscoding could be a potential source of 
error. Currently, about 1.3% of coding errors are seen in the Medicare population (Bur-
rus MT et al 2015). Additionally, the population of FM may not be a true representative 
as it evaluated only one insurer’s data Lastly, it did not consider other comorbid condi-
tions and adverse events that may be present in this cohort and is underreported.  
Although the studies included demonstrated a positive correlation between FM and 
postoperative complication such as pneumonia and postoperative anaemia and an indi-
rect effect on increased readmission rates, length of stay and cost of treatment, the re-
view identifies the need for further research in which all the possible risk factors are 
assessed and controlled for to reach strong evidence in this area. 
3. CSS and QOL and patient satisfaction following surgery 
Two studies demonstrated that high CSI scores and PCS scores are related to worse 
QOL and improvement following surgery (Bennett et al 2015, Duckworth et al 2018). 
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However, study by Bennett is a poor-quality study due to its retrospective nature and 
no comparator with a selection bias. It is difficult to comment on quality and evidence 
of Duckworth study as only abstract is available. 
One study demonstrated that patients with FM were less satisfied with the surgery (Bi-
can et al 2011). The main limitation of this study is that it is a small cohort study and 
lacks published information on the severity of fibromyalgia, duration of its treatment, 
and the preoperative psychological status of the patients 
Three studies did not show any difference in QOL following surgery between patients 
with and without FM. All of these studies showed comparable improvement in symp-
toms in both groups (Soler et al 2008, Leung et al 2019, Deconde et al 2014). The study 
by Leung and his group whilst having a large number of patients included only a single 
measure for CS (QST) and also did not include other predictors such as pain catastro-
phizing and fulfilment of expectations. Also, the result of this study should be inter-
preted carefully as 1. the sample size in this study was underpowered to demonstrate a 
statistically significant association between PPTs and KR outcomes. 2. PPTs, measured 
using a handheld digital algometer, have little predictive value as it measured a single 
static QST parameter and does not measure dynamic QST parameters and 3. The au-
thors did not include other predictors of CS such as pain catastrophizing or depression.  
The study by Soler had an overall incidence of FM patients as 9% and there is a possi-
bility that they may have missed some patients with FM as only those who had a pre-
vious diagnosis of FM were included. The review concluded that there is conflicting 
evidence on the impact of CSS on QOL and patient satisfaction after surgery. 
 It is increasingly acknowledged that satisfaction is one of the important but complex 
concepts to assess post-surgical outcomes as there is a shift in paradigm in patents care 
towards greater involvement of the patient in decisions regarding their treatment. 
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(Kitson et al 2013). Also, it is important to meet the expectations and needs of the pa-
tients. To meet the requirement of this shared decision-making process clinicians 
should be aware of the factors responsible for poor post-operative recovery. Despite the 
difficulty of how to interpret and measure patient satisfaction, it is recognized to be an 
indicator of the quality of care. (Jaensson M et al 2019). Therefore, well-designed stud-
ies are required to provide robust and valuable evidence on the role of CSS on patient 
satisfaction following surgery  
The strengths of this review are that this is the first systematic review to evaluate the 
relationship between CSS and postoperative clinical outcomes in terms of patient sat-
isfaction, QOL, complications, length of stay and physical functioning. The limitations 
of this review are that it has not included studies with pain as the primary outcome 
which can affect functioning and QOL indirectly and also there was wide variation in 
types of studies, outcome measures and length of follow up. 
Despite these limitations, the results of this review have positive clinical implications. 
It does highlights that there is a need to pay greater attention to biopsychosocial con-
siderations in surgical intervention to nurture better outcomes. If the identification of 
patients at risk of poor outcomes is evaluated early in the surgical assessment, potential 
suffering could be reduced by utilizing a broader therapeutic approach including that 
targeting desensitization of the central nervous system before considering a more inva-
sive/ surgical approach. 
4.12. Conclusion- The results of this systematic review demonstrate that limited evi-
dence is currently available on the impact of CSS and CS on clinical outcomes of sur-
gery. Overall, patients with FM and CS appear to have higher preoperative symptom 
severity and worse functional outcome with a higher rate of complications after surgery 
but the evidence on QOL and patient satisfaction is conflicting However, the relatively 
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limited evidence from this review does not suggest that presence of CSS/ fibromyalgia 
should be considered an absolute contraindication to surgical treatment. The evidence 
to date does suggest that the potential negative effects this syndrome can have on post-
operative outcomes must be adequately explained to the patients so that expectations 
can be managed more realistically. 
 Future studies should be designed to specifically address the impact of CSS and CS on 
surgical outcomes specifically in the field of gynaecology since to date we have used 
data from other specialities as a surrogate marker. This is addressed in the next part of 
the study where we studied the role of CSS in pelvic organ prolapse surgery 
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Chapter 5 - A prospective cohort study to compare the outcomes of prolapse sur-
gery between women with evidence of Central Sensitivity Syndrome (CSS) and 
women without CSS 
 
Abstract-  
Introduction- Pelvic organ prolapse has significant impact on quality of life. The 
lifetime risk of surgery for POP can vary from 11-20%. Conditions such as fibromyal-
gia, Chronic fatigue syndrome (CFS), Temporomandibular disorders collectively 
known as central sensitivity syndrome (CSS) may affect the outcome of surgery. The 
aim of this paper is to compare the outcomes of pop surgery between women with 
CSS and women without CSS. 
Method- This was a prospective cohort study conducted between 2014-2017 at four 
centres (Plymouth, Bristol, Truro and Swansea) due to the training rotation of the re-
searcher. Central sensitisation Inventory (CSI) was used to identify women with evi-
dence of CSS.  Subjective and objective outcomes following surgery were compared 
between two groups using POP-SS, EGGS, Pain scores and POP-Q. Non- parametric 
test was used for analysis. 
Result- Total 78 women were recruited. Complete data was available in 62 patients. 
23 patients were with evidence of CSS and 39 patients were without evidence of CSS. 
Women with evidence of CSS have higher pre- and post-operative POP-SS scores 
This was statistically significant (P- <0.0005, p-0.004).  Seventeen (73.9%) women 
with CSS compared to 38 (97.4%) women without CSS demonstrated improvement 
of minimum 6 points on POP-SS scale. McGill’s pain scores were higher in women 
with CSS both pre- and post- surgery.  
95% of women without CSS achieved their goals and were satisfied with the surgery 
whereas, only 69.5% of women with CSS achieved their goals and were satisfied. 
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Conclusion- There is less favourable outcome of surgery in women with CSS espe-
cially in terms of persistence of symptoms, pain and overall satisfaction. 
Key words- 
Central sensitivity syndrome, pelvic organ prolapse, POP-Q, POP-SS (Prolapse symp-
tom score) 
5.1. Introduction 
Pelvic organ prolapse (POP) is a frequent indication for hysterectomy and pelvic sur-
gery and accounts for 15-18% of all hysterectomies. It is the most common indication 
for hysterectomy in postmenopausal women (Whiteman MK et al., 2008). 
Pelvic organ prolapse is a complex condition with both functional and structural com-
ponents to manage (Vitale SG et al., 2016) and therefore can have a significant impact 
on quality of life and psychological well-being (Hefni M et al., 2013). 
According to the National Health Service (England) Hospital Episode Statistics (HES), 
the number of admissions for prolapse surgery was 1/1000 women in 2005 and 36% 
between 2008 - 2017 (see p.34/35). 
The principal symptom manifested in prolapse is the perception of a bulge within the 
vagina (Barber MD et al., 2006). A significant proportion of women, however, may 
also complain of a dragging sensation or pelvic pressure (Barber MD 2005). Women 
with such pressure or dragging sensation might not have significant objective prolapse 
on examination. 
Having excluded the time of the examination (objective POP tends to be more obvious 
later in the day), bladder and bowel fullness during the examination, as well as the 
patient position, a possible explanation for this discrepancy is the presence of an under-
lying central sensitivity syndrome. As mentioned previously CSSs includes conditions 
such as fibromyalgia, IBS, temporomandibular joint disease (TMJ), chronic fatigue 
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syndrome, tension headache/ migraines, restless leg syndrome, multiple chemical sen-
sitivities, interstitial cystitis, myofascial pain syndrome and post-traumatic stress disor-
der (PTSD). As discussed earlier in the thesis, research studies have demonstrated that 
the patients suffering from this syndrome have higher symptom bother from their pro-
lapse than those without (Adams K et al., 2014). Likewise, surgical intervention can be 
less effective for the relief of pain as seen following decompression in shoulder im-
pingement syndrome (Gwilym SE et al., 2011). 
It is currently unclear whether women who complain of a disproportionate dragging 
sensation to the objective pelvic organ prolapse or who have evidence of CSS benefit 
as much from POP surgery compared with women with no evidence of CSS. There are 
no published studies to date to answer this question. 
The aim of our study was to compare the outcomes of pelvic organ prolapse surgery 
between women with evidence of CSS and women without evidence of CSS. 
5.2. Method 
This was a multicentre prospective cohort study. The study was approved by the West 
of Scotland Research Ethics Committee(13/WS/0319). 
Using the PICO format: 
Patients: Women scheduled for pelvic organ prolapse surgery (as agreed by patient and 
surgeon) 
Inclusion criteria: Women scheduled for POP surgery who were willing to participate, 
could give informed consent and be able and willing to comply with all study require-
ments. 
Exclusion criteria: 
• Women who could not give informed consent. 
• Women who had concomitant urinary or faecal incontinence surgery. 
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• Who had previous prolapse surgery in the same vaginal compartment.   
• Women with severe vaginal pain were excluded from the study.  
Intervention: Surgical treatment for pelvic organ prolapse. Outpatient/ Telephone fol-
low-up was used to assess subjective and objective outcomes of surgery using interna-
tionally recommended outcome measures. 
Comparison: Women without central sensitivity syndrome. 
Outcomes: Both subjective and objective outcomes were compared using  
internationally recommended outcome measures as per the International Urogynaeco-
logical Association/ International Continence Society (IUGA/ICS) POP outcomes 
(Toozs-Hobson P et al., 2012). 
The primary outcome was the prolapse symptomology using the validated Pelvic Organ 
Prolapse Symptom Scale (POP-SS) between the two groups at 3 months after surgery.  
The secondary outcomes were: 
1. Patient global impression of improvement-(PGI-I)  
2. Prolapse stage at original site by POPQ  
3. Subjective pain experience by using Short-form McGill’s pain Questionnaire 
for somatic pain  
4. Satisfaction with surgery by using the acronym EGGS (E- Expectations, G-goal 
setting, G-goal achievement, S-satisfaction between the two groups). 
The following study questionnaires and forms were used in the study: 
1. Central sensitisation inventory (CSI) – See pg-30 for description of the scale 
2. PGI-I –This has been validated and consists of a single item that asks the par-
ticipant to rate improvement of their condition using a seven-point scale with 
the following anchors: very much better, much better, a little bit better, no 
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change, a little bit worse, much worse, very much worse. Participants are con-
sidered to have had a positive outcome if they respond that they are “very much 
better” or “much better” (Yalcin I et al., 2003; Srikrishna S et al., 2010). This is 
a commonly used global index to rate the response to the treatment and is now 
frequently used in outcome studies. It is simple, direct and easy to scale. 
3. POP-SS – This consists of seven items, each with a 5-point Likert response set 
(0 = never, 1 = occasionally, 2 = sometimes, 3 = most of the time and 4 = all the 
time). Total score ranges from 0-28. The question format and response set were 
modelled to standardise outcome measures in pelvic floor dysfunction research 
and clinical practice (Hagen S et al., 2009). This questionnaire was used as it is 
simple, brief and has been found acceptable to women. This is now been fre-
quently used in research and clinical arena. This is also found to be very sensi-
tive to detect a change in pelvic organ prolapse symptom score following con-
servative or surgical intervention (Hagen S et al., 2009). 
4. Short form McGill’s pain questionnaire (SF-MPQ)– There are three different 
parts to assess pain experience. The main component of the SF-MPQ consists 
of 15 descriptors (11 sensory; 4 affective) which are rated on an intensity scale 
as 0 = none, 1 = mild, 2 = moderate or 3 = severe. Three pain scores are derived 
from the sum of the intensity rank values of the words chosen for sensory, af-
fective and total descriptors. The maximum score is 45 (33 on somatic sub-
scale). There is no cut off for a clinically significant value, but higher scores 
indicates worse somatic pain. The other two parts are: The Present Pain Inten-
sity (PPI) index of the standard MPQ (range from 0-5) and a visual analogue 
scale (VAS) ranging from 0-10 (Melzack R 1987). Although, the questionnaire 
was designed for the descriptive purpose, a mean improvement of >5 on total 
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scores (0-45) demonstrated a significant clinical change in patients with mus-
culoskeletal conditions after rehabilitation and surgical intervention (Strand LI 
et al., 2008). 
5. EGGS –The acronym EGGS was used to improve clinician understanding of 
the surgical outcomes. These are: E- expectations, G-goal setting, G-goal 
achievement, S-satisfaction using a visual analogue scale. (Brubaker L et al., 
2005). This was used in the study because patient selected goals are now in-
creasingly used to assess the improvement in the symptoms following any in-
tervention. This has also been used widely in urogynaecology arena as an out-
come assessment tool (e.g. following pessary use, pelvic floor muscle training, 
anti- muscarinic therapy for overactive bladder).  
Women undergoing pelvic organ prolapse surgery were recruited and asked to complete 
these questionnaires and forms pre-operatively and 3-6 months after the surgery. The 
CSI was used to screen patients with symptoms suggestive of CSS and not as a treat-
ment outcome measure. 
The objective assessment of prolapse was undertaken using the pelvic organ quantifi-
cation system (POPQ) (Bump RC et al.,1996) (see pg. 36) by vaginal examination to 
assess the stage of prolapse pre-operatively and at follow up. 
The prolapse surgery was conducted with the surgeons being blinded to the patient’s 
status of central sensitisation. Data on basic demographics including age, parity and 
BMI were also collected.  
A successful outcome of surgery was defined as: 
 1) If there was a minimal improvement of 6 points in POP-SS score for the ques A1-
A4 (the minimally important difference (MID) for the POP-SS). 
2) Symptom rating as “very much better” or “much better” on the PGI-I scale.  
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3) Patient expectations met, and goals achieved and satisfaction with the outcome of 
their surgery using the ‘EGGS’ instrument. 
4) Improvement in subjective pain experience as measured by McGill’s pain instru-
ment. 
 5) Improvement in the POP-Q stage. The objective prolapse is said to be persistent if 
the prolapse is up to or beyond hymen during maximum Valsalva manoeuvre. The def-
initions equate with those used in a previous large epidemiologic study looking at the 
prevalence and trends of pelvic organ prolapse (i.e. each POP-Q point greater than -1 
cm) (Wu JM et al., 2014). 
Women with evidence of CSS were designated as group 1 and women without evidence 
of CSS were named as group 2 
Sample size: Hagen et al., 2008 reported that the POP-SS scale, which is scaled from 
0-28 is likely to be skewed, therefore for the evaluation of suitable sample size to ade-
quately power the study we used non-parametric tests. Again, from Hagen’s data, the 
type of differences in scores may be 6 points on the scale, with two group average points 
being 9 and 3. We did not have any good estimates for the variance so choosing a con-
servative value equal to the difference (6 points) using a Mann-Whitney rank sum test 
we would need at least 20 per group for a power of 80% at a 0.05 significance level 
(two-sided). 
Statistical analysis was performed using SPSS VERSION 25.  Chi Square test and 
Mann Whitney U tests were used to compare the data. Statistic calculation was under-
taken by the author and counterchecked by the statistician. 
 
 
 
117 
 
5.3. Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
78 women were recruited. Complete data were available in 62 patients. Out of these 
62 patients, 23 patients had evidence of CSS and 39 patients were without evidence of 
CSS. 
There were few repeat POPQ assessments as some patients within the study declined 
vaginal examination (4 patients declined in group 1 and 6 in group 2) Some patients 
had telephone follow up consultations (6 in group 1 and 8 in group 2) because they 
did not attend outpatient clinics. 
The mean BMI was 28.9 in group 1 and,26.7 in group 2 with mean Parity of 2 (table 
10). The mean age was 60 yrs. in group 1 and 63.3 yrs. in group 2 (table 10). 
A cut off CSI score of 40 was used to identify women with evidence of CSS as demon-
strated by Neblett R et al (See chapter 3). The mean CSI score in group 1 was 53.13 
(std dev (SD)11.90). The mean CSI score in group 2 was 21.23 (SD 9.76) (table 23).. 
Two sample Kruskal Wallis test was used to compare the distribution of CSI scores, 
demonstrate that both groups followed a different distribution(p<0.0005) . 
Women recruited-(n-78) 
Complete data-(n-62) 
Women with CSS (n-23) 
Women without CSS (n-39) 
Post op POPQ assessment (13) 
(((13)(13)13131313) 
Post op POPQ assessment (25) 
((n2525) 
Lost to Follow up-16 
Figure 7: Central sensitivity syndrome Results 
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Table 23: Showing demographics and CSI scores in both groups. 
Demographics 
(mean value) 
Women with 
CSS 
Women without CSS 
BMI 28.9 26.7 
AGE (years) 60  63.3  
PARITY 2 2 
Mean CSI score 
(+/- SD) 
53.13(+/-11.90) 21.23(+/-9.76) 
 
 
 
Mean stage of prolapse in group 1 before surgery was stage II for anterior compartment 
(mean POP-Q system point Ba, 0 +/- 1.41, stage II for posterior compartment (system 
point Bp, 0.3 +/- 0.7) and stage I for apical, uterine (mean point C, -2.60 +/- 2.7). None 
of the patients had previous repair or hysterectomy.  
 In group 2 the mean stage of prolapse for anterior compartment was stage III (mean 
POP-Q system point Ba, 1.5 +/-2.56), for posterior compartment stage II (mean system 
point Bp-.1+/- 1.64) and stage II for apical compartment (mean system point C, -1.05 
+/- 2.85). In this group,4 patients had a previous abdominal hysterectomy and 2 had a 
previous prolapse repair in a different compartment. 
POP-SS score 
Regarding the primary outcome of prolapse symptomology, women with evidence of 
CSS had higher pre- and post-operative POPSS scores compared with women without 
CSS. This was statistically significant (tables 24 & 25). The study also demonstrated 
that women with evidence of CSS (Group 1) had higher bother with their symptoms 
with less objective prolapse compared with women with no evidence of CSS (table 26) 
(p<0.0005). 
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Table 24: Showing pre-operative POPSS scores in both groups. 
Groups Mean Range Std Dev Mann Whit-
ney u test 
Group 1-Women 
with CSS (N-23) 
18.08 16.00 4.53 P< 0.0005 
Group 2-Women 
without CSS(N-
39) 
12.35 20.00 4.74  
 
Table 25: Showing postoperative POPSS scores for both groups. 
Groups Mean Range Std dev Mann Whit-
ney u test 
Women with 
CSS (N-23) 
5.69 26.00 6.90  
P=0.004 
Women with-
out CSS(N-39) 
1.71 11.00 2.35  
  
Table 26: Showing preoperative POPSS scores with POP-Q system point quantification for both groups. 
Groups Mean pre-op-
erative POP-
SS score 
Mean system 
point Ba on  
POP-Q 
Mean system 
point Bp on  
POP-Q 
Mean system 
point C 
Women with 
CSS (Group1) 
   18.08 0 +/- 1.41 0.3 +/- 0.7 -2.60 +/- 2.7 
Women with 
no evidence of 
CSS (Group 
2) 
   12.35 1.5 +/-2.56 1+/- 1.64 -1.05 +/- 2.85 
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Seventeen (73.9%) women in group 1 demonstrated improvement of minimum 6 
points on POP-SS scale (a1-a4) whereas 38(97.4%) women showed improvement in 
group 2. This was not statistically significant (p=0.15). 
McGill’s pain score- 
Although both groups had improvement in McGill’s pain score following surgery, 
pain scores were higher in group1 than group 2 both pre and post- surgery (table 
27,28). 
In women with CSS (Group 1), the mean pre and post-operative VAS (for pain) on 
SF-MPQ was 3.91 and 1.60 respectively and the mean pre and post-operative PPI in-
dex was 1.69 and 0.91 respectively compared with women without CSS (group 2) 
where pre and post-operative VAS was 1.84 and 0.71 and the pre and post-operative 
PPI index was 0.12 and 0.10 respectively.  
Table 27: Showing preoperative McGill’S pain scores in both groups. 
Groups Mean Range Std Dev Mann Whit-
ney U test 
Women with 
CSS 
16.17 32.00 9.69  
P<0.0005 
Women with-
out CSS 
6.48 25.00 7.58  
 
Table 28: Post-operative McGill’s Score in both groups. 
Groups Mean Range Std Dev Mann Whit-
ney U test 
Women with 
CSS 
4.82 26.00 6.91  
P<0.0005 
Women 
without CSS 
0.84 14.00 2.5  
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EGGS 
Ninety-five per cent (37/39) of women in group 2 were much or very much satisfied 
with the surgery with an average satisfaction score on VAS of 8.2, while only 69.5% 
(16/23) were satisfied with the outcome of the surgery in group 1 (p-0.005) (table 29). 
The average satisfaction score in this group was 6.2. The expectations and goals of both 
groups are shown in tables 30 and 31. 
 
Table 29: Showing Satisfaction in both groups on VAS. 
Groups  Patient satisfied Patient not 
satisfied 
 
With CSS (Group-1)    16 (69.5%) 7 (30.5%) P<0.005 
Without CSS (Group-2)   37 (95%) 2 (5%)  
 
Table 30: Showing expectations and Goals of women with CSS. 
     Expectations (23)         Goals (23) 
No bulge (14) 60.8%  Be comfortable, walk comfortably and 
return to normal (8) 
More comfortable (3) 13.3% Relief from periods (2) 
Dragging sensation to go (2) 8.6% Sex without pain (1) 
Open bowels effectively (4) 17.3% Not to use pessary (1) 
 Open bowels easier (6) 
 Not to digitate (4) 
 No bleeding (1) 
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Out of 14 women whose expectation was to feel no bulge,13 achieved those goals. Out 
of 3 women whose expectation was to become comfortable and have no pain only 1 
achieved this goal. Only 1 of the 4 women whose expectation was to ‘open their bowel’ 
more effectively, achieved this goal. There was no difference in the mean POP-SS score 
between women whose predominant expectation was to get rid of the bulge vs to be 
comfortable vs to open bowel effectively (17.85 vs 17.33 vs 16.5). 
Table 31: Showing expectations and Goals of women without CSS. 
Expectation (39) Goals (39) 
No bulge (31) 79.4 % Comfortable-(20) 
Dragging sensation to go (6) 15.4 % Walk comfortable (5) 
Bowel function to improve (1) 2.6% Return to normal life (4) 
Bladder function to improve (1) 2.6% Able to go to the gym- more ac-
tive (2) 
 No pessary (1) 
 No recurrent UTI (1) 
 Pain free (1) 
 Relief in heavy periods (1) 
 Normal toilet (n-2) 
 No dragging sensation (2) 
 
In group 2 (women without CSS), only 2 did not achieve their goals. One was in the 
cohort with the expectation of no bulge and due to worsened bladder function, and the 
other who had the expectation of improving bowel function which did not happen fol-
lowing surgery. There was no much difference in the mean pre-operative POP-SS score 
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in this group between women whose expectation was no bulge (12.03) vs whose ex-
pectation was to have no dragging sensation (13) vs whose expectation was to improve 
bladder /bowel function (11).   
PGI-I 
Seventeen (73.9%) reported their symptoms to be very much better or much better on 
the PGI-I scale in group 1 compared with 97.4% women in group 2 (table 32) (p< 
0.0005).  
 
Table 32: Showing PGII scale in both groups. 
PGII scale   Women with 
CSS 
Women without 
CSS 
Chi square test 
1-2 (very much 
better, much bet-
ter) 
          17(73.9%)             38(97.4%)  
P<0.0005 
3-6 (little better, 
no change, worse, 
very much worse 
            6(26.1%)              1(2.6%)  
 
POP-Q 
In terms of persistence of objective prolapse (i.e. if the prolapse was up to or beyond 
the hymen during maximum Valsalva manoeuvre), 2/13(15%) women in group-1 had 
objective persistence of prolapse compared with 2/25(8%) in group 2. (p<0.0005) (table 
33,34). 
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Table 33: Showing persistence of objective prolapse in both groups. 
Persistence of 
Objective pro-
lapse 
  Women with 
CSS 
Women without 
CSS 
Chi square test 
Persistent pro-
lapse 
2(15%) 2(8%)  
P<0.0005 
No prolapse 11(85%) 23(92%)  
 
 
Table 34: Showing pre and post-operative POP-Q in group1. 
GROUP-
1 with 
CSS 
 
Pt no 
POP-Q Before surgery  POP-Q after surgery (4-6-month 
FU) 
 
Ba 
Leading 
edge an-
teriorly 
Bp-leading 
edge poste-
riorly 
C Ba 
Leading 
edge an-
teriorly 
Bp 
leading 
edge poste-
riorly 
C 
1 -1 0 -1 -2 -2 -6 
2 -1 1 -3 +2 -2 +2 
3 0 -2 -5 -2 -2 -5 
4 -3 0 -6 -2 -2 -6 
5 -2 0 -5 -2 -2 -6 
6 0 -2 0 -2 -1 -5 
7 +2 +1 -1 0 -1 -6 
8 0 2 -7 -3 -3 -7 
9 2 -2 -1 -2 -2 -7 
10 -3 0 -6 -2 -2 -5 
11 -1 -2 +1 -3 -1 -4 
12 -2 +3 -5 -2 -3 -5 
13 +2 -1 -4 -2 -2 -5 
 
Note-The above table (34) displayed the leading edge of prolapse as per International 
Continence Society, the stages of Pelvic organ Prolapse determined by POP-Q meas-
urements are based on the most distal prolapse and is used in most researches (Ingrid 
N et al., 2004). 
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Multiple linear regression analysis was also conducted to see if the preoperative POP-
SS, McGill’s scores. patient perception of improvement (PGI-I), EGGS and Post-oper-
ative POP-SS, McGill’s) is related to the severity of CSI scores treating CSI as contin-
uous data. This revealed a non- significant model with moderate effect of CSI scores 
(Table 35). Individually, only pre-operative POP-SS scores approached a significant 
Beta of 0.682 (Table- 36). Inspection in the trend in the data suggest that there was no 
linear relationship of CSI scores with patient satisfaction and patient global impression 
of improvement. This may be due to the small numbers as multiple regression usually 
works well with large number 
Table 35: Model summary of the Multiple Regression analysis. 
R R square Adjusted R 
square 
Std Error OF 
the estimate 
.694 .482 .240 10.38223 
 
Table 36: Showing coefficients of each predictors after multiple regression analysis. 
 Unstandard-
ized B 
Coefficients 
Std Error 
Standardised 
coefficients 
Beta 
t Sig 
constant -3.494 18.002  -.194 .849 
PGII -.718 1.772 -.085 -.405 .691 
Preop McGill .253 0.253 .206 1.001 .333 
Preop 
POPss 
1.791 .601 .682 2.981 .009 
Post op 
MCGILL 
1.121 .509 .652 2.203 .044 
Post-op 
POPss 
-.530 .771 -.307 -.686 .503 
EGG 4.934 6.246 .186 .790 .442 
Satisfaction 
score 
2.035 1.365 .561 1.491 .157 
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5.4. Discussion 
Our study has demonstrated that women with evidence of CSS have less successful 
outcomes from POP surgery in terms of patient satisfaction, goal achievement and per-
sistence of pain are concerned. Although, there was no persistence of objective prolapse 
in 11/13 women (85%), the global impression of improvement was seen only in 74% 
in women with evidence of CSS, whereas in women without CSS, the global impression 
of improvement was seen in 97.4% women with no persistence of objective prolapse in 
92% women (see tables 19,20). There was no linear relationship seen between CSI 
scores and patient global impression of improvement and satisfaction  
These findings demonstrate that for patients in group 1 with CSS, the subjective out-
come is less favourable than in patients in group 2. Jacob N et al demonstrated that 
patients with presurgical evidence of Fibromyalgia/FMS-like symptoms experienced a 
less significant improvement in pain and no improvement in somatic symptoms as op-
posed to patients without evidence of FMS. The latter group experienced significant 
improvement in both pain and other symptoms after surgery (Jacob NA et al., 2017). 
This is similar to the findings of our study where patients with evidence of underlying 
CSS have less satisfaction (based on Satisfaction part of EGGS) with the surgery and 
less improvement in their symptoms despite a clinically evaluated, good anatomical 
outcome. 
As mentioned previously, Central Sensitisation is a concept developed over recent years 
to explain the manifestation of chronic pain in which there is no clear anatomical basis. 
The understanding of both CS and CSS is more than a semantic consideration and ap-
pears to carry important practical relevance.  Patients can potentially be stratified ac-
cording to the intensity or periodicity of the symptomology relating to the underlying 
CSS. This information might help tailor treatment modalities used to improve the 
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chance of a successful outcome from treatment. The management of women who are 
considered candidates for prolapse/POP surgery typically includes anatomical evalua-
tion by vaginal examination/POPQ staging and the severity and effect of prolapse 
symptoms on women’s quality of life. While these measures will be important in the 
process of surgical decision-making, the results of the current study imply that addi-
tional factors may be worthy of evaluation. e.g. presence of a CSS as this might lead to 
persistent symptoms despite anatomical correction.  
Issues such as disturbed or unrefreshing sleep, symptoms of irritable bowel, difficulty 
with memory and concentration, the presence of widespread pain, previous diagnosis 
of fibromyalgia, CFS, TMJ, PTSD and depression, are all common features of CSSs 
and can be helpful in the assessment and diagnosis of CSS. 
It also seems appropriate to include identification of myofascial trigger points during 
vaginal examination as a part of prolapse assessment. It is likely that that levator myal-
gia, which has previously been shown to be present in 24% of gynaecological patients 
presenting with pain might represent another manifestation of central sensitisation and 
might contribute significantly to chronic pain in women with pelvic floor dysfunction 
(Adams K et al., 2014). Treatment modalities may then be tailored accordingly.  
Surgically induced neuropathic pain (SNPP) is seen around in 10-50% of patients after 
common surgical procedures such as groin hernia repair, breast and thoracic surgery 
(Kehlet H et al., 2006) while, severe SNPP has been observed in around 2-10% of pa-
tients (Kehlet H et al., 2006). The presence of pre-operative pain (Gerbershagen HJ et 
al., 2010), and the patient’s psychological state (Hinrichs-Rocker A et al., 2009) can 
increase the risk of persistent SNPP. There is also evidence in the literature that baseline 
preoperative pain is a predictor of chronic postoperative pain after hysterectomy 
(Theunissen M et al., 2016). Similarly, a meta-analysis of patients undergoing total 
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knee arthroplasty found that pain at other sites, catastrophizing, and depression were 
found to be predictors of chronic postoperative pain (Lewis GN et al., 2015). Our study 
also demonstrates, unsurprisingly, that there is persistent higher somatic pain score in 
women with evidence of CSS. Borsook proposes that it is important to identify the 
predictors of persistent SNPP (such as patients with manifestations of CSSs) before any 
surgical treatment is undertaken (Borsook D et al., 2013).  
Women with fibromyalgia (FM) were also found to report pelvic floor symptoms at a 
severity greater than women presenting to a urogynaecology practice without FM de-
spite being the same age (Jones KD et al., 2015) and therefore, it is possible that en-
hanced sensory processing makes women with FM more aware of pelvic organ prolapse 
symptoms than women without FM. This was similar to the findings of our study above 
which demonstrated that CSI score and POP-SS scores have linear relationship. 
FM is also found to be a risk factor for the development of pelvic pain after vaginal 
mesh implantation for treatment of pelvic organ prolapse (Elizabeth JG et al., 2017). 
This was not a procedure undertaken in our study. However, it might suggest that in-
creased central sensitisation as part of a deteriorating CSS could be another reason for 
the sustained post-operative pain noted after mesh surgery in addition to any localised 
irritation from the mesh itself. 
There is a large body of evidence that sensation can be enhanced through a variety of 
dysfunctional pain pathways (Julien N et al., 2005). This might explain why these pa-
tients are highly symptomatic.  
Various treatment modalities have been used in an effort to desensitise the CNS in pa-
tients with CS. These include pharmacological (pain modulators), manual therapy (re-
lease of myofascial trigger points) and psychological stress management.  Regarding 
the pharmacological approach – drugs will work primarily by (1) blocking the 
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peripheral drive which is maintaining the sensitisation or (2) interacting with the central 
transmitter systems involved in the facilitated gain (Arendt-Nielsen L et al., 2018). Ex-
amples of drugs which can have an inhibitory effect on temporal summation include 
dextromethorphan (Price DD et al.,1994), ketamine (Arendt-Nielsen L et al., 1995), 
imipramine (Enggaard TP et al., 2001), gabapentin (Arendt-Nielsen L et al., 2007), ox-
ycodone (Suzan E et al., 2013), and venlafaxine (Yucel A et al., 2005). Serotonin-nor-
adrenaline reuptake inhibitors (SNRI’s), such as duloxetine, have a broad efficacy 
across a number of different chronic pain conditions, such as osteoarthritis, fibromyal-
gia and peripheral neuropathic pain (Lunn MP et al., 2014). SNRI’s drugs activate nor-
adrenergic descending pathways along with serotonergic pathways (Millan MJ, 2002).  
The a2-d ligands centrally inhibit the release of neurotransmitters (e.g. noradrenaline, 
serotonin, substance P) and potentially reduce CS by decreasing descending pain facil-
itation (Donovan-Rodriguez T et al., 2006). Gabapentin and pregabalin are the two 
drugs that exert their effect by binding to the a2-d subunit of calcium channels (Thorpe 
AJ et al., 2010). Pregabalin is found to be effective and remarkably safe and mitigates 
the symptoms of various types of neuropathic pain (Verma V et al., 2014).  
Tapentadol is a centrally acting analgesic and the CPM enhancing effect is due to its 
dual action (µ-opioid receptor agonist plus a norepinephrine reuptake inhibitor) and has 
been observed with repeated dosing over weeks. This is found to be effective and well 
tolerated in various chronic pain conditions (Riemsma R. et al., 2011) such as OA pain 
(Steigerwald I et al., 2012b), low back pain (Buynak R et al., 2010), painful peripheral 
diabetic neuropathy (Schwartz S et al., 2015), and cancer pain (Kress HG et al., 2014).  
Non -pharmacologic strategies such as cognitive behavioural therapy and biofeedback 
can influence pain sensitisation in some patients e.g.  A recent metanalysis has shown 
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mixed efficacy from CBT in pain management in patients with fibromyalgia. CBT was 
found to be better for reducing depression and increasing pain coping skills but was not 
found to be effective in improving pain and fatigue (Bernardy K et al., 2010). Electro-
myographic (SEMG) biofeedback has been found to be effective in improving pain. 
Babu et al demonstrated a significant reduction in VAS score for pain as well as a re-
duction in the tender points in patients with FM with the use of EMG biofeedback 
(Babu AS et al., 2007), however, Glombiewski et al reviewed seven different studies 
on biofeedback in patients with fibromyalgia. Biofeedback was found to be effective in 
reducing pain intensity, but the trials were of poor quality. There was no benefit on 
fatigue and sleep (Glombiewski JA et al., 2013). Taken this into consideration, biofeed-
back is not recommended by European League Against Rheumatism (EULAR) 
(Macfarlane GJ et al., 2016). 
Some of the symptoms associated with POP such as back pain, vaginal pain, bowel and 
bladder dysfunction can be due to a non-relaxing pelvic floor, or presence of levator 
myalgia which may also be a manifestation of central sensitisation (Adams K et al., 
2014). Physical therapies to alleviate hypertonicity can be undertaken in these women 
before surgery. For example, Thiele in his study of 324 patients with coccydynia re-
ported improvement in 62% patients with massage only. He performed the massage by 
applying pressure along the fibres of pelvic floor muscle (according to the patient tol-
erability) about 10-15 times on each side of the pelvis during one session (Thiele GH 
1963). 
Strategies such as moderate aerobic exercise is an integral part of the treatment of pa-
tients with fibromyalgia. Recently, tai chi intervention was found to have greater ben-
efit than aerobic exercises in terms of improvement of symptoms of fibromyalgia 
(Wang C et al., 2018). Tai chi is a multicomponent mind body intervention which 
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combines physical, spiritual, psychosocial and behavioural components to boost health 
and fitness. Wang C et al randomly assigned patients either to aerobic exercise (24 
weeks, twice weekly) or to tai chi intervention (12-24 weeks, once or twice weekly). 
Patients were then followed for 52 weeks. Maximum improvement was seen at 24 
weeks (Wang C et al., 2018). 
Various other strategies have been described in the literature for non-relaxing pelvic 
floor such as injection of local anaesthetics on trigger points, acupuncture, biofeedback 
and neuromodulation. For example, Clemens et al reported an improvement with bio-
feedback in chronic pelvic pain on visual analogue score reduction from 5/10 to 1/10 
(Clemens JQ et al., 2000). Ger et al found good short- term relief with local injections 
but minimal long- term benefits (Ger GC et al., 1993). Short wave diathermy was used 
by Sinaki reporting good results in terms of symptom improvement (Sinaki M et al., 
1977). 
Professor Michael Hyland developed a body reprogramming guide for patients with 
central sensitivity syndrome. Body reprogramming is an approach to help recovery in 
these patients based on the theory of Hyland model. He compared the body with a com-
puter that sometime can go wrong, and which can have software (consists of instruc-
tions sent to the whole body) and hardware (different parts of the body such as eyes, 
ears, lungs and heart) problems. The software is not visualised, but it directs the func-
tioning of the hardware. The guide has 4 sections: The first section describes the theory. 
The second section gives information about what to do to promote recovery (such as 
stress reduction and avoidance, creative positive emotions, deep relaxation, optimal 
movement, medicines and eating). The third section helps with managing symptoms 
(such as pain, fatigue, sleep, IBS). The final section gives advice to put everything into 
practice (such as looking after yourself, finding a routine) (Hyland ME et al., 2016).  
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Although, a broader approach to desensitise the CNS could be adapted in these group 
of patients (Baert I et al., 2016) we raise the question of whether there is any role of 
these treatment modalities in improving the outcome of surgery in women with POP 
and CSSs? Further research is required to clarify this.  
The strength of this study is that it is the first study to compare the outcomes of prolapse 
surgery between women with underlying CSS and women without CSS.  
There are several limitations in this study : 1) Measurement of pain perception was 
undertaken with the help of SF-MPQ, which is a widely used instrument to measure 
characteristics of pain (sensory and affective), however its use for assessment of neu-
ropathic pain diagnosis is limited as relevant descriptions for characteristics of neuro-
pathic pain were not used in this version (Dworkin RH et al., 2009). 2) Central Sensi-
tisation inventory(CSI) was used to identify women with CSS which is a validated 
questionnaire (see page 30) however, there was no quantitative sensory testing done to 
assess the severity of pain sensitisation. 3) The other limitation of this study is the small 
numbers with a relatively short period of follow-up. However, there were no previous 
studies to guide us on numbers and the power calculation was made based on POP-SS 
and not CSI scores. 4) Another limitation of the study was that few patients had a post-
op POPQ, due to either to telephone follow up or refusal of some patients to be exam-
ined vaginally at the time of follow up. However, the primary outcome was as interna-
tionally recommended, a subjective/symptomatic one with POPQ being a secondary 
outcome and on regression analysis patients with higher CSI scores were found to have 
worse prolapse symptom scores. 5) There was no linear relationship of CSI scores seen 
with patient satisfaction and patient global impression of improvement. This may be 
due to the small numbers as multiple regression works well with large number 6) 
Around 21% patients lost to follow up. Along with this, information on POP-q was 
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available only in 61% patients. This is a potential of bias and may be leading to over-
estimation of effect of CSS on pelvic organ prolapse surgery in terms of poor subjective 
outcomes 
Therefore, it is important to note that the results of the current study should not be 
interpreted as recommending the avoidance of prolapse surgery in patients with CSS 
(as there was an improvement seen in 70% of women.  Also, to note that one of the 
patients had recurrence of prolapse (although in another compartment). This has possi-
bly led to the dissatisfaction of the surgery. Although, this skewed our results i.e. if we 
assume that this patient would be satisfied then improvement in CSS group will in-
crease to 74% but still it is less when compared to those without CSS (95%)  
Even with these limitations, the result suggest that careful considerations should be 
given to this group of women with a detailed understanding of their needs and evalua-
tion of the severity of their global symptomology. Also, adding alternative treatment 
strategies before considering surgery might be appropriate in many to reduce the degree 
of sensitisation. Full discussion at counselling and robust informed consent regarding 
the risk of persisting symptoms should be undertaken with the patient actively involved 
in the decision-making process.  
The study highlights the need to find strategies to best manage women with POP and 
CSS. For example, should physiotherapy be offered in all stage 1 and 2 POP in this 
group of women or a trial of the vaginal pessary to assess its effect on symptoms? Sur-
gery would then only be undertaken if symptoms are improved or a trial of desensitising 
pharmacotherapy or other non-pharmacological options given if they are not. Further 
research is required to answer these questions.  
The results of this study suggest that screening women for CSS before POP surgery 
especially where there is a difference between symptoms and the degree of prolapse on 
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an objective assessment might facilitate potential management. This would include bet-
ter counsel and informed consent. 
5.5. Conclusion 
Our study has demonstrated less favourable outcome of surgery for POP in women with 
CSS within our patient cohort, especially in terms of persistence of symptoms including 
dragging sensation and overall patient goal achievement and satisfaction. 
The main expectation of women in both groups was to become comfortable, however, 
only 70% of women in group 1 felt their goals were met and were satisfied compared 
with 95% of women in group 2. These results are similar to study by Blcan and his team 
where they found that patients with FM had less satisfaction despite of improvement 
comparable to the controls. (BIcan O et al 2011). This should enable us to counsel 
women for realistic expectations especially where there is evidence of underlying CSS 
and optimise the shared decision-making process.  
Additional research is indicated in order to evaluate the interaction between CSS and 
surgical interventions, the interaction between CSS and treatment interventions target-
ing CS and the impact on the symptoms of pelvic organ prolapse. 
Recommendations for future research- 
1. Further research is advised with large numbers (to calculate sample size ) based on 
our regression model to assess the relationship of the CSI scores with patient satisfac-
tion  and with long term follow up (With a medium effect size (f’ = .15), a power of 
80%, and a p < .05 criterion,  we will need 103 participants in each group ). 
2. Role of Pain catastrophising on the outcome of pelvic organ prolapse surgery  
3. The results of our work have enabled us to pilot another study in assessing the out-
come of mesh excision surgery undertaken at Singleton Hospital, Swansea. On basis of 
this, our unit is currently practicing more conservative approach and aggressive pain 
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management programme in patients with CSI score of over 40 compare to those who 
have CSI score less than 40. 
4. Another protocol for a randomised trial to compare the effect of physiotherapy vs 
physiotherapy and psychology on symptoms of POP in patients with CSS is also ready 
for future research. This will help us to find evidence on best management strategy in 
this cohort of patients. This will be undertaken with co authorship of clinical psycholo-
gist and physiotherapist 
The protocol is as follows:  
Aims 
The research aims to assess the impact of psychological support on outcomes for treat-
ment of patients with pelvic organ prolapse (POP) who have symptoms suggestive of 
central sensitivity syndrome (CSS).  It will: (i) compare the benefits of combined PFMT 
and psychotherapy with PFMT alone in women with POP and evidence of CSS; and 
(ii) establish whether expectations of treatment efficacy prior to treatment impact on 
outcomes and can be modified by psychological support.   
Background  
Pelvic organ prolapse (POP) is defined as the descent of one or more of the following: 
anterior vaginal wall, posterior vaginal wall, apex of the vagina (cervix to uterus), or 
vault (cuff) after hysterectomy.  POP affects almost half of all women over 50 years of 
age, with a lifetime prevalence of 30% to 50%.  Women with a normal life expectancy 
will have an 11% to 12% chance of undergoing at least one operation for prolapse, with 
a re-operation rate of 29% by the age of 79 years. The principal symptom manifested 
in prolapse is the perception of a bulge within the vagina.  A significant proportion of 
women, however, complain of a dragging sensation without a physically confirmed 
bulge on examination, but these women may still proceed to prolapse surgery.  It is 
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known that anomalies exist between the pathology (i.e. prolapse) and degree of drag-
ging sensation, and there is on-going debate regarding the most appropriate manage-
ment for this cohort of patients.  
One increasingly popular explanation for this discrepancy between the ‘dragging’ per-
ception and degree of prolapse is related to variability in the processing of sensory 
stimuli.  The mechanism suggested involves the augmentation of pain transmission, 
secondary to a process known as Central Sensitisation (CS).  Central Sensitisation is a 
pathological process that affects the central nervous system, leading to reduced pain 
threshold, and an altered sensation of a normally non- painful stimulus.  There is an 
exaggerated pain response (hyperalgesia) – an extension of the response and pain sen-
sation to normal touch and pressure (allodynia).  
This condition has been proposed as root aetiology for several conditions, such as-Fi-
bromyalgia, Chronic Fatigue Syndrome, Temporo-mandibular Joint Disorders, and 
Complex Regional Pain Syndrome, which are collectively termed as Central Sensitisa-
tion Syndrome (CSS). The patients suffering from this syndrome have higher symptom 
bother, due to underlying central sensitisation.  Furthermore, CSS can result in consid-
erable psychosocial impairment, work disability, and increased utilisation of health care 
resources by patients.  Despite increased understanding of the mechanisms involved in 
CS pain, its treatment remains a challenging issue.  
Pelvic Floor Muscle Training (PFMT) is the mainstay of conservative management of 
POP.  The purpose of conservative treatment is the reduction of symptoms, the preven-
tion of worsening POP, increased support of the pelvic floor musculature, and avoiding 
or delaying surgery.  However, PFMT may not be that successful for women who pre-
sent evidence of CS.  Certainly, studies have shown that women undergoing PFMT for 
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a variety of pelvic floor dysfunctions (including POP) fare less well with this treatment 
if they also exhibit psychological problems, such as those involved with CSS. 
Our hypothesis is that women with POP and evidence of CS will have better outcomes 
with a combination of PFMT and psychological support than with PFMT alone.  This 
view is based on a similar study showing the advantage of such a combination treatment 
for women with pelvic floor dysfunction and mild psychological problems.  This latter 
study noted that brief psychological support offered to these women increased patient 
co-production, involving improved attendance and treatment outcomes.  A similar find-
ing from the current sample would allow roll-out of such psychological support to 
women with POP and CSS, and the improved treatment outcomes would have the po-
tential to offer substantial cost-savings in terms of avoidance or delay of surgery, im-
proved co-production, and enhanced patient experience of treatment.       
Participants and Recruitment 
Consecutive women patients referred for PFMT treatment in the physiotherapy depart-
ment for Grade 2 POP will be asked if they would like to participate in this study.  To 
allow sufficient time to consider participating in the study, all women will receive a 
patient information sheet regarding the study along with their appointment letter.  This 
information sheet will make clear that their treatment will not depend on their partici-
pation in the study.  On arrival at their initial appointment, women will be given the 
chance to discuss their participation with the treatment team, and will give their consent 
by completing and signing a Consent Form, after they have had time to think about 
their participation and ask any questions that they may have. 
Inclusion Criteria  
• Participants willing and able to give informed consent for participation in the 
study.  
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• Females aged 18 years or above.  
• Participants able and willing to comply with all study requirements.  
• Women with Grade 2 pelvic organ prolapse (as they are more likely to comply 
with PFMT). 
• Women with evidence of CSS. 
Exclusion Criteria 
• Females under the age of 18 years. 
• Women who are unable to give informed consent. 
• Women with Grade 3/4 POP (who are more inclined towards a pessary or sur-
gery). 
Design and Methodology 
Following their consent, the patients will be asked to complete a battery of assessment 
questionnaires (taking about 15min in total).  The Central Sensitisation Inventory (CSI) 
score will be used to identify women with evidence of CSS.  Women with evidence of 
CSS will then be randomised for PFMT alone or for PFMT with psychological support.  
The randomisation will be performed by a random number generator. 
All patients will then experience their PFMT treatment as usual, which will entail one 
group session each month over four/five months, along with two individual appoint-
ments at the start and end of the PFMT treatment.  In addition, the experimental group 
will receive psychological motivational support in addition to their medical treatment 
based on that previously shown to be effective in supporting women with pelvic floor 
dysfunction undergoing PFMT.  This will entail a 20min group-based session focusing 
on motivation and health values after the 2nd, 3rd, and 4th PFMT sessions.  
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After the last session of treatment, the patients will complete the same battery of tests.  
The changes across the objectively- and subjectively reported health status and in the 
patient-reported outcomes will be measured. Additionally, the relationship between the 
baseline patient-reported expectation of improvement and the objective (physical 
measures), and subjectively reported (general health and quality of life) outcomes, will 
be assessed. 
The difference in the change in levels of functioning in the primary and secondary out-
come variables in the two groups will be assessed using independent groups t-tests.  
Based on adopting a p < 0.05 rejection criterion, 80% power, and a medium-sized effect 
d = 0.5 (Osborne et al., 2016, indicates a large effect size, but an assumption of a me-
dium-sized effect will be more conservative), then 102 participants (51 per group) will 
be needed for a one-tailed hypothesis.  On the assumption of a large effect size, d = 
0.70, this would be 52 participants (26 per group).  It has been estimated that between 
30% to 40% of patients display CSS , and given that upwards of 200 patients per year 
are referred to Women’s Health at Singleton Hospital for PFMT, the estimated numbers 
above should be achievable.  These numbers will also allow sufficiently powered cor-
relational analysis between predictor outcomes and improvements to be conducted.  
Outcome Measures 
Primary Outcome 
Pelvic Organ Prolapse Symptom Scale (POP-SS,) is a patient-reported outcome, meas-
ured by 7 questions relating to the number and frequency of prolapse symptoms, each 
with a 5-point Likert scale (0 = never to 4 = all of the time).  A total score range of 0 to 
28 is calculated by summing the seven questions to derive the POP-SS score.  The 
question format and response set were modelled to standardise outcome measures in 
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pelvic floor dysfunction research and clinical practice.  Internal reliability (Cronbach 
α) ranges from 0.72 to 0.83. 
Secondary Outcomes 
Euro-qual 5D (EQ-5D) is a quality of life (QoL) instrument in which patients describe 
and value their health on five domains (mobility, self-care, pain, usual activities, and 
psychological status), and rate their general health on a visual analogue scale of 1-100.  
It has been extensively validated and its reliability proven. 
Patient Global Impression of Improvement (PGI-I) has a single item relating to how 
much the patients’ perceive their condition to have improved, scored 1 (“very much 
improved”) to 7 (“very much worse”).  This tool has been validated, and participants 
are considered “successfully” treated if they respond that they are “very much better” 
or “much better”. 
McGill’s Short Pain Questionnaire (MSPQ, ) measures pain through 15 descriptors 
(11 sensory; 4 affective) which are rated on an intensity scale (0 = “none” to 3 = “se-
vere”).  The scale has good test-retest reliability. 
Questionnaires 
Central Sensitisation Inventory (CSI; ) is a published and validated questionnaire, as-
sessing 25 health-related symptoms commonly noted in CSS, such as:  “I feel unre-
freshed when I wake up in the morning” or “I am sensitive to bright lights”. These 
questions are scored on a scale of 0-4 (0 = “never” to 4 = “always”) giving a score from 
0 to 100.  It is suggested that a cut off score of 40 indicates the presence of central 
sensitisation. 
Stanford Expectations of Treatment Scale (SETS,) measures patients’ positive and 
negative treatment outcome expectancies through six items, each scored on 7-point 
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scale (“strongly disagree” to “strongly agree”).  It produces two subscales: positive ex-
pectancy (Cronbach α = 0.81–0.88) and negative expectancy (Cronbach α = 0.81–0.86). 
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Chapter 6 - A qualitative study of women’s experiences of prolapse surgery in 
those with evidence of central sensitivity syndrome  
6.1.  Introduction 
It is well known that there are better results from a treatment when patients are in-
volved in their care. Surgeons often presuppose the outcome of the surgery which 
may not be the same for the patients. The document “No decisions about me without 
me” demonstrated that the concept of concordance should be applied to achieve the 
greatest outcome from a treatment (Snowden A et al., 2013) and therefore, there is an 
increasing trend to include outcome measures based on patient’s expectations (Toozs-
Hobson P et al., 2012). 
Patient reported outcome measures can be affected by several factors such as previous 
personal experience, those of friends and relatives, patient expectation and understand-
ing of the condition, mental/psychological state and attitude of the clinician. These fac-
tors can impact on the understanding of the concept of cure or successful outcome in 
surgery.  
Achieving normal restoration of anatomy might be the aim of the surgeon but, not nec-
essarily of the patient. Cure is difficult to define in this context e.g. the patient might 
be cured of their presenting complaint anatomically but that would not necessarily mean 
a successful outcome if there is development of new symptoms or complications e.g. 
in the case of POP surgery: bowel, bladder or sexual dysfunction (Srikrishna S et al., 
2008).  
Several qualitative studies have been undertaken to understand women’s preference of 
treatment such as for pelvic organ prolapse (Basu M et al 2011), their perception of risk 
reduction (Brain K et al., 2004), exploring patient experiences both pre and post-oper-
atively to produce positive outcome following treatment (De Graenreid-Yates Sacha L 
2015).  
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For example, Brain and her colleagues (Brain K et al., 2004) found limited understand-
ing of the concept of prophylactic oophorectomy in the prevention of ovarian cancer 
while Sacha L in 2015 demonstrated the importance of education and understanding of 
the patient’s needs in order to have an effective partnership with healthcare providers. 
He also discovered the need for patients to be cared for as individuals, with considera-
tion for their whole life experience during the entirety of surgical care.  
The understanding of patient’s needs, and expectation enables patients to be involved 
in decision making for the proposed treatment and this might potentially enhance out-
come where provider and recipient have mirrored expectations. 
It has been previously demonstrated in a prospective cohort study (see chapter 4) that 
there is poor subjective benefit following prolapse surgery in women with central sen-
sitivity syndrome. The current qualitative study was, therefore, undertaken to under-
stand patient’s experiences, individual needs, expectations and views on the reasons for 
the poorer outcome of surgery i.e. in those with central sensitivity syndrome (CSS). 
This might help us to identify areas of where improvement in management can result 
in better outcomes.   
To facilitate this aim, we interviewed women with poor outcomes in CSS group of the 
above prospective cohort study (see chapter 4). Poor outcomes were defined on the 
basis of persistence of symptoms and suboptimal responses on the patient global im-
pression of improvement scale (see chapter 4).  
6.2. Method 
A qualitative study, using semi-structured interviews with women with Central Sensi-
tivity Syndrome, who had subjectively poor outcome following pelvic organ prolapse 
surgery was conducted in the month of July 2018. The research investigation was en-
dorsed by the Scotland Research Ethics Committee. 
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The women previously described in chapter 5 were followed at 4-6 months post-sur-
gery. Those with poor outcomes based on the persistence of symptoms and the patient 
global impression of improvement scale (PGI-I) were identified. Having confirmed that 
formal consent had been documented during the original trial, semi-structured inter-
views were scheduled. The opportunity was provided for further questions during the 
telephone confirmation of the initial consent. 
The structure of interview -The interview contained set of predetermined questions. 
There were 5 open and 2 closed ended questions. The open-ended questions were 
used. This allowed us to capture independent thoughts of each patient with CSS who 
had poor outcome with the surgery. All the questions were designed to capture the 
journey of these patients from symptom diagnosis to surgical treatment in order to un-
derstand their expectation and satisfaction 
The two closed ended questions – “Do you feel that persistence of your symptoms is 
something to do with your nerves?” “Have you ever heard about central sensitisation 
or central sensitivity syndromes” were used keeping in mind the objective of our 
study to assess the awareness of CSS among the patients  
The wordings of the interview questions were developed with the help of a psycholo-
gist. The questions were tested within the department with non- clinical staff (clean-
ers, secretaries, and receptionist) before the patients were interviewed. 
Interviews were then conducted by two independent researchers who had not been in-
volved in that patient’s care (psychologist and author). All interviews were conducted 
in a private room within the hospital and university (Swansea). Demographics data and 
details of surgical interventions were recorded in a standard proforma prior to inter-
view. Interviews lasted from 15 -25 minutes (Mean length: 17.8 minutes) and were 
tape-recorded.  
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All recordings were anonymised and transcribed using Trint software by the author. 
6.3. Analysis  
A thematic approach-based framework was utilised for the analysis based on that pre-
viously described by Marshall & Rossman (Marshall C et al1999). 
Thematic analysis is a generic approach to data analysis and is widely used in qualita-
tive research. It enables data sources to be analysed in terms of the principal concepts 
or themes and to enable the data to be reduced to key ideas.   
The structure of the analysis used for the whole interview in this study is shown below: 
1. Organization and familiarization with the data. Interviews were listened to and tran-
scripts read and re-read by 2 investigators to familiarize themselves with their content. 
2. Identification of categories and themes which reflected and addressed the core re-
search questions. 
3.Interviews were listed and coded according to these categories. 
4. Interviews were summarised using the QSR NVivo 8 Computer-Assisted Qualitative 
Data Analysis Software.  
5. Once the coding system is completed, the primary themes are identified and summa-
rised to determine the conclusions. 
6.4. Results  
A total of 23 women with evidence of CSS had POP surgery during the prospective 
cohort study. Out of 23, 7(30%) had poor subjective outcomes in terms of patient global 
impression of improvement, goals achievement and satisfaction, 1 patient had achieved 
their goals partially. These 7 women with poor outcome were approached. Five women 
replied and agreed to the interview. The demographics, detail of surgery, CSI scores 
patient global impression of improvement scores, POPSS scores, McGill’s score, POP-
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Q, expectation and goals of these women are shown in tables 37 and 38. All the ques-
tionnaires used have been explained in chapter 5. 
 
Table 37: Demographics, type of surgery, PGII, POP-SS scores, McGill’s pain scores in this group of 
women. 
Patient 
no 
BMI Par-
ity 
Type 
of sur-
gery 
P
G
II 
POPSS scores McGill’s Pain 
score 
CSI 
scores 
Before 
sur-
gery 
After 
sur-
gery 
Before 
sur-
gery 
After 
Sur-
gery 
 
1 32 P3 Post 
repair 
6 24 20 12 12 49 
2 25 P3 Poste-
rior 
repair 
2 18 10 1 1 52 
3 25 P3 Post 
repair 
3 14 7 13 6 44 
4 38 P1 Post 
repair 
5 22 26 21 18 66 
5 31 P2 Vag 
hyst, 
a&p 
repair 
3 14 8 25 26 58 
  
Table 38: Showing expectation, goals, satisfaction and POP-Q scores in this group of women. 
PATIENT Expectation 
From sur-
gery 
Goals 
achieved 
Satisfaction 
From sur-
gery 
POP-Q (be-
fore sur-
gery) 
POP-Q (after 
surgery) 
1 Opens 
bowel effec-
tively 
Not met Not satis-
fied 
Grade 2 rec-
tocele 
Tel FU  
No examina-
tion 
2 Improve 
Bowel 
Partially met Not satis-
fied 
aa-2, ap-0, 
bp-0, c-5 
aa-2, ap-2, 
bp-2, c-5 
3 Easier to 
open bowel, 
not feel 
bulge 
Not met 
Still digitate 
Sex painful 
Not satis-
fied 
aa-3, ap-0, 
c-6 
aa-2, ap-2, 
c-5, ap-2, 
bp-2 
4 Improves 
dragging 
sensation 
Not met Not satis-
fied 
aa-1, ap+1, 
c-3 
Aa+2, c+2, 
ap-2 (im-
proved com-
partment of 
surgery) 
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5 Not to feel 
prolapse 
Not met 
Persistent 
dragging 
sensation 
Not satis-
fied 
Aa+2, c-1, 
ap-0 
Aa-0, c-6, 
ap-1 
 
Four categories were identified. 
1. Understanding  
Women’s understanding of their symptoms and their relationship with prolapse was 
poor. The majority sought help due to their bowel, bladder problems rather than feeling 
of bulge/prolapse; in fact, only one patient had the symptom of dragging sensation. 
They were made aware of prolapse only during the clinic appointment for bowel or 
bladder symptoms, following an examination by their clinician. Typical examples in-
clude: 
“Initially I went to doctors for haemorrhoids and during smear test, they told me I had 
a prolapse.” (patient 2) 
“I saw the GP due to feeling of urgency to urinate, burning sensation when I would 
urinate, and it was getting worse and not manageable. My first thoughts were that I 
was suffering from cystitis.” (patient 4) 
“Below were very uncomfortable with leakage of stuff coming down with often pains in 
the lower back.” (patient 5) 
“I got a lot of diarrhoea, I had difficulty in emptying the bowel properly, it was very 
uncomfortable. I had to put my hand up and press my perineum to empty my bowels 
and, in the end, I had to do irrigation which was not fun.” (patient 1) 
Some women expanded on this theme with comments that shows their worries and 
concerns rather than them being bothered with the symptoms. 
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“I understood if this is prolapse, then that can get worse and can actually become ex-
ternal and that’s something I did not want.” (patient 2) 
“My concern was the worsening of urinary leakage and worsening of back pain “(pa-
tient 5) 
“I think everybody in their mind think cancer.” (patient 2) 
“I was concerned of it getting worse and with old age more likely to have lots of prob-
lems.” (patient 3) 
2. Expectations 
All Women were hoping to have normal bladder, bowel, sexual function along with 
complete resolutions of discomfort and back pain except one  
“I would be able to function normally, not have problems in opening bowels, able to 
have normal sex.” (patient 1) 
“I expected it really improve my bowel control.” (patient 3) 
“I hoped it would all go away- the discomfort, back pain, pain on passing urine and 
urgency.” (patient 5) 
“I have little expectation other than to prevent the problem getting worse” (patient 4) 
3. Reasons for failure 
None of the women felt that there was any relevance between persistence of their symp-
toms or poor outcome and the presence of an underlying central sensitivity syndrome. 
They all felt that persistence of symptoms were either due to poor surgical repair or 
some unidentified internal pathology in the bowel/ bladder. 
“I would say that the reasons for no improvement in my symptoms is due to bowel and 
nobody says anything. I believe I have got cyst in the bowel. In terms of repair, the 
smear people did not say anything that anything changed, or I have prolapse so I as-
sume everything’s okay.” (patient 2) 
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“I don’t know whether things have come back down again or something like that I don’t 
know, I had a full hysterectomy but repair jobs? I don’t know whether one did well.” 
(patient 5) 
“I know repair was not good, I could feel stiches turning around. (patient 1) 
“I had no issues with healing, the defect is gone however, it has make vagina very tight 
and has been very- very uncomfortable and painful which I am not happy about.” (pa-
tient 3) 
“I felt my all my symptoms are due to prolapse totally.” (patient 4) 
4. Dissatisfaction, Frustration and Anger 
Women felt that their concerns for the persistence of their symptoms after surgery had 
been dismissed and not properly listened and addressed. They felt frustrated and started 
developing disbelief in the advice offered by the medical professionals. 
“They said it healed all well and held nicely up and that it’s all in my head. Till now I 
haven’t done anything about it because I thought should I be making a fuss about this?” 
(patient 3) 
“I was actually more concerned with my haemorrhoids and bowel and no further treat-
ment for this was offered. Very sensitive subject. I was told that there is nothing wrong. 
I am only constipated.” (patient 2) 
“I knew the repair had not worked but nobody believed me. To be honest, I just gave 
up and stopped going to the hospital.” (patient 1). 
6.5. Discussion  
The outcome assessment and definition of cure is poorly defined in clinical settings 
(Robinson D et al., 2003; Freeman RM 2010). Objective cure has often been favoured 
in clinical trials whereas subjective cure is more relevant in clinical practice (Robinson 
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D et al., 2007). Barber et al have shown that definitions based on anatomic success have 
weak correlation with patient perception of outcome (Barber MD et al., 2009). 
The objective data may lack the sensitivity to compare the outcomes in a meaningful 
way to women and so, POP outcomes are now shifting from being objective to subjec-
tive as recommended by an international collaboration (IUGA/ICS, Toozs-Hobson P et 
al., 2012) i.e. that the subjective outcome should be the primary one for POP surgery. 
In this qualitative study we have explored women’s views on prolapse surgery and the 
reasons for poor subjective outcome, in a cohort of women with a central sensitivity 
syndrome. The results suggest that most of these women presented with bowel and 
bladder dysfunction, back pain, dragging sensation or sexual dysfunction which are not 
necessarily cured by surgery. This finding is similar to previous studies (Srikrishna S 
et al., 2008).  
Dissatisfaction is not found to be related to the type of surgical procedure but appears 
to relate to unrealistic expectations from surgery. For example, Finley et al in their 
study demonstrated that the degree of satisfaction was high if orthognathic surgery pa-
tients were well adjusted psychologically although, majority sought surgery for aes-
thetic reasons. Dissatisfaction was not related to sex, age or procedure. Patients who 
were dissatisfied tended to have higher neuroticism scores on the Eysenck Personality 
Inventory and had unrealistic expectations regarding post-surgical pain, numbness and 
swelling (Finlay PM et al.,1995). 
In the current study, it would have been helpful therefore to have considered psycho-
logical factors which might be relevant for the sexual dysfunction rather than prolapse. 
Similarly, there may be a primary bowel problem leading to constipation/obstructed 
defaecation and again not due to prolapse but possibly due to rectal intussusception, 
which would not usually be corrected by posterior repair (as seen in 5 of 7 patients 
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here). If these are not identified pre-operatively and considered during selection for 
surgery then risk of dissatisfaction from surgery is high. Also, to note that one of the 
patients had recurrence of prolapse in other compartment which led to the dissatisfac-
tion of the surgery.  
Equally, there may be underlying central sensitisation responsible for a heightened per-
ception of the dragging sensation or equally be responsible for the back pain in women 
with POP. Those expressing a wish for cure of these symptoms may face high level of 
dissatisfaction in the post-operative period if those symptoms are unaltered. This find-
ing has been demonstrated in the study. For example: One of the patients out of 7 pa-
tients (with CSS and poor outcomes), had complaints of dragging sensation and pelvic 
pain along with prolapse. Her expectation from the surgery was to feel normal and have 
no pain. However, the pain persisted after the surgery despite of the anatomical correc-
tion of the prolapse. This results into high level of dissatisfaction and numerous clinic 
appointments. She was subsequently referred to pain specialist for pain management. 
Unfortunately, she was unavailable for the interview.  
None of the women had heard about the concept of central sensitisation or the symptom 
severity noted in central sensitivity syndromes either at presentation or following treat-
ment. All of them felt that poor outcome was either due to poor surgical repair (this 
may be correct as one of the patients presented with prolapse in different compartment 
but for the patient it is still a recurrence) or an internal unidentifiable pathology of 
bowel/ bladder.  
Many felt frustrated and angry at what they described as “not been listened to” or be-
lieved regarding the persistence of their symptoms. This might be due to a lack of un-
derstanding amongst clinicians and patients of a potential underlying condition 
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responsible for a heightened symptom profile such as CSS (see chapter 3b, 6). Alterna-
tively, patients might not have revealed this to the surgeons but did to the interviewer.  
This study is possibly the first qualitative study to explore women’s views of poor sur-
gical outcome from prolapse surgery in women with a Central Sensitivity Syndrome. 
The limitations are the small numbers and therefore, the data should be interpreted with 
caution. It is also important to consider whether all the questions (There were 5 open 
and 2 closed questions in the interview) were sufficient to capture adequately the views 
of these women. Also, there were some potential flaws in the structure of the interview-  
1. A semi-structured interview was used to allow the patients to elaborate and explain 
the issues through open ended questions but the questions were not piloted for the type 
of response ( The questions were piloted only to check the wording of the question and 
not to see how much information it can extract). 2. There were 2 closed ended questions 
which did not help in obtaining patients opinion in depth about CS/CSS. 
 However, by undertaking this study, we have gained insight into women’s concerns, 
frustration, and anger after poor outcome from surgical treatment especially when they 
perceive that clinicians dismiss their concerns. This same concern was raised in the 
Scottish Mesh enquiry (Wilkie L et al., 2017). Possibly, more emphasis needs to be 
placed on the pre-operative expectations and counselling of likely outcomes. Studies 
need to make patient reported outcomes, the primary outcome rather than the anatomi-
cal. 
This appears to highlight the need for the involvement of other health professionals 
such as pain management specialists, psychologists, physiotherapists, bowel and con-
tinence nurses to help identify other conditions which might be responsible for the 
symptoms.   
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6.6. Conclusion 
This qualitative study highlights that there is little understanding by women that central 
sensitisation can affect the outcome of the surgery. This might be due to a lack of aware-
ness and understanding of this condition amongst clinicians and so inadequate counsel-
ling regarding surgical outcomes in those with a CSS. It would be interesting to assess 
whether women with evidence of a central sensitivity syndrome but positive outcomes 
post- prolapse surgery have a greater understanding of the condition (via their clini-
cian), or whether awareness of central sensitivity syndromes might affect their decision 
regarding surgery or result in more realistic expectations. This is an exciting area for 
future research. 
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Summary of Findings of the thesis 
Quite often patients present having had multiple re-operations for their symptoms but 
with little anatomical prolapse and therefore, we undertook this project to gain insight 
into the reasons for the poor outcomes in this group of patients. The hypothesis was 
that the presence of underlying CSS could be one of the factors responsible.  
One of the primary findings of this project is the identification of a gap in the 
knowledge, understanding and awareness of central sensitivity syndrome amongst cli-
nicians as well as patients (chapters 2 and 6). There is still disagreement amongst cli-
nicians that patients with central sensitivity syndrome might have more bothersome 
symptoms compared to those without, but the study in this thesis (chapter 5) has sug-
gested that they do. However, patients rejected the hypothesis that central sensitisation 
could play a role in the negative outcomes following POP surgery; they believe that a 
lack of improvement in their symptoms is due to poorly performed surgery or some 
internal pathology which has not been identified. 
The second part of the study (chapter 3b) revealed that around 32% of women with 
pelvic organ prolapse presented to gynaecological outpatient clinics with evidence of 
CSS as judged by the validated CSI questionnaire and around 40% with other gynae-
cological problems had evidence of CSS. This suggests that CSS is common in many 
patients but in many is not identified. 
The prospective cohort study conducted to compare the outcomes of pelvic organ pro-
lapse surgery between two groups i.e. (those with and without CSS), found that women 
with CSS had less satisfaction, impression of improvement and persistence of symp-
toms than in those without CSS (chapter 5). 
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Although the predominant expectation from surgery in both groups was to become 
more comfortable with respect to prolapse symptoms, only 70% of women in group 1 
with CSS felt their goals were met and that they were satisfied while, 95% of in group 
2 without CSS felt their goals were met and were satisfied.  
Only 74% of women with CSS reported the symptoms to be “very much better” or 
“much better” compared to 97.4% of women without. This was statistically significant. 
However, if we do not dichotomise the CSI data then there was no linear relationship 
found between CSI scores with patient satisfaction and patient global impression of 
improvement. This may be due to the small numbers as multiple regression works well 
with large number. There was positive relationship seen with pre-operative POP-SS 
scores and CSI scores confirming higher bother with symptoms in these group of pa-
tients. 
In those with pain (not a usual symptom of prolapse), there was persistence after sur-
gery in women with CSS with higher pain scores compared to women without CSS. 
These findings are likely to be of interest to clinicians as it will enable them to ade-
quately counsel those women with CSS during consenting for the possible outcomes of 
the surgery while also enabling those patients to have more realistic expectations from 
the surgery. 
Implications and conclusions 
Several factors account for poor outcomes following POP surgery such as patient char-
acteristics, co-morbidities, unrealistic expectations, high BMI, infection, smoking and 
poor surgical technique/surgeon factors (Vergeldt TF et al., 2015). 
One of the factors identified in this study is the presence of underlying central sensitiv-
ity syndromes which might contribute to an unfavourable outcome from surgery. 
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There is growing evidence in orthopaedics that presence of markers of altered central 
pain modulation (e.g.CSS) before surgery can result in weaker outcomes and do not 
guarantee complete pain resolution or full functional recovery resulting in a negative 
emotional impact on patients (Baert I et al., 2016; Lewis GN et al., 2015). 
There is nothing in the literature regarding outcomes of pelvic organ prolapse surgery 
in patients with CSS and as far as we know our study is the first study to demonstrate 
that in women with CSS, fewer have complete resolution of symptoms compared to 
women without CSS. This can lead to dissatisfaction and frustration.  
Therefore, in those with CSS who might require surgery, pre-operative treatment of 
CSS could be considered to ameliorate some of the perceptual changes due to central 
sensitisation (Jacob NA et al., 2017). However, further research is needed to evaluate 
the effect of preoperative treatment of CSS on the outcomes of surgery.  
Another important feature highlighted in the qualitative part of the thesis is that patients 
perceive that some surgeons do not listen or believe their concerns as evidenced by 
some women’s statements. This could result in challenging consultations and disen-
gagement by the patient with perceptions that the clinician thinks that “the symptoms 
were all in their head” (Sharpe M 2013) and the poor outcome has nothing to do with 
the surgery which in many cases might have produced a good anatomical result. How-
ever, women with CSS in the qualitative study did not feel that the poor outcome was 
due to altered pain modulations but due to poorly performed surgery. 
 There are clearly gaps in the awareness and understanding of CSS and CS by both 
clinicians and patients. It might, therefore, be important to screen women for CSS and 
educate them about the condition so that they have a better understanding of the cause 
of their bothersome symptoms. This might help surgeons to better counsel patients on 
the possible outcomes. This might also impact on the decision to proceed with surgery 
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or not. Further work to replicate our findings will be required before this form of screen-
ing is undertaken. 
In addition, health care professionals need to be educated about this topic to empower 
them with the ability to manage women with these conditions. 
Limitations  
The current project contains a number of limitations. Firstly, the clinician survey, like 
many surveys had a low response rate (of 35%).  
Secondly, in the prospective study, measurement of pain perception was undertaken 
with the help of SF-MPQ (see pg.114) and no quantitative sensory testing (e.g. pain 
mapping) was done to assess the severity of pain sensitisation (although POP rarely 
produces acute pain but rather heaviness or dragging). The numbers were small and 
there was a relatively short period of follow-up (chapter 5). 
In chapter 5, the study was powered on the POP-SS as there is now more emphasis on 
capturing patient related outcomes of surgery to understand the expectations from the 
recipients perspective. 
The CSI questionnaire used to identify women with CSS is a validated questionnaire 
and there were no previous studies to evaluate women with POP for underlying CSS to 
help with a more robust power calculation. However, our data might help power a larger 
study. 
Another limitation was that few patients had post-operative POPQ evaluation due to 
either telephone follow up or refusal of patients to be examined vaginally at the time of 
follow up. The POPQ data was not completed by an independent researcher which 
might result in observer bias. Overall this would be likely to have only a minor impact 
on findings so far as the POPQ was a secondary outcome of the study. 
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In the qualitative study, the limitation was the small numbers and so the data might not 
generalisable and so should be interpreted with caution. It is also unknown whether the 
questions were sufficient to capture adequately the views of these women and as the 
interviews were undertaken sometime after surgery and therefore the answers might be 
affected by recall bias. 
Recommendations 
POP significantly affects a woman’s quality of life and results of treatment can be un-
predictable It is important to identify risk factors responsible for poor outcome after 
surgery and the findings of our study suggest that patients with underlying CSS can be 
one such group. Therefore, screening women for CSS prior to undertaking surgery for 
POP might be a useful way to identify and subsequently counsel patients.  A broader 
therapeutic approach in terms of physiotherapy and cognitive treatment should be ac-
tively considered in these women especially if there are bothersome symptoms but little 
prolapse objectively e.g. stage 1 or 2 prolapse.  
Before proceeding with surgery in such patients, a trial of vaginal pessary could be 
undertaken to assess the impact of prolapse reduction on their symptoms before con-
sidering surgery. If no improvement is noted then surgery might not help, whereas if 
the pessary helps then surgery can be offered (or alternatively to continue with the pes-
sary). 
Further studies should be designed with long-term follow up and adequate sample size 
(as calculated in chapter 5)- 1. To assess the impact of CSS on pelvic organ prolapse 
surgery and 2.To evaluate the effect of  desensitisation by pre-surgical pharmacologic 
or non-pharmacological intervention on pop surgery in order to provide guidance on 
how to best manage women with the presence of POP and CSS. There is likely to be a 
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role for physiotherapists and psychologists in the management of these patients both 
before and after surgery.   
Finally, both care providers and women need to be educated about CSS and clinicians 
need to know how to assess and manage the various manifestation of central sensitisa-
tion. In the short term, our evidence suggests that the validated questionnaire CSI could 
be used before a patient is considered for pelvic organ prolapse surgery but further 
research is required to optimise its use in this clinical arena.  
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APPENDICES 
 
Appendix 1: Central Sensitisation Inventory 
Please circle the best response to the right of each 
statement. 
    
1 I feel unrefreshed when I wake up in the 
morning. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
2 My muscles feel stiff and achy. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
3 I have anxiety attacks. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
4 I grind or clench my teeth. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
5 I have problems with diarrhoea and/or 
constipation. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
6 I need help in performing my daily activ-
ities. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
7 I am sensitive to bright lights. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
8 I get tired very easily when I am physi-
cally active. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
9 I feel pain all over my body. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
10 I have headaches. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
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11 I feel discomfort in my bladder and/or 
burning when I urinate. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
12 I do not sleep well. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
13 I have difficulty concentrating. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
14 I have skin problems such as dryness, 
itchiness or rashes. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
15 Stress makes my physical symptoms get 
worse. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
16 I feel sad or depressed. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
17 I have low energy. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
18 I have muscle tension in my neck and 
shoulders. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
19 I have pain in my jaw. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
20 Certain smells, such as perfumes, make 
me feel dizzy and nauseated. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
21 I have to urinate frequently. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
22 My legs feel uncomfortable and restless 
when I am trying to go to sleep at night. 
Never Rarely Some-
times 
Of-
ten 
Al-
ways 
23 I have difficulty remembering things. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
24 I suffered trauma as a child. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
25 I have pain in my pelvic area. Never Rarely Some-
times 
Of-
ten 
Al-
ways 
     To-
tal= 
 
 
Central Sensitization Inventory: Part B 
Have you been diagnosed by a doctor with any of the following disorders? 
Please check the box to the right for each diagnosis and write the year of the diagnosis. 
  NO YES Year Diagnosed 
1 Restless Leg Syndrome    
2 Chronic Fatigue Syndrome    
3 Fibromyalgia    
4 Temporomandibular Joint Disorder (TMJ)    
5 Migraine or tension headaches    
6 Irritable Bowel Syndrome    
7 Multiple Chemical Sensitivities    
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8 Neck Injury (including whiplash)    
9 Anxiety or Panic Attacks    
10 Depression    
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Appendix 2: McGill Pain Questionnaire 
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Appendix 3: PGI-I 
                        PGI-I FOR PELVIC ORGAN PROLAPSE        
Study number       
 
 
                                                                  Date  d d m m y y y y 
 
Age       
 
Check the number that best describes how your post-operative condition is now com-
pared with, how it was before you had the surgery 
 
 
1. Very much better                               
 
2. Much better                             
 
3. Little better 
 
4. No change 
 
5. A little worse          
 
6. Much worse 
 
7. Very much worse 
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Appendix 4: POP-SS 
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Appendix 5: Questions used for survey – chapter 2 
Q1- Describe your role - 
Role 
Gynaecologist with special interest in 
urogynaecology 
Subspecialist urogynaecologists 
General Gynaecologists 
Physiotherapist 
Incontinence specialist nurse 
General practitioner 
Q2- How often do you see patients with pelvic organ prolapse complaining of 
dragging sensation rather than bulge? 
Frequency 
Rarely (once in 2-3 months) 
Occasionally (once in a month) 
Frequently (every week) 
Almost always (every patient) 
Q3- In your practice how often do you see patients whose symptoms of prolapse 
are out of proportion to/ with degree of prolapse? 
Frequency 
Rarely (once in 2-3 months) 
Occasionally (once in a month) 
Frequently (twice in a month) 
Almost always (every week) 
 
Q4- Do you believe that there is an element of central sensitisation in women 
where their symptoms are out of proportion to the objective prolapse? 
Yes 
No 
Do not Know 
Q5- Do you believe that women with Fibromyalgia, chronic fatigue syndrome, 
ME or some vaginal pain have worse symptoms than women who do not have 
these conditions? 
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Yes 
No 
Do not Know 
Q6a- Have you heard the term Central sensitivity syndrome? 
Yes 
No 
Q6b Please circle the following conditions that can contribute to central sensiti-
sation syndrome.  
Conditions 
Fibromyalgia 
Chronic fatigue syndrome 
Migraine 
Anxiety 
Depression 
Neck whiplash injury 
Temporomandibular joint dysfunction 
All of the above 
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Appendix 6: CONSENT FORM (Study 2/3)- version2, 8/11/13 
TITLE: “An Investigation of the impact of Central Sensitisation in women with 
symptoms of pelvic floor dysfunction.” 
Name of Researchers:    Prof Freeman, Dr Monika Vij, Mr Bombieri, Dr Anupreet 
dua, Dr Davies, Dr Madhu  
Please initial the boxes 
1 I confirm that I have read and understand the information sheet (Version -1) 
for the above study and have had the opportunity to ask questions.  
2 I understand that my participation is voluntary and that I am free to withdraw 
at any time without my medical care or legal rights being affected.  
  
3.         I am willing to allow access to my medical records by authorized people but 
understand that strict confidentiality will be maintained. The purpose of this is to en-
sure that the study is being carried out correctly. 
All documents and forms will be kept in a locked cabinet in a secure research office at 
Derriford Hospital. On all study-specific documents, other than the signed consent, 
the participant will be referred to by the study participant number/code, not by name. 
4 I agree to take part in the above study. 
 
5           I agree to take part in the interview.      
 
_________________  _____________  _____________ 
Name of patient   Date    Signature 
________________  ____________     _____________ 
Name of person taking consent   Date    Signature 
________________  ____________     _____________ 
Researcher   Date    Signature 
(one copy for patient, one for researcher, one for medical notes) 
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Appendix 7: Questions for interview- (chapter 6) 
1. What were your symptoms? 
2. What were your expectations from the surgery? 
3. How did you feel the surgery go? 
4. Why do you think that your symptoms have not improved? 
5. What do you think is the reason behind no improvement in your symptom after sur-
gery? 
6. Do you feel that persistence of your symptoms is something to do with your 
nerves? 
7. Have you ever heard about central sensitisation or central sensitivity syndromes be-
fore? 
 
Appendix 8: Ethics Approval letter 
     The letter is attached. 
 
